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Abstract 
Directive 2007/47/EC of the European Parliament amending Medical Device Directive 
(MDD) provides medical device manufacturers with a compliance framework. However, 
the effects of the amendments to the MDD on competition in the U.S. medical device 
software industry are unknown. This study examined the impact of this directive on the 
competitiveness of U.S. medical device software companies, the safety and efficacy of 
medical device software, employee training, and recruitment. The conceptual framework 
for this study included 3 dimensions of medical device regulations: safety, performance, 
and reliability. The overall research design was a concurrent mixed method study using 
both quantitative and qualitative techniques. The qualitative techniques involved case 
studies of 5 purposively selected companies. Data collection involved both surveys and 
interviews. The sample consisted of 56 employees within medical device firms with 
markets around the European regions. Qualitative data analysis consisted of descriptive 
thematic analysis along the study questions and hypotheses and summative evaluation. 
Quantitative data analysis included descriptive statistics and correlation to test the 4 
hypotheses. The results suggested that the MDD has realigned medical device software 
manufacturing practices, and US medical device companies have gained global 
competitiveness in improving product safety and increasing sales revenue. Key 
recommendations to medical device manufacturers include adopting MDD 93/42/EEC, 
using model-based approaches, and being comprehensive in model use. Adopting the 
MDD will provide positive social change to patients, as human safety improves with 
better product quality while companies experience fewer product recalls. 
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Chapter 1: Introduction to the Study  
Introduction  
The medical devices market in Europe is one of the sectors actively regulated by 
directives (European Commission [EC], 2012). The directive regulating the medical 
devices market is the Medical Devices Directive (MDD) 93/42/EEC, issued on June 14, 
1993, by the Council of European Communities and took effect on January 1, 1995. The 
MDD 93/42/EEC replaced the earlier directive known as the MDD 76/764/EEC as well 
as amended two other directives, Directive 84/539/EEC and Directive 90/385/EEC, 
previously used to regulate the medical devices market in Europe (Bright, 1999; EC, 
1993).The main objective of this study was to determine the impact of the amendments to 
Medical Devices Directive 93/42/EEC (MDD) on the U.S. medical device software 
industry. The medical device industry is a key component of healthcare systems. 
However, software-containing medical devices are prone to failure and carry inherent 
risks that can cause injury to the patients, the user, or service personnel. Reports of device 
failure and glitches in software have been frequent and exemplified by the high rate of 
recall of medical devices containing software (Halperin et al., 2008). The recall of 
medical devices is a problem that encumbers the health care industry (Halperin et al., 
2008; Maisel, Sweeney, Stevenson, Ellison, & Epstein, 2001). Damaged or contaminated 
medical device may pose life-threatening injuries. According to the FDA, a Class I recall 
indicates that there is a reasonable probability that the use of or exposure to a damaged or 
contaminated product will cause substantial harm or death (FDA, 2014). People who are 
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injured after using or been exposed to a violative product may make products liability 
claims. Regulatory agencies may use the statutory and regulatory process that governs 
product recalls to take action against the manufacturer of a violative product. 
As more medical products have become dependent on embedded software, safety 
regulations for those devices have shifted to the reliability of software systems. The 
European Union (EU) states that a consistent and coherent implementation of the MDD 
with amendment 2007/47/EC (M5) is necessary to ensure human health protection. 
Compliance to the MDD amendment targeting software safety and efficacy is a costly 
venture before a firm receives certification or accreditation to export to European markets 
(Panesar-Walawege, Sabetzadeh, Briand, & Coq, 2010). The recent amendment to the 
MDD by the introduction of M5 tightened the medical device software specifications by 
requiring medical device manufacturers to provide additional documentation to prove 
compliance with further safety and efficacy standards. Nitz (2004) criticized the MDD 
93/42/EEC for burdening the medical device industry with high approval costs and 
causing manufacturers to waste time due to the lengthy approval process. Despite actions 
taken by the EU against nonconforming companies and their products (European 
Council, 2007), the growth of the medical device software industry correlates with good 
health and economic outcomes. 
The global medical devices market is worth approximately $315 billion (Merritt, 
2012). According to researchers at the International Trade Administration (International 
Trade Administration [ITA], 2012), 76% of global medical device use occurs in the 
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United States, Japan, Italy, and France, yet these countries account for only 13.1% of the 
world’s population. The United States has the largest medical device market in the world, 
with an estimated worth of $110 billion, that accounts for approximately 35% of the 
global medical devices market (U.S. Department of Commerce, n.d.). Estimates by Chase 
(2004) indicated that the global market for medical devices was worth $169 billion in 
2000. In the same year, the US market for medical devices was worth approximately $72 
billion and followed by the EU market with an estimated worth of $35 billion. The 
medical devices market in Japan was worth approximately $25 billion while the rest of 
the world accounted for nearly $13 billion of the global medical devices market (Chase, 
2004). 
According to researchers at International Trade Administration (ITA, 2012), the 
growth of the medical device software industry correlates with good health and economic 
outcomes. For example, medical devices containing software have played a critical role 
in reducing the burden of heart disease and improving the quality of life and health 
outcomes of people with cardiovascular disease. Mortality due to heart attacks decreased 
by 40% between 1980 and 2000, and researchers have linked the decrease to an increase 
in the use of devices such as pacemakers, stents, and defibrillators (Myerburg, Reddy, & 
Castellanos, 2009).  
Other benefits from the medical device industry include multiplier economic 
effects associated with expenditures by the employees in the industry, the procurement of 
goods and services for use as inputs by the firms in the industry, and revenues and 
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earnings arising from the sales and marketing of medical devices. According to estimates, 
employees of medical device firms earn about $24 billion and spend close to $18 billion 
on consumer goods and services (Lewin Group, 2010). The money spent has multiplier 
effects on other sectors of the economy. Medical device firm employees spend the 
remaining $6 billion on taxes, savings, and investments. The data in the Lewin report 
indicated that each job in the medical devices sector generates another 1.5 jobs (Lewin 
Group, 2010). 
However, software-containing medical devices can expose users to risks that may 
cause injury or endanger their health. They may also expose users to hackers and 
breaches of privacy and put their safety at risk. Reports of device failure and glitches in 
software have been frequent and exemplified by the high rate of recall of medical devices 
containing software. Maisel et al. (2001) and Halperin et al. (2008) demonstrated that the 
recall of medical devices is a problem that encumbers health care. Wallace and Kuhn 
(2001) carried out a study of software-containing medical devices recalled between 1983 
and 1997. Wallace and Kuhn identified these recalls by examining the US Food and Drug 
Administration’s (FDA) database of failures of medical devices. According to their 
findings, 2,792 recalls of medical devices with or without software occurred between 
1983 and 1991. Only 165 (6%) of these recalls had computer software. For the entire 
duration (1983-1997), there were 383 recalls of medical devices containing software. 
There was a progressive decline in the number of software recalls between 1994 and 
1996. Eleven percent, 10%, and 9% of the recalls were for medical device software in 
5 
 
1994, 1995, and 1996, respectively, and attributed to the rapid increase in medical device 
software (Wallace & Kuhn, 2001). Most of the failures were due to software malfunction 
(29%) and performance (22%). Sandler, Ohrstrom, Moy, and McVay (2010) reported that 
the FDA made 23 recalls in the first half of 2010. All the recalls were for Class I medical 
devices, and six defective devices had flaws in the software (Sandler, Ohrstrom, Moy, & 
McVay, 2010). Overall, the medical device software sector has helped to improve the 
economic well-being of the employees, their families, and the communities. Medical 
device companies usually lead to disposable incomes that are higher than the national 
average, resulting in higher demand for consumables and other goods, and that lead to the 
creation of more jobs (Lewin Group, 2010). 
This introductory section provided a description of the research problem. The 
following sections briefly summarize research literature as it related to the scope of the 
current study, as well as a description of different aspects of the research problem 
addressed in the study and the gap in knowledge. The purpose of the study contains an 
indication of the mixed methods paradigm, as well as a description of the study 
independent, dependent, and covariate. 
This introductory chapter provided general information about the current study. 
Chapter 1 provides the background that undergoes evaluation in subsequent chapters to 
detail how complying to changes in the MDD 93/42/EEC affects firms’ net income and 
share stock prices, training and recruitment needs, project expenditures, and device recall 
incidents. The chapter includes the problem, the nature of the study, the purpose of the 
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study, it significance, the research questions, and hypotheses to guide subsequent 
chapters. The chapter also includes the scope, limitations, delimitations, and assumptions. 
The end of chapter includes a summary of the main points of the chapter.  
Chapter 2 contains the literature review, which is a critical evaluation of literature 
on medical device software and its regulation. Chapter 3 includes a discussion on the 
methods used to conduct the study, while Chapter 4 contains the results and their 
analysis. Chapter 5 contains a discussion of the findings, as well as the conclusions and 
study recommendations. 
Background of the Problem 
The European Union (EU) is a regional economic and political bloc comprised of 
27 nations in Europe. Some of the member states of the EU are Italy, Hungary, Austria, 
Ireland, Belgium, Germany, Bulgaria, France, Denmark, Finland, Cyprus, Estonia, the 
Czech Republic, and Cyprus. Others are the United Kingdom, Latvia, Portugal, Sweden, 
Lithuania, Spain, Poland, Slovenia, Luxembourg, Netherlands, Romania, Malta, and 
Slovakia (EU, 2012).  
The partnership between these countries has evolved over time, culminating in the 
abolition of border controls and the creation of one large market with the euro as the 
common currency (EU, 2012). Treaties, which are the primary legislation, form the 
ground rules that govern all the activities of member countries, and the countries must 
adhere to them. Secondary legislation consists of decisions, directives, regulations, 
recommendations, and opinions formulated from the objectives and principles outlined in 
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the treaties (EU, 2012). Regulations are binding legislative acts applied in their entirety in 
all the member states of the EU. Directives are types of legislation that stipulate a goal 
that all member states of the EU must attain. However, the member states have flexibility 
to decide how they are going to attain these goals (EU, 2012).  
The Council of European Communities gave member states five years, starting in 
December 1, 1994, to put devices that conformed to earlier directives (Directive 
76/764/EEC, Directive 84/539/EEC, and Directive 90/385/EEC) into the market or into 
service, after which all products on the market or in service must have met the 
requirements of MDD 93/42/EEC. For devices meeting the requirements of Directive 
76/764/EEC, member states were able to have them in market or in service until June 30, 
2004. Amendments to the MDD 93/42/EEC made in 2007 led to a new standard for 
governing the medical devices market in Europe known as the MDD 2007/47/EC, where 
EC refers to the European Commission. The MDD 2007/47/EC came into operation 
March 21, 2010, and introduced changes in MDD 93/42/EEC, Directive 90/385/EEC, and 
Directive 98/79/EC (EC, 2007, 2012). 
The International Electrotechnical Commission (IEC) also instituted a new system 
controlling software-containing medical devices. The EN/IEC 62304 system is 
synthesized under an EN, or European Standard, designation. It is the world standard for 
managing the software development life cycle. The EN/IEC 62304 standard has become 
a global benchmark for managing the software development life cycle; however, 
implementation of the standard has been slow. This is due to unintended consequences 
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including its effect on costs to manufacturers of medical devices, the competitiveness of 
companies, and the effect on employee training and hiring requirements. Implementation 
of the MDD 93/42/EEC requirements means that the EN/IEC/62304 requirements have 
also been met (Hall, 2010).  
United States medical device manufacturers selling or marketing their products in 
the EU must comply with the MDD 93/42/EEC requirements. Nitz (2004) criticized the 
MDD 93/42/EEC for burdening the medical device industry with high approval costs and 
causing manufacturers to waste time due to the lengthy approval process. In terms of 
financial performance, the investment into research and the cost of compliance to 
EN/IEC/62304 is expensive. Before a firm receives certification or accreditation to export 
to European markets, safety and efficiency compliance to the MDD 93/42/EEC 
amendment targeting software is a costly venture (Panesar-Walawege et al., 2010). The 
recent amendment to Directive 93/42/EEC by the introduction of M5 (2007/47/EC) 
tightened the medical device software specifications by requiring medical device 
manufacturers to provide additional documentation to prove compliance with further 
safety and efficacy standards. This amendment further empowered oversight authorities 
to take firm action against nonconforming companies and their products (European 
Council, 2007). Failure to comply with MDD 93/42/EEC will prevent US medical device 
manufacturers to export to European markets, and to compete in European markets with 
other firms meeting the MDD requirements. The ultimate objectives of these directives 
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were to ensure medical devices produced and used in the EU region not only are effective 
and safe but also provide more benefits to users.  
According to Gross and Loh (2006), the growth of the medical device software 
industry correlates with good health and economic outcomes. Each job in the medical 
devices sector generates another 1.5 jobs (Lewin Group, 2010). The total global demand 
for medical devices was approximately $307.7 billion in 2012 (Espicom, 2012). The 
United States and Europe accounted for 45% and 30% of this demand, respectively (Frost 
& Sullivan, 2010). This study included a concurrent mixed method study and involved 
administering questionnaires to a convenient sample of professionals from companies in 
the medical device software industry.  
Problem Statement 
This study involved examining how amendments to the MDD 93/42/EEC have 
affected the competitiveness of the U.S. medical device software industry and their 
impact on the safety and efficacy, employee training and recruitment of medical devices 
manufactured in the United States. Wallace and Kuhn (2001) conducted a study of 
software-containing medical devices recalled between 1983 and 1997, and documented 
2,792 medical devices recalls between 1983 and 1991. According to Geissler (2010), 
balancing safety and effectiveness with security and privacy was a significant challenge 
facing the development of effective and safe medical device software. Although the 
MDD 93/42/EEC has helped to make the devices safer, researchers and medical devices 
manufactured have not done much to investigate the effect of the amendments to the 
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MDD 93/42/EEC on the market share, employment, and earnings and profitability of US 
exports to European markets. Databases searched were the Institute of Electronic and 
Electrical Engineers (IEEE) database, the Science Direct (Elsevier) database, the Wiley 
Online Library, Google Scholar, Science by the American Association for the 
Advancement of Sciences, Oxford University Press database, Wiley-Blackwell, Springer 
Link, ProQuest, EBSCOhost, Sagepub, and JSTOR. The main objective of this study was 
to determine what impact the MDD 93/42/EEC has had on medical device software in the 
United States.  
Purpose of the Study 
The purpose of this concurrent mixed method study was to examine the impact of 
the EU MDD 93/42/EEC on the U.S. medical device software industry. Specifically, the 
study involved determining how amendments to the directive have affected the 
competitiveness of U.S. medical device software companies, the safety and efficacy of 
medical device software, employee training and recruitment. The mixed method study 
involved both quantitative and qualitative techniques. The qualitative technique involved 
systematic literature review, interviews, and case study. This study includes the 
justification for safety regulations to guide the design and application of the device 
software in pursuit of better product quality, efficacy, and reliability. For many U.S. 
medical device manufacturers, regulatory compliance is a considerable effort that 
requires a great deal of training and expertise, all of which could be expensive. Under the 
cost aspects, the MDD 93/42/EEC revisions are somewhat uncertain about the 
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fundamental cost issues of the medical devices because the wordings are ambiguous 
(Andersson, 2012). This study examined the impact of the MDD 93/42/EEC on the 
variable costs of employee training and recruitment trends with evidence collated from 
the interviewees. Compliance with the MDD 93/42/EEC has improved the business 
results of many companies. Adopting the MDD contributes to social change as human 
safety improves with better product quality, efficacy, and reliability, while companies 
experience fewer product recalls. Chapters 4 and 5 contain the results of the findings. 
Nature of the Study 
The nature of this study was a concurrent mixed method study. The mixed method 
study involved both quantitative and qualitative techniques. Qualitative research was 
suitable for this study because it involves narratives instead of numerical data and is 
based on explanatory rather than exploratory inquiry. However, the results obtained from 
qualitative studies are not generalizable to entire populations (Maylor & Blackmon, 
2005). Quantitative research was suitable for this study because I gathered numerical 
data, thus enabling the use of statistical techniques to look for relationships between 
defined variables.  
The study examined the impact of the MDD 93/42/EEC on the competitiveness of 
the U.S. medical device software industry and their impact on the safety and efficacy, 
employee training, and recruitment with evidence collated from the interviewees. The 
dependent variable was compliance to the changes in the MDD, and the independent 
variables were individual company net income and stock share prices, training and 
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employment needs, compliance project costs, and recall statistics. This study had four 
main questions and hypotheses addressed by interviews, and a case study of five medical 
device manufacturers purposively selected. Through case studies, I was able to conduct a 
first-hand examination of how EU medical directive influences medical device software 
firms in the United States. I used audiotapes to record the interviews. I analyzed the 
qualitative data using thematic descriptions along the study questions and hypothesis and 
summative evaluation. I tested hypotheses using Analysis of Variance (ANOVA), at a 
95% confidence level and gathered data from 56 respondents. The statistical software 
SPSS was suitable to analyze the collected data (SPSS Inc., 2008). I provided a 
comprehensive discussion of the research design in Chapter 3. 
Significance of Study 
The study is important because it demonstrates the impact of the amendments to 
Medical Devices Directive (MDD) 93/42/EEC on the U.S. medical device software 
industry. Many empirical studies have examined relationships between economic impact 
of the medical technology industry, healthcare reform, medical devices, dimensions of 
quality, and safety and effectiveness of medical devices. Pfleeger (2012) proposed a look 
at safety and effectiveness of software in medical devices. Peck (2011) investigated 
medical devices security. Werling (2010) analyzed the impact of healthcare reform on the 
medical device sector. On the other hand, there is little evidence of the relationship 
between Medical Device Directive (MDD) 93/42/EEC and performance of U.S. medical 
device companies.  
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The study offers further support for a fundamental premise, which is that good 
employee training is necessary to a firm’s success. However, because hiring a workforce 
with previous experience with the MDD 93/42/EEC is often challenging, employees who 
lack experience with could develop products that do not meet regulatory requirements, 
thus posing safety or security risks to the users or the patients. Recruiting strategies are 
critical in attracting the right talent. A successful training can increase products 
efficiencies and safety, resulting in financial gain. 
My dissertation addresses the gap in the current literature on how amendments to 
the MDD 93/42/EEC have affected the competitiveness of the U.S. medical software 
industry and their impact on the safety and efficacy, employee training and recruitment of 
medical devices manufactured in the United States. The results of this study help reduce 
the gap in the literature and increase the certainty for the safety of medical products 
dependent on embedded software. I hope to provide the EU Commission Services input 
to improve the implementation of EN/IEC/62304. Recommendations address legislative 
weaknesses in the MDD and hence reduce software development costs; reduce time to 
market; enhance the interoperability, safety, and privacy of medical devices; and enhance 
compliance with the regulatory requirements. In addition, the recommendations made 
may help to reduce off-label use and software recalls, which may enhance the 
competitiveness of the medical device software industry in the United States.  
This study evaluated economic and social changes in the medical device industry 
with regard to providing safe and viable solutions to the health care system. Overall, the 
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findings in this study help close the literature gap, as the various medical device 
manufacturers enhance safety and performance of the embedded software. Furthermore, 
the outcomes of the study are applicable to various medical device manufacturers 
targeted by the EU MDD (Panesar-Walawege et al., 2010). This study will help to 
promote the mission of social change by developing solutions to the problems associated 
with medical devices, thereby helping to improve their effectiveness and the safety 
factors that will enhance the health and safety of the users of these devices. There is a 
positive association between enhanced health and safety and better social conditions.  
Research Questions and Hypotheses 
The following research questions guided the study: 
Research Question 1: What is the impact of changes to the MDD to the net 
income of medical device software firms in the United States? 
H10: There has not been a decrease in the net income of medical device software 
firms in the United States due to changes to the MDD. 
H1a: Changes to the MDD have led to a significant decrease in the net income of 
medical device software firms in the United States. 
Research Question 2: What is the impact of changes to the MDD on the 
employees training costs for each EN/IEC 62304 compliant software year of medical 
device software firms in the United States? 
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H20: Changes to the MDD have not significantly reduced the employee training 
costs for each IEC62304 compliant software year of medical device software firms in the 
United States. 
H2a: Changes to the MDD have significantly reduced the employee training costs 
for each EN/IEC 62304 compliant software year of medical device software firms in the 
United States. 
Research Question 3: What is the impact of changes to the MDD on the project 
costs for each EN/IEC 62304 compliant software year of medical device software firms 
in the United States? 
H30: There has not been a significant decrease in the project costs for each 
EN/IEC 62304 compliant software year of medical device software firms in the United 
States due to changes to the MDD. 
H3a: Changes to the MDD have led to a significant decrease in the project costs 
for each IEC62304 compliant software year of medical device software firms in the 
United States. 
Research Question 4: What is the impact of changes to the MDD on the recall rate 
of medical device software firms in the United States? 
H40: There has not been a significant decrease in the recall rate of medical device 
software manufactured by firms in the United States due to changes to the MDD. 
H4a: Changes to the MDD have led to a significant increase in the recall rate of 
medical device software manufactured by firms in the United States. 
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Theoretical and Conceptual Framework of the Study  
Wallace and Kuhn (2001) carried out a study of software-containing medical devices 
recalled by examining the FDA’s database of failures of medical devices. According to 
their findings, 2,792 recalls of medical devices occurred between 1983 and 1991. Over 
the past 20 years, both the United States and the EU have passed legislative reforms in 
response to the increased numbers of medical incidents and malfunction. These reforms 
have had the goal of making medical devices safe and effective. (EU, 2012; FDA, 2011). 
Recent high-profile cases where too many unsafe medical devices, such as hip prosthesis 
or Poly Implant Prosthèse breast implant for instance, have brought into question the 
effectiveness of current regulations. To date, failure to comply with these regulatory 
requirements could results strong sanctions (Great Britain, 2012). However, Medical 
device manufacturers often perceived these regulatory requirements as government-
induced restrictions on international trade. U.S. small and medium-sized enterprises 
(SME) in the healthcare highlighted a lack of mutual recognition of licensing as a 
problem that affect exporting to the EU. United States SMEs and related industry 
associations reported many EU trade barriers, particularly those related to standards and 
regulations, affect their exports (O'Laughlin, 2014). 
The European Council published new methodology of harmonization designed to 
remove trade barriers within the EU. The result was three new directives governing the 
safety and performance requirements of medical devices adopted as the benchmark 
standard for medical devices all over the world. These new directives require that 
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manufacturers provide evidence that support the safety and efficacy of the medical 
devices. The following three directives form the EU regulatory framework for medical 
devices: 
1. Directive 90/385/EEC for active implantable medical devices, amended by the 
Directive 2007/47/EC. 
2. Directive 93/42/EEC for medical devices, amended by the Directive 2007/47/EC. 
3. Directive 98/79/EC for in vitro diagnostic medical devices. 
The MDD 93/42/EEC is the main directive regulating the medical devices 
industry in the EU. Compliance to the MDD 93/42/EEC amendment targeting software 
safety and efficacy is a costly venture before a firm receives certification or accreditation 
to export to European markets (Panesar-Walawege et al., 2010). The recent amendment 
to Directive 93/42/EEC by the introduction of M5 (2007/47/EC) tightened the medical 
device software specifications by requiring medical device manufacturers to provide 
additional documentation to prove compliance with further safety and efficacy standards. 
Because of the medical device regulations, medical devices companies have more than 
one overhead with indirect costs. Medical device regulations require that companies 
provide training on medical device regulations and standards to their employees to ensure 
regulatory compliance (CENELEC & ISO, 2012). U.S. SMEs argued before the U.S. 
International Trade Commission that complying with EU regulations was costly for all 
firms, and that such costs did not take firm's size or export revenue under consideration, 
and that these regulations affect their exports (O'Laughlin, 2014).  
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To understand how the 2007/47/EEC amendment to the MDD 93/42/EEC has 
affected the competitiveness of the U.S. medical device software industry, it is necessary 
to examine two performance levels, quality performance and business performance. 
Quality performance measurements focused on the recall rate of medical devices, training 
and recruitment needs, while business performance was assessed using compliance 
project costs, company net income and stock share prices. Business performance was 
important to verify whether changes to the MDD have affected the project costs and the 
net income of medical device software firms in the United States. Quality performance 
was important to verify whether changes to the MDD have affected the recall rate of 
medical device software firms in the United States. The independent variable was 
compliance to the changes in the MDD 93/42/EEC, and the dependent variables were the 
competitiveness parameters affected by the directive: (a) individual company net income 
and stock share prices, (b) compliance project costs. Recall statistics, training and 
recruitment needs were the mediator variables as shown in Figure 1. According to Baron 
and Kenny (1986), “a given variable may be said to function as a mediator to the extent 
that it accounts for the relation between the predictor and the criterion.”(p. 1176).  
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Figure 1. Study conceptual framework. 
Definitions of Terms 
Article 1 of MDD 93/42/EEC contains the definitions and scope of the directive 
and states that the stipulations in the directive are to govern the manufacture and sales of 
medical devices and their accessories.  
Article 13 stipulates that at least one qualified person be available in each 
company to lead compliance with the regulations. The qualified person must have 
specified academic achievement and not less than 5 years of experience in the medical 
device industry (Andersson, 2012). 
The CE marking: this term indicates a product’s compliance with all relevant 
essential requirements specified in the applicable EU directive(s) and if stipulated in the 
directive(s), had it examined by an independent notified body (EC, 2014). 
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Compliance: This term means to abide by the rules, regulations, policies, laws, or 
values generated from a consensus process or body of authority such as the EU in 
relevance to this study (Hall, 2010). 
Directive: This term refers to a decree or order that stakeholders must follow 
because there are terms and conditions applicable for nonconformance, for example to 
MDD 93/42/EEC (EC, 1993). 
Intended purpose: This term refers to the intended use for the device according to 
the data supplied by the manufacturer on the labeling, in the instructions, or in 
promotional materials (EC, 1993). 
Manufacturer: This term refers to the natural or legal person with responsibility 
for the design, manufacture, packaging, and labeling of a device before it goes on the 
market under the manufacturer’s name, regardless of whether the manufacturer or a third 
party carries out the operations (EC, 1993). 
Medical device. Any implement, apparatus, machine, object, or any other item 
usable in combination or singly and usable by human beings to diagnose, prevent, 
monitor, treat, or alleviate a disease; to diagnose, prevent, monitor, treat, or alleviate or 
compensate for a disability or injury; or to control conception or investigate, replace, or 
modify an anatomical or physiological feature (EC, 1993). The definition includes any 
software required for the proper operation of the device.  
Placing on the market. Making a device other than a device intended for clinical 
investigation available for the first time in return for payment or free of charge, with a 
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view to distribute or use it on the EC market, regardless of whether it is new or fully 
refurbished (EC, 1993).  
Product recall. The process in which a device manufacturer notifies consumers or 
users of its products to return devices because they have failed a test such as quality, 
reliability, safety, or durability and hence pose a risk to human health or lives (Sandler et 
al., 2010).  
Patient safety. Prevention of human harm to patients. (Aspden & IOM, 2004). 
Quality. The degree to which health services for people increase the probability of 
desired health outcomes and are consistent with current professional knowledge (IOM & 
Lohr, 1990). 
Reliability: The probability that a product, system or service will perform its 
intended function adequately for a specified period of time, operating in a defined 
operating environment without failure (Crossley, 2008). 
Performance: The metric against which a complete action is compared (ASQ, 
2014). 
Software item: Any identifiable part of a software product, including the top and 
bottom levels (IEC & ISO, 2006). 
Software system: A subsystem of the medical device or a medical device by itself 
(IEC & ISO, 2006). 
Software unit: The lowest achievable level of software decomposition for the 
purposes of testing or software configuration management (IEC & ISO, 2006). 
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Assumptions 
I made the following assumptions in this study: (a) U.S. medical device 
manufacturers comply with Article 2 and Article 3 of the MDD 93/42/EEC. During this 
study, I assumed that U.S. medical device manufacturers selling medical devices in the 
EU comply with Article 2 of the MDD 93/42/EEC, which regulates how to place medical 
devices into the market and how to put them into service. The regulations state that EU 
member states should take all the requisite steps to make certain that only those products 
shown to be effective and safe go into market and into service. Furthermore, I assumed 
that these medical device manufacturers meet the requirements of Article 3 of the 
MDD/93/42, which defines the essential requirements that medical devices must adhere 
to before they can enter the EU market. These essential requirements are in Annex 1 of 
the directive and include general requirements and requirements guiding the design and 
construction of the devices. I also assumed that the findings from the case studies and the 
views expressed by the interviewees would provide a generalization of the medical 
device industry status. Therefore, the challenges and successes of the companies 
complying with the changes in MDD 93/42/EEC are shared and replicable with a fair 
degree of confidence. 
Limitations 
The limitations of this study were the research methodology and the use of 
available data. When considering the study findings, a primary limitation of this study 
was the potential limitation of purposive sampling. While purposeful sampling actively 
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seeks to enrich the data by including participants with a specific type of experience or 
understanding of the research topic, the potential disadvantage is the possibility to focus 
the data collection on the experience of the participants, thus missing the broader picture. 
The study included stringent inclusion and exclusion criteria to select the respondents, 
which has led to a limited sample size. A primary limitation of this study was the 
potential for selection bias and response bias, which might occur if respondents answer 
questions in a way that is not consistent with their true beliefs. The survey administration 
was anonymous to help reduce such a bias. The basis of the responses collected from the 
survey questionnaires was the opinions of the interviewees. These opinions constituted a 
threat to the overall credibility of the study. Triangulation helped to increase the validity 
and the reliability of the study results. The duration of interviews with the representatives 
of the two organizations might have limited the findings in the study. A threat to the 
external validity may exist due to the convenience method of sampling and the use of 
archival data. 
Based upon the results of this study, I was not able to reject or accept some 
hypotheses. A plausible explanation for the lack of significant results was the small 
sample size. Because of the lack of existing research in this area, the sample size further 
limited this study. The small sample size resulted from the inability to recruit additional 
participants. 
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Scope and Delimitations 
I limited the scope of this research to studying the impact of the EU MDD on 
medical device software in the United States. The study included only those firms 
manufacturing medical devices containing software. The study did not include an attempt 
to determine the effect of the directive on medical devices that do not contain software. 
The respondents were from firms within a certain geographical region, which may have 
led to selection bias with a possible negative effect on validity.  
Summary and Transition 
The European Council published new three new directives governing the safety 
and performance requirements of medical devices. These new directives require that 
manufacturers provide evidence that support the safety and efficacy of the medical 
devices. This chapter contained an introduction to the study topic and a background that 
undergoes evaluation in subsequent chapters to detail how complying to changes in the 
MDD 93/42/EEC affects firms’ net income and share stock prices, training and 
recruitment needs, project expenditures, and device recall incidents. The nature of this 
study was a concurrent mixed method study involving both quantitative and qualitative 
techniques. The chapter included the problem, significance, research questions, and 
hypotheses to guide subsequent chapters. The chapter also included the scope, 
limitations, delimitations, and assumptions. A primary limitation of this study was the 
potential limitation of purposive sampling. 
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Chapter 2 is the literature review and contains a critical evaluation of the literature 
on medical device software and its regulation. Chapter 3 includes a discussion on the 
methods used in conducting the study, and Chapter 4 contains the results, their analysis, 
and the findings. Finally, Chapter 5 includes my conclusions and recommendations for 
further study. 
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Chapter 2: Literature Review 
Introduction 
The main objective of this dissertation was to determine the impact of the 
amendments to the MDD 93/42/EEC on the United States medical device industry. This 
chapter reviewed the regulations governing medical device software in the United States, 
the EU, as well as in other countries. I examined the medical device software industry in 
the United States using a wide corpus of data from peer-reviewed articles, industry 
reports, studies by government and quasi-government agencies, and books. The aim was 
to describe the elemental features that characterize the industry as well as ascertain the 
competitiveness of this industry while mapping the drivers of growth and the inherent 
challenges. I looked at the competitiveness of the medical device industry broadly with 
reference to markets in other countries such as Japan, Canada, Australia, China, Brazil, 
India, and Member States of the EU. Non-regulatory. I examined the regulatory factors 
affecting the medical device industry in these countries, and outlined the MDD 
93/42/EEC in detail. I conducted the investigation of the impacts of medical devices on 
the economies of these nations and completed the identification of the amendments to the 
Directive, and pointed out the weaknesses of the legislation. I provided a description of 
the outlook of the industry. The literature review serve as a backdrop for the research into 
the impact of the amendments to the MDD 93/42/EEC on the U.S. medical device 
software industry.  
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Literature Search Strategy  
I performed a literature review using a collection of materials from peer-reviewed 
journals, government statistics, databases, online vendors. I used the following databases 
to identify systematic reviews: the Institute of Electronic and Electrical Engineers (IEEE) 
database, the Science Direct (Elsevier) database, the Wiley Online Library, Google 
Scholar, Science by the American Association for the Advancement of Sciences, Oxford 
University Press database, Wiley-Blackwell, Springer Link, ProQuest, EBSCOhost, 
Sagepub, and JSTOR. The Food and Drug Administration (FDA) website, the European 
Union (EU) website, and websites of individual companies manufacturing and 
distributing medical devices were addition source of information. Reference sources used 
included the Cochrane Library and textbooks. The scope of the literature search was 
limited to articles, abstracts, journals, books, theses, conference proceedings, essays, 
news, editorials, perspectives, and review papers relevant to the topic under investigation. 
The search terms that were used to query the databases were medical devices, medical 
device software, medical device recall, medical device safety, medical devices market, 
medical devices outlook, EU medical devices, Europe medical devices, US medical 
devices, Asia medical devices and global medical devices. 
I used the snowballing technique to get more literature. In the snowballing 
method, the bibliography section of relevant journals and texts already identified was 
examined and used to locate useful texts and journals, which were then searched in the 
databases. I used stringent inclusion and exclusion criteria to sort the articles for use. The 
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criteria entailed inclusion of only those articles published in English and dated between 
1974 and 2012. The rationale for setting 1974 as the lower time limit was because the 
MDD/74/64/EEC originated in that year.  
Medical Devices Software: Definitions and Scope 
Medical devices are defined by The Federal Food Drug & Cosmetic Act as 
implements, in vitro reagents, apparatuses, implants, contrivances, or other analogous 
products that are meant for use in the diagnosis, treatment, cure, prevention, or mitigation 
of disease in humans and in animals and are listed in the United States Pharmacopoeia, 
legitimate Formulary, or any addenda to these (FDA, 2011). Medical devices can help 
change human or animal bodily function or structure, but they must not attain their 
primary effect through their metabolism or chemical action (FDA, 2011).  
As opposed to drugs, medical devices do not undergo metabolism in the body and 
do not undergo or mediate chemical reactions. Accessories are not medical devices 
except where the manufacturer has intended it used in combination with a medical device 
to facilitate the attainment of the device’s objective (Global Harmonization Task Force 
[GHTF], 2005). There may be variations in designating certain items as medical devices 
in different countries. Items that have not yet been harmonized and which, therefore, fall 
under this category include spare parts for medical devices, aids used by the handicapped 
and disabled, devices used to diagnose and treat injuries and diseases in animals, and 
gadgets in which human and animal tissue is integrated and which may adhere to the 
definitions above, but are regulated by different rules (GHTF, 2012).  
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According to the European Commission’s MDD 93/42/EEC, a medical device is 
any implement, apparatus, machine, object, or any other item that can be used in 
combination or singly that is meant for use by human beings to diagnose, prevent, 
monitor, treat, or alleviate a disease or to diagnose, prevent, monitor, treat, or alleviate or 
compensate for a disability or injury or to control conception or investigate, replace or 
modify an anatomical or physiological feature. The definition includes any software 
required for the proper operation of the device. The device should not attain its main and 
intended action through metabolic, immunological, or pharmacological effects. In this 
context, accessories are defined as articles that are not devices but are meant to be made 
use of in combination with the medical devices in order that the intended use of the 
device as designed by the manufacturer will be attained. Medical devices also encompass 
in vitro diagnosis devices and custom-made devices (EC, 1993). Presently, the medical 
device sector is versatile and besides the more traditional products such as syringes and 
bandages, it now encompasses modern cutting-edge techniques in the fields of 
bioinformatics, engineered cells, and nanotechnology (Pammolli et al., 2005).  
Classification of Medical Devices 
FDA Classification Schemes 
The Food and Drugs Administration (FDA) classifies medical devices into three 
classes (FDA, 2012b). This classification is based on the probable health risks associated 
with the software-containing medical device and is meant to ensure that the devices are 
not only effective but are also safe (Peña et al., 2007). The three classes are Class I, Class 
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II, and Class III. Class I medical devices are devices which are governed by general 
controls while Class II medical devices are under special controls and stricter regulatory 
controls. Class III Medical Devices are premarket approval (PMA) devices and these 
require a premarket approval before their marketing begins. There is inadequate data 
about these devices to determine their safety or effectiveness. Under this class also are 
devices that potentially present an unreasonable risk of injury or illness or those devices 
that are of critical importance in averting harm to human health (FDA, 2012b).  
Examples of PMA devices include deep brain stimulators (DBS) devices (Peña et 
al., 2007). Class I products have a simple design, are not strictly regulated and are not 
associated with significant risks to the safety or health of users. Crutches are examples of 
Class I medical devices (FDA, 2012b). Class II products are more complex in design, 
tightly regulated and pose minimal risks to the users. Examples of Class II devices are 
magnetic resonance imaging (MRI) systems (FDA, 2012b). Class III products are highly 
advanced, tightly regulated, devices and can cause significant health and safety risks to 
users. Pacemakers and cardiac stents are examples of Class III products (FDA, 2012b).  
The FDA classifies medical devices by categories. These categories comprised of 
codes that reflect the medical specialty of the product. The specialties relate to advisory 
committees that supervise the device regulation. They also include product codes, which 
relate to the function and features of the devices. The FDA has defined 19 medical 
specialties, i.e. Anesthesiology, Dental, Hematology, Pathology, or Radiology (FDA, 2012b). 
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The North American Industry Classification System (NAICS) 
The U.S. Census Bureau does not classify medical devices based on the FDA 
classification system but uses the North American Industry Classification System 
(NAICS). U.S. manufacturers and government use NAICS to classify business the 
American medical industry according to type of economic activity. This system classifies 
medical devices into eight classes as follow: surgical appliances and supplies, surgical 
and medical instruments, electro-medical equipment, in-vitro diagnostic substances, 
dental equipment and supplies, ophthalmic goods, dental laboratories, and irradiation 
apparatus (US Census Bureau, 2012).  
Surgical appliances and supplies. The North American Industry Classification 
System (NAICS) code for surgical appliances and supplies is NAIC 339113. Surgical 
appliances and supplies refer to wheelchairs, artificial joints and limbs, surgical 
dressings, surgical kits, orthopedic appliances, surgical gloves, hydrotherapy appliances, 
rubber medical gloves, stents, and disposable surgical drapes (US Census Bureau, 2012). 
Surgical appliances and supplies form the biggest subsector in the U.S. medical devices 
market. According to ITA (n.d.), surgical appliances and supplies comprise 28% of 
medical devices by value of shipment (VOS).  
Surgical and medical instruments. The NAICS code for surgical and medical 
instruments is NAIC 339112. Surgical and medical instruments include catheters, 
syringes, blood transfusion devices, anesthesia apparatus, hypodermic needles, and 
optical diagnostic apparatus (US Census Bureau, 2012). After surgical appliances and 
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supplies, surgical and medical instruments are the largest subgroup by VOS of medical 
devices in the United States, as they comprise of 26% of these devices (ITA, n.d.). 
Dental goods. Dental goods comprise of dental equipment and supplies and 
dental laboratories. The NAICS code for dental equipment and supplies is NAIC 339114. 
Medical devices under this category include dental chairs, drills, dental hand instruments, 
amalgams, sterilizers, and cements (US Census Bureau, 2012). They form nearly 5% of 
medical devices by VOS (ITA, n.d.).  
Dental laboratories. On the other hand, dental laboratories include orthodontics, 
crowns, bridges, and dentures. The NAICS code for these devices is NAIC 339116 (US 
Census Bureau, 2012). They make up 4% of medical devices in the United States by 
VOS (ITA, n.d.). 
Irradiation equipment. The NAICS code for irradiation equipment is 334517 
(US Census Bureau, 2012). These devices make up close to 8% of medical devices in the 
U.S by VOS and include CT, X-ray, and diagnostic imaging equipment (ITA, n.d.). 
Ophthalmic goods. The NAICS code for ophthalmic goods is 339115. 
Ophthalmic goods include lenses, frames for eyeglasses, and other magnification and 
optical products (US Census Bureau, 2012). They form about 5% of medical devices by 
VOS (ITA, n.d.). 
Substances for carrying out in vitro diagnosis. Substances for carrying out in 
vitro diagnosis form close to 10% of medical devices by VOS and are identifiable by a 
NAICS code of NAIC 325413. They include radioactive, biological and chemical 
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substances used to carry out diagnostic tests using machines, Petri dishes, test tubes, and 
other devices for diagnostic tests (US Census Bureau, 2012). 
Electro-medical equipment. The NAICS code for electro-medical equipment is 
NAIC 334510. Electro-medical equipment form close to 19% of medical devices by VOS 
and include pacemakers, ultrasonic scanning devices, MRI machines, patient-monitoring 
equipment, and patient-monitoring systems (US Census Bureau, 2012). Implantable 
medical devices (IMDs) fall under this category. These devices are used to examine the 
physiological conditions in the body and treat them. They are used to treat a variety of 
conditions such as Parkinson’s disease, diabetes, and cardiac arrhythmias. IMDs include 
neurostimulators, pacemakers, drug delivery systems, and implantable cardiac 
defibrillators (ICDs) (Halperin, Heydt-Benjamin, Fu, Kohno, & Maisel, 2008b). 
EU Classification Scheme 
The European Union assigns medical devices into four classes based on their 
perceived risks to the safety of consumers. These classes are Class I, Class IIa, Class IIb, 
and Class III (Bright, 1999; EC, 2010). Class I devices are not subjected to the premarket 
approval process although they must meet the safety and efficacy guidelines when they 
are being designed, manufactured and labeled (Bright, 1999; EC, 2010). Producers of 
medical devices belonging to Class II, Class III or Class I devices that have sterility 
requirements or measuring functions are required to send a Declaration of Conformity to 
the relevant European Commission (EC) Directives before they can undergo the pre-
market approval process. They are also required to submit particulars about the procedure 
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used to conduct the conformity assessment (Bright, 1999; EC, 2010). Manufacturers of 
devices that are associated with very high risks are required additionally to submit the 
relevant EC Certificates originating from a notified body (World Health Organization 
[WHO], 2003). 
Classification of Medical Devices in Other Countries 
Classification of medical devices in Canada occurs in four classes namely Class I, 
Class II, Class III, and Class IV. Class I devices do not require premarket approval 
although they must meet the requirements for efficacy, safety and labeling (Bright, 1999; 
EC, 2010). Manufacturers of Class II devices need only to declare that their products are 
effective and safe before their introduction into the market. Class III and Class IV 
products are strictly regulated (Bright, 1999; EC, 2010).  
Regional authorities usually grant pre-market certification referred to as 
Todokede to Class I devices in Japan. Regional authorities could also grant pre-market 
certification to Class II and Class III devices if their efficacy and safety has been proven 
beforehand. For devices above Class II to be launched into the market however, the 
central government through the issuance of a license allowing market entry must approve 
them. The Pharmaceutical Administration Law (PAL) was amended recently in a bid to 
streamline the regulation of medical devices and make them in line with the principles of 
GTHF (WHO, 2003).  
The Australian Therapeutic Goods Administration (TGA) requires that all 
medical devices be included in the Australian Register of Therapeutic Goods (ARTG) 
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before they can be market in Australia. Registrable medical devices are subjected to 
premarket evaluation prior to their being allowed in the market. There are also devices, 
which are not regulated as strictly, although they are assessed for safety if concerns have 
been raised with regard to the devices’ risk profile (WHO, 2003).  
In order to harmonize the classification scheme, the Global Harmonization Task 
Force (GHTF) came up with a proposal that would ensure that different countries use the 
same scheme to group the devices based on a common risk assessment approach (WHO, 
2003; GHTF, 2005). The European Commission produced a guidance document that is 
based on the MDD 93/42/EEC Directive on medical devices for use in classifying 
medical devices. This classification system aims at ensuring that manufacturers of 
medical devices apply uniform conformity assessments. It is largely similar to the GHTF 
classification rules (MEDDEV 2.4/1 Rev 9, 2010) (EC, 2010).  
The guidelines require that each medical device meet the minimum requirements 
of the MDD 93/42/EEC and be subjected to the reporting requirements outlined in the 
medical device vigilance system notwithstanding its class. The guidelines also require 
that each medical device with the exception of devices that are designed for clinical 
investigations and those customized to be affixed with a label that has the "Conformité 
Européenne" or CE marking. This CE mark means that the product has conformed to 
European standards and is a declaration that it has satisfied the stipulated regulations and 
provisions contained in the directive (Kreuzer, 1998; EC, 2010). 
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Classification of Medical Devices Based on Function 
Classification of medical devices containing software can occur based on the 
main function of the medical device. Under this scheme, medical device software can be 
categorized as cardiovascular devices, orthopedic devices, diagnostic devices, or general 
hospital devices. Other categories are surgery devices, radiology devices, anesthesiology 
devices, and neuromodulation devices. Cardiovascular devices include pacemakers, 
stents, defibrillators, and cardiac monitors. Orthopedic devices include artificial limbs 
and artificial joints while examples of diagnostic devices are chemistry analyzers. 
Electric wheelchairs are examples of general hospital devices while radiology devices 
include ultrasound imaging systems. An example of an anesthesiology device is the 
anesthesia gas machine (FDA, 2012b).  
Neuromodulation devices include device used in movement disorders and bladder 
control among others. Many devices that perform neuromodulation for movement 
disorders utilize Deep Brain Stimulation for the treatment of dystonia, essential tremor, 
and Parkinson’s disease (Jiang et al., 2011). Neurostimulation is also used to assist in 
bladder control. Urinary retention and overactive bladder symptoms can be minimized 
through the use of medical device software providing neurostimulation for bladder 
control. Drug pumps are implantable devices that help manage pain through 
neuromodulation. They transmit medication for relief against pain to the fluid 
surrounding the spinal cord. They provide relief using a minimum amount of the dose 
that would otherwise have been taken orally. There are also several software-containing 
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medical devices used to perform neurostimulation for gastroparesis. These medical 
devices transmit weak electrical impulses to the lower stomach thereby providing respite 
from emesis and chronic nausea originating from gastroparesis caused by diabetes or by 
unknown mechanisms (Jiang et al., 2011).  
Intrathecal baclofen therapy (ITB) Therapy is a neuromodulation technique that 
involves the delivery of the drug called baclofen to the intrathecal space for the treatment 
of spasticity (Jiang et al., 2011). Neuromodulation devices have also been used to provide 
neurostimulation for psychiatric disorders. Surgically implanted devices that resemble 
pacemakers are used transmit electrical impulses to specific regions of the brain in the 
treatment of psychiatric disorders such as obsessive compulsive disorder (OCD) (Jiang et 
al., 2011). 
Biomimetic implants are also examples of medical device software used in 
neuromodulation. Biomimetic implants are software-containing medical devices that are 
used in the treatment of neurodegenerative illnesses and injuries. Through imitation of 
the biological world, they substitute lost brain pathways. In the ReNaChip project, 
interfacing of a synthetic biomimetic chip with the rain allows the completion of neuronal 
circuits, which are impaired in old age thereby helping in the rehabilitation of behavior 
among the aged people (Silmon, 2010). Other medical devices used in the central nervous 
system include cochlear implants for restoration of impaired hearing, neuroprosthetics for 
impaired movement, and retinal implants for impaired sight. Deep brain stimulation 
(DBS) has also been used in the treatment of Parkinson’s disease, dystonia, tremor, and 
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chronic pain. It works through the replacement of lost brain function in which implanted 
electrodes cause stimulation of the brain but is unsuitable for all neurological conditions 
since it does not have the necessary specificity that would allow the manipulation of local 
circuits in the brain. The biomimetic approach offers more promise in the therapy of 
neurological conditions than DBS (Silmon, 2010). 
Implantable medical devices (IMDs) are devices that have found widespread 
application and are used to monitor and treat physiological conditions inside the body 
(Halperin et al., 2008). Examples of IMDs include insulin pumps, defibrillators, drug 
delivery systems, pacemakers, and neurostimulators (Halperin et al., 2008). According to 
(Hanna et al., 2001), there were more than 25 million Americans in 2001 who depended 
on medical devices for survival. The first IMD was introduced in 1958 (Leavitt, 2010) 
and the number of people in US who currently use IMDs is 1.6 million (Leavitt, 2010). 
Many of IMDs are now linked wirelessly to bedside monitors that transmit information to 
servers that then make this data available to caregivers. The ZigBee wireless standard is 
one of the main protocols used by IMDs in data transfer and transmission (Leavitt, 2010). 
The ZigBee standard is used to specify high-level communication protocols that utilize 
applications which are built on the IEEE 802 standard and which need secure networking, 
extended battery life, and low data rate.  
The U.S. Medical Devices Industry 
According to the United States Department of Commerce (DOC), the United 
States is the largest market for medical devices in the world. The United States market for 
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medical devices is worth approximately $110 billion (U.S. Department of Commerce, 
n.d.). This represented approximately 35% of the global medical device market in 2012. 
Exports of medical devices from the United States exceeded $44 billion in 2012 (U.S. 
Department of Commerce, n.d.). This number increased by more than 7% from the 
previous year. 
The number of medical device companies in the United States was approximately 
6,500 in 2014 (U.S. Department of Commerce, n.d.). Most of these firms were small and 
medium-sized enterprises (SMEs) with more than 80% of the companies having fewer 
than 50 employees (U.S. Department of Commerce, n.d). The percentage of firms in the 
medical device industry with 100 employees was only 15% (ITA, n.d.). The Lewin 
Report put the number of workers employed in the medical devices industry at 422,778 
as at 2008. The total amount of money paid in wages during the year was $24.6 billion 
(Lewin, 2010). The report states that each job in the medical devices sector generates 
another 1.5 jobs. Whereas firms dealing with medical devices were scattered all over the 
country, there were clusters of these firms in particular areas, which are renowned for 
their vibrant biotechnology and microelectronics industries. States such as Minnesota, 
California, Georgia, Michigan, Massachusetts, Pennsylvania, Illinois, New York, and 
Florida had high concentrations of medical device companies. Some of the leading 
manufacturers of medical devices in the United States are Medtronic Inc., Abbott Labs, 
Beckman Coulter, Becton Dickinson, and GE Healthcare Technologies (ITA, n.d.). 
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Porter (2012) provides a list of the leading global manufacturers of medical 
equipment. Fifteen firms alone account for 60% of all global sales of medical devices. 
The market is largely dominated by U.S. companies such as Johnson & Johnson, Baxter 
Scientific, General Electric, Coviden, Becton Dickinson, and Medtronic among others 
and European firms most notably Philips, Siemens, and Braun (Porter, 2012). The 
medical devices industry in the United States has averaged an annual growth rate of 6%. 
Even in the face of the global economic recession, this industry was able to employ 
hundreds of thousands of workers and bring more than 1,700 medical products to the 
market in 2009.  
The impact of the global recession on the medical devices industry was 
significantly less when compared to other sectors of the economy. Whereas employment 
shrunk by 4.7% and manufacturing payroll decreased by 1.4% in 2009, employment in 
the medical devices industry reduced by just 1.1% and the payroll by a mere 0.7%. Sales 
of medical devices rose by 3.05% compared to the 2.8% posted by total product sales in 
2009 (Medical Devices, 2010). 
The industry contributes immensely to the U.S economy. According to ITA (n.d.), 
the medical devices industry employed more than 365,000 people in 2007 with average 
yearly incomes of close to $60,000 (ITA, n.d.). Earnings in the medical devices industry 
are on average $16,000 more than the average national earnings, bearing in mind that the 
average national earnings were $42,000. In Arizona, South Dakota, and Wisconsin, 
earnings in the medical devices industry exceed the national average by more than 50%. 
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The medical technology industry in the United States also pays higher medical premiums 
than other sectors (Lewin Group, 2010).  
The United States medical devices industry remains highly competitive thru 
innovation. The future growth remains positive. By 2013, the value of the medical 
devices market in the United States will be slightly over $120 billion while that of 
Western Europe will be just over $80 billion (Gross & Loh, 2006; Johnson et al., 2007). 
Markets in Asia Pacific, Central and Eastern Europe, and the Middle East and Africa 
Region will be worth about $60 billion, $15 billion, and $5 billion respectively (ITA, 
n.d.). The top export markets for the U.S. medical products are Japan, Netherlands, 
Canada, Germany, Belgium, Mexico, China, Australia, United Kingdom, and France 
respectively. Others are Switzerland, Sweden, Brazil, Korea, and Singapore.  
The surgical appliance and manufacturing segment employs the largest number of 
workers and has the highest amounts of sales in the medical devices industry. According 
to market analysts at the Lewin Group (2010), manufacturers of surgical appliance 
employed about 114,500 persons with a payroll of $6.4 billion and sales totaling $35.3 
billion in 2008. The surgical and medical instruments segment was in second place with 
approximately 109,300 employees. This segment has an annual payroll of $6.2 billion 
and produced sales totaling $33.6 billion (US Census Bureau, 2009; Lewin Group, 2010). 
The electro-medical and dental laboratories segments employed 65,300 and 50,000 
people respectively and their payrolls amounted to $4.8 billion and $1.8 billion 
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respectively. Sales from the electro-medical and dental laboratories segments were $27.6 
billion and $4.7 billion respectively. (Lewin Group, 2010).  
California held the highest number of employees working in the medical device 
industry in 2010. It contributed close to a fifth of all people employed in the industry in 
2010 (Lewin Group, 2010). Other states with the highest number of employees include 
Minnesota, Massachusetts, Pennsylvania, Florida, New Jersey, Indiana, New York, 
Texas, and Wisconsin. The number of people working in the industry increased by 20% 
between 2005 and 2007. However, this rate decreased to 12.5% from 2007 to 2008 
(Lewin Group, 2010). The decline in employment registered in the medical devices 
industry in 2008 was just 1.1% and this was smaller than the 4.8% recorded for the entire 
manufacturing industry in the US (Lewin Group, 2010). 
There has been an increase in the use of medical device software in the past few 
decades. The United States is the world’s largest consumer of medical device software. 
Approximately 1.6 million people in the United States use implantable medical devices 
(IMDs) (Leavitt, 2010). Hegde and Raheja (2010) estimate that the medical device 
market in the US is the largest globally and is worth $91.3 billion dollars. This accounts 
for almost 41% of the total world medical devices market (Hegde & Raheja, 2010). 
According to Sandler et al. (2010), the total number of pacemakers implanted in the 
United States was close to 350,000 while that of ICDs was 140,000 in 2009. Estimates by 
the Freedonia Group (2008) show that the demand for IMDs in the United States will 
increase by 8.3% every year. Demand for these devices will peak at $48 billion by 2014 
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(Freedonia Group, 2008). This growth is expected to occur in the backdrop of reduced 
product recalls arising from enhanced effectiveness and safety. Market research analysts 
at the Freedonia Group also estimated that cardiac implants in the United States will 
growth by 7.3% every year and that the revenues will reach the $16.7 billion mark in 
2014 (Freedonia Group, 2008). 
Growth Trends and Competitiveness of the U.S Medical Devices Industry 
The medical device industry in the United States has continued to post good 
growth. A study by the Lewin Group (2010) indicated a rise of 11.4% in the shipments of 
medical devices manufactured in the United States from 2005 to 2008. However, there 
was a 0.7% decline in the value of aggregate earnings for the industry during the same 
period. This decline was however smaller than the 1.4% decline for the entire 
manufacturing sector. The report by The Lewin Group also shows that the national 
earnings premium for the medical devices industry was 40% and this was more than 
double the national premium, which was just 21%. The higher premium is attributed to 
the highly specialized skills needed in the industry and this is bound to get even higher as 
the industry adopts technologies that are highly advanced. However, the average national 
earnings from some states such as Alaska, Washington DC, Connecticut, Idaho, 
Louisiana, Virginia, and New York are way above those of employees in the medical 
devices industry. The biggest differences are seen in New York and Alaska where the 
average earnings are $56,983 and $39,937 versus earnings of $46,507 and $39,937 for 
employees in the medical devices industry respectively (Lewin Group, 2010). 
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The trade surplus enjoyed by the United States in the medical devices market has 
however declined over the years because of the increase in the value of medical devices 
imported into the country. The majority of the imports into United States include 
products such as surgical gloves and instruments (Johnson et al., 2007). According to 
available statistics by ITA (n.d.), the value of surgical gloves and instruments reached 
61.54% between 2002 and 2007. During the same period, imports of these devices grew 
by more than 2 times. The leading exporter of surgical gloves and instruments into the 
United States is China. There was also growth in the trade of dental equipment over the 
same period. The percentage increase in imports of ophthalmic goods was 59.2% while 
exports grew by 32.7% (ITA, n.d.).  
The competitiveness of the medical device industry has been associated with 
several factors. Increased healthcare spending continues to drive the growth in the 
revenues of medical device software. According to Keehan et al. (2007), healthcare 
spending in the United States in 2008 stood at $2.4 trillion and could reach $4.3 trillion 
mark in 2016. Keehan et al. (2007) estimate that the United States will spend 20% of its 
GDP on healthcare by 2017.Healthcare expenditure in the United States has largely 
contributed to the competitiveness of the medical devices market in the country (Johnson 
et al., 2007).  
According to market analysts at AdvaMed (2004), the United States leads the 
world in the production of medical devices. The investments in R&D, the adoption of 
high-end technology, high quality products, and a good regulatory end development 
45 
 
environment have made the Unites States medical devices industry very competitive. The 
United States maintains a competitive advantage in several other industries such as 
software development, biotechnology, microelectronics, instrumentation, and 
telecommunications that complement the medical devices industry (ITA, n.d.). Growth of 
healthcare expenditure in other markets such as China help fuel the demand for medical 
device software. Factors such as higher life expectancies, enhanced adoption of 
preventative and diagnostic services, and increased emphasis on geriatric care of the 
aging baby boomer generation are factors that drive the costs of healthcare up (Keehan et 
al., 2007; Halperin et al., 2008b).  
Challenges and Drivers of the United States Medical Devices Market 
A number of challenges facing the U.S. medical devices market have been 
identified and these include legislation on healthcare reform, which proposes to tax the 
industry billions of dollars, heightened regulatory oversight, and cost reduction efforts 
(Gross & Loh, 2006). Other challenges are entry barriers in foreign markets occasioned 
by lax intellectual property (IP) laws, counterfeits, and laws that have not been 
harmonized. Reimbursement policies also pose formidable challenges to the U.S. medical 
devices market. Many reimbursement schemes require that the manufacturers submit 
dossiers about the safety, efficacy, and quality of their medical devices. The amount of 
information required is usually burdensome and results in the manufacturers wasting a lot 
of money and time to carry out extra clinical trials, find out the requirements and pay 
extra user fees. Such requirements are put in place with the intention of earning the 
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government income or protecting the local industry. Healthcare reform, access to 
finances and venture capital funds, industry consolidation, product convergence, 
demographics, health information technologies, group purchasing organizations (GPOs), 
and comparative effectiveness are the other challenges facing the medical device 
software industry in the United States (Gross & Loh, 2006; Johnson et al., 2007; Porter, 
2012). 
Healthcare Reform. The Patient Protection and Affordable Care Act was passed 
by the House of Representatives in March 2010 after being approved by the Senate 
earlier on. The effect of this bill on the medical device industry will be widespread and 
varied when it comes into full force (Medical Devices, 2010). One of the salient features 
of the law that has a direct bearing on the medical devices industry is the 2.3% Excise 
Tax to be levied on sales of the devices as from 2013. The tax is tax deductible and this 
means that the effective impact of the tax is nearly 1.5%. The tax is expected to bring in 
$20 billion in taxes over a period of 10 years (Medical Devices, 2010). 
This amount is exclusive of medical devices that are bought by members of the 
public at retail or export sales. The impact of the tax may be small on bigger companies 
such as Abbott Labs while smaller ones such as Boston Scientific may be affected 
greatly. The tax is seen to benefit firms that produce proprietary or unique products since 
they can increase their profit margins. Other beneficiaries of the reform will be 
manufacturers who deal with medical devices that are directly paid for by consumers. 
The reforms are expected to have a positive effect on the sales of medical devices that are 
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used at home. Firms, which are likely to be affected by the tax are those, that produce 
products that are not differentiated and are costly and commodity-type (Medical Devices, 
2010).  
The healthcare reform bill also compels everyone to be insured by 2014 else they will be 
levied penalties. This requirement is projected to add about 32 million people to the 
insurance plans by 2019 with between 12 and 15 million of the new additions joining 
Medicaid. Alongside with this, there is a push for the tightening of the minimum medical 
cost ratios (MCRs) by health management organizations (HMOs) and insurers. This 
means that insurers will likely have more power when it comes to negotiating 
reimbursements and rates with doctors and hospitals. This will obviously have an effect 
on the medical devices manufacturers, as they will be compelled to reduce the costs of 
their products. If this happens, it is likely that the manufacturers will slash their budgets 
for research and development and this will hamper innovation (Medical Devices, 2010). 
The reforms require the firms to make annual reports on “sunshine payments” that are 
made to hospitals or doctors. The manufacturers are now required to adhere to codes of 
conduct that guide such payments (Medical Devices, 2010). 
Reimbursement. According to Porter (2012), reimbursement is a crucial non-
regulatory factor affecting the growth of the medical devices industry in the United 
States. The Veterans Administration and the Department of Health and Human Services’ 
Center for Medical and Medicaid Services (HHS/CMS) administer reimbursement. 
Reimbursement is an important non-regulatory factor since it can influence the demand 
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and price of medical devices. It can also influence the future earnings of manufacturers as 
well as the incentives to create new products (Baumler, 2008). 
Access to Finances and Venture Capital Funds. Most of the firms dealing with 
medical devices in the United States are SMEs. These firms largely depend on venture 
capital funding in order to come up with innovative products that can boost their bottom 
line (Johnson et al., 2007; Porter, 2012). According to ITA (n.d.), the global economic 
recession negatively affected the funding of these businesses by venture capitalists. The 
recession led to the withdrawal of many venture capitalists from the early stages of 
investing and they opted to hold on to their money awaiting the return of better certainty 
asset valuations. According to reports by the National Venture Capital Association 
(NCVA), the total amount of money invested by venture capitalists in third quarter of 
2009 in the medical device industry was $617 million against $890 million invested in 
2008 over the same period (cited in ITA, n.d.). Factors other than the global recession 
that may have contributed to less investment by venture capitalists include the long 
reimbursement periods and the drawn out process of product approval (Gross & Loh, 
2006). 
Industry Consolidation. Mergers and acquisitions are a constant feature in the 
medical devices industry. Usually, small companies, which are unable to draw large 
amounts of resources required to roll out innovative products, usually merge with larger 
companies that have the resources to bankroll such innovations. Such mergers help the 
bigger firms to obtain novel technologies and hence maintain their share of the market. 
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The smaller firms get access to resources that help them to actualize their innovations. 
The global economic recession is one of the factors fuelling increased consolidation of 
companies in the medical devices market (Johnson et al., 2007). In recent times, firms 
such as Medtronic, Covidien and Abbott Labs have consolidated their operations. Other 
forms of consolidation witnessed in the medical devices industry include outsourcing and 
firms combining their profit centers. There have also been a number of joint ventures 
between firms located in different countries. Notable examples include the collaboration 
between firms in China and those in United States. Such operations not only enhance 
efficiency but also lead to technology transfer and open up new markets for companies. 
This acts as a driver for the growth of medical devices companies (Gross & Loh, 2006; 
Johnson et al., 2007; Porter, 2012). 
Product Convergence. Product convergence is an important non-regulatory 
factor affecting the medical devices industry. The convergence of the products of 
biotechnology and medical devices portend hope that medical devices can be used as 
delivery systems for these biotechnological products. Convergence between products of 
nanotechnology and medical devices can enhance the growth of the medical devices 
market (ITA, n.d.). 
Demographics. Demographics are significant drivers for the growth of medical 
device companies. According to Johnson et al. (2007), one of the most important 
demographic that continues to shape the medical devices industry is aging. The increase 
in the average age of citizens both at home and in foreign countries has opened up a big 
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market comprising of senior citizens and companies are rushing in to serve the health 
needs of this burgeoning population. The growth in the population of senior citizens has 
also led to growth in home healthcare (US Census Bureau, 2009). According to Gross 
and Loh (2007), home healthcare is one of the segments of the medical device industry, 
which are growing at a very fast rate. As such, many companies are focusing on the 
production of highly advanced medical devices that patients or unskilled caregivers can 
use at the patients’ homes (Gross & Loh, 2007). 
Health Information Technologies. The U.S. government currently fosters the 
increase use of IT in health, in order to boost the use of medical devices. The American 
Recovery and Reinvestment Act (AARA) allocated $19 billion in 2009 for the promotion 
of electronic health records use and for creating boards that would formulate standards 
and policies that would govern the use of IT in health. The Office of the National 
Coordinator for Health IT (ONC) under the HHS has also played an important role in 
drafting rules that govern the use of electronic health records in a consequential manner. 
In light of these, the medical device industry plays an increasingly pivotal role in the 
utilization of health IT (ITA, n.d). 
Group Purchasing Organizations (GPOs). Group purchasing organizations 
(GPOs) act on behalf of healthcare provider cooperatives to negotiate contracts with 
health suppliers. According to Rasmussen (2002), the economic recession has enhanced 
the role of GPOs since many care providers resorted to cost-cutting measures. In order to 
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save the hospitals money, the GPOs look for those medical devices that are cost-effective 
(Rasmussen, 2002). 
Comparative Effectiveness. Comparative effectiveness refers to the relative 
advantages conferred by a particular system as compared to other similar systems. An 
increase in the costs of healthcare is expected to lead to increased use of comparative 
effectiveness where research is carried out to compare the clinical efficacy of various 
devices in order to use solutions that are not only effective but also less costly (Porter, 
2012). 
The European Union Medical Devices Market 
The European Union forms the largest market for medical devices after the United 
States. France, Germany, Italy and the U.K. form the largest markets for medical devices 
in the EU. Most exports of devices manufactured in the United States are to the EU. In 
2008, the United States exported medical devices worth $13.8 billion (ITA, n.d.). 
Leading manufacturers of medical devices in Germany are Braun and Siemens while 
Phillips Electronics is a leading manufacturer in Netherlands. Covidien is a leading 
manufacturer of medical devices in Bermuda (Johnson et al., 2007).  
Factors that have made EU an attractive market for medical devices include a large and 
aging population. Besides, many countries in Western Europe boast of mature and stable 
economies, which have consistently performed well on the economic front. This has 
provided a good market for medical devices. Estimates show that the device markets in 
most of the western European countries will experience steady growth. There are many 
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multinationals specializing in medical devices, which have set up shop in these countries 
in order to benefit from the relatively good market (Gross & Loh, 2006).  
Regulations have also contributed to the competitiveness of the medical devices 
market in Europe. The Medical Device Directives (MDD) regulates the medical devices 
market in EU (Bright, 1999). These regulations were formulated on the basis of globally 
accepted standards and were amended to increase the threshold for “clinical evidence” as 
well as empower the authorities so that they can be better placed to put in place stricter 
mechanisms for ensuring that only safe, effective and authorized devices are on sale. The 
large per capita income of many European countries has played a big role in enhancing 
the growth of the medical devices industry (Bright, 1999; Cookson & Hutton, 2003). 
Another factor that has worked to the advantage of western European countries is that 
they are located near the emerging markets of eastern and central Europe. The U.S. is the 
leading foreign supplier of medical devices in this market (Gross & Loh, 2006; Porter, 
2012). In Eastern and Central Europe, the market for medical devices is much smaller but 
it is forecast to expand. The major supplier of medical devices in this region is Russia 
while the leading foreign supplier is Germany (Johnson et al., 2007). 
China’s Medical Devices Market 
China has experienced tremendous economic growth over the past few decades. 
The strong economic growth combined with a large spending class has fuelled the growth 
of a big market for medical devices (Gross & Loh, 2006). In addition, healthcare reforms 
have also opened up opportunities in the medical device market. The U.S. is China’s 
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largest supplier of medical devices (Liu & Pecht, 2010). The value of exports from the 
US to China in 2008 was approximately $1.5 billion and they are expected to increase at 
a rate of 5%-10% every year (Gross & Loh, 2006). However, factors such as 
unpredictable regulatory environment, widespread corruption, laws that do not effectively 
safeguard intellectual property (IP) and massive counterfeiting, and policies that are tilted 
against foreign players diminish the attractiveness of this market (Luo, 2000).  
The Chinese medical devices market is worth approximately $5 billion (ITA, 
n.d.). Locally, the country is self-sufficient in the production of low-end medical devices 
such as drapes and gowns, sponges, and dressings. It imports most of high-end medical 
devices. The Chinese market is still small as it only makes up about 5% of the global 
demand whereas it has 20% of the global population. In recent years however, the 
Chinese market has experienced double-digit growth. Estimates indicate that the market 
will expand at an annual rate of 15% for the next 10 years. This expansion could propel 
the country to the second largest market for medical devices in the world by 2020 (Gross 
& Loh, 2006). 
Features of the Chinese healthcare system that have significant impact on the 
country’s medical devices industry and affect the imports of these devices have been 
discussed by several authors. The country’s hospital system is one of the factors that 
continue to impact negatively on China’s medical devices industry. The number of 
private hospitals in china is small compared to that of public hospitals (Gross & Loh, 
2006). According to Xinhua (2010), private hospitals are 5,736 in number and make up 
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just 29% of hospitals in the country. The rest of the hospitals are more than 14,000 in 
number and are public hospitals run and managed by the country’s Ministry of Health 
(MoH) and other government agencies. There are three classes of hospitals in China: 
class I, class II, and class III. The quality of healthcare provided, the medical devices 
used, and the services on offer vary across the three classes. Class I hospitals provide 
comprehensive healthcare and usually make use of advanced medical devices. The 
number of beds in these hospitals usually exceeds 500. There are about 1,000 such 
hospitals in China. Class II hospitals are about 5,000 in number, are medium in size, 
operate in cities, districts, or counties and have between 100 and 500 beds. Class I 
hospitals are very limited in the type of services that they provide. Such hospitals are 
about 12,500 in number and they normally operate in villages or small towns and have 
old equipment (Yip & Eggleston, 2001). 
The poor healthcare infrastructure has considerably affected the growth of the 
medical devices market in China. Cognizant of this state of affairs, the Chinese 
government plans to refurbish or build some 29,000 clinics and 3,000 hospitals in China. 
The plans will lead to an increase in the number of beds as well as better infrastructure 
including new equipment. This plan can boost demand for medical devices in the 
country. An uptake of low-end devices is projected to rise due to the expansion of 
hospitals and improvement of the hospital system (Liu & Pecht, 2009; Merritt, 2011).  
Majority (70%) of the Chinese are rural dwellers (Shi, Liu, Zhang, Lu, & Quan, 
2008). A report by Epsicom Business Intelligence (Epsicom, 2006) reveals that close to 
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87% of the rural population in China paid for their medical costs out of pocket in 2000 
and that 75% do not have medical insurance. According to Merritt (2011), there were 
about 700 million in China with no health insurance coverage in 2006. To increase the 
number of people residing in the rural areas who are covered by medical insurance, the 
Chinese government reformed the New Cooperative Medical Scheme (NCMS). Other 
health insurance schemes in the country are the Urban Employee Basic Medical 
Insurance (UEBMI), which targets employed people living in the urban areas, and the 
Urban Resident Basic Medical Insurance (URBMI), which targets people who live in 
urban areas but are not formally employed. There are also medical programs financed by 
taxes and which target the poor in both rural and urban areas (Yip & Eggleston, 2001; 
You & Kobayashi, 2009).  
To further reform the healthcare system in the country, the Chinese government 
has announced plans to harmonize the different insurance schemes as well as introduce 
insurance premium subsidies. These efforts are expected to increase health insurance 
coverage to 90% of the country’s population. By increasing health insurance coverage to 
700 million more people, the demand for medical devices in the country will indubitably 
increase (You & Kobayashi, 2009; Cao, Shi, Wang, & Dong, 2012). The low coverage of 
the population has negatively affected the growth of the medical devices industry in the 
country. This is however bound to change as the country has embarked on an ambitious 
reform program that seeks to have 90% of its citizens covered by medical insurance by 
2020 (Cao et al., 2012; You & Kobayashi, 2009). This reform program promises to open 
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up more opportunities for manufacturers of medical devices not just in the country but 
also throughout the world (You & Kobayashi, 2009).  
Widespread corruption, high taxes, and the collapse of the medical cooperative 
movement have also removed the sheen off the Chinese medical devices market (Gross & 
Loh, 2006). Demographics of the country will influence the direction of the country’s 
medical devices market. There are presently more than 160 million people in China 
whose are 60 years older. This population is projected to increase to 240 million by 2020. 
The aging population presents new health challenges that provide opportunities for the 
medical devices industry. With the increase in the population of the aged, it is expected 
that incidences of stroke, cancer, and cardiovascular diseases will rise. Estimates show 
that patients with cardiovascular diseases are increasing by a factor of 20-30% every year 
(Shi et al., 2008; Sun et al., 2011). 
Reimbursement is one of the main factors affecting the medical devices industry 
in China. The Chinese government has put in place several reimbursement schemes in a 
bid to restrict the prices of medical devices. The limited amount of health insurance funds 
has necessitated this action. Hospitals are not allowed to buy medical equipment costing 
more than $250,000 on their own. Instead, they are required to buy such equipment 
collectively with other institutions to reduce corrupt practices as well as the costs. In 
addition, the tendering process is centralized and there is a maximum allowable mark up 
on medical equipment that is meant to keep the prices of medical equipment and devices 
low. These have had significant ramifications on the Chinese medical devices industry 
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and have reduced the attractiveness of the Chinese market among foreign manufacturers 
of these devices (Yip & Eggleston, 2001; Ngorsuraches, Meng, Kim, & Kulsomboon, 
2012).  
Economic performance is one of the factors that is driving the growth of the 
medical devices market in China and is expected to improve the sector’s fortunes in 
coming years. China has posted tremendous economic growth over the past few decades 
(Subramaniam, 2011). The good economic performance is expected to continue in the 
coming years and this will increase the disposable income of people hence drive up 
demand for medical devices in the country. This is projected to increase the demand for 
high-end devices from countries such as US as well as boost the capacities of local 
Chinese firms to manufacture advanced medical devices (Gross & Loh, 2006). 
Another factor that will have a significant impact on the development of China’s 
medical devices market is government policy (Gross & Loh, 2006). The government has 
formulated the 12
th
 Five Year Plan, which identifies some sectors as being critical to the 
country’s long-term strategic interests. One of the sectors that are identified is 
biotechnology of which medical devices form a part. Towards this end, the government 
has initiated plans to provide more support to these sectors. Tax credits are one of the 
ways through which the sector will be boosted by the government. This is expected to 
provide Chinese companies with a competitive edge and to increase the barriers foreign 
firms face in their bid to service the Chinese market (Casey & Koleski, 2011). 
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Additionally, more stringent regulatory and quality assurance standards are being 
formulated in a bid to enhance the quality and competitiveness of medical devices 
produced in China. This is expected to make local consumers have more confidence in 
goods produced in China and therefore reduce their reliance on medical devices produced 
in foreign countries. This is expected to pose significant challenges especially to devices 
made in the US, bearing in mind that the U.S is the leading exporter of medical devices to 
China. This is especially true since China is able to provide goods that are more 
competitively priced (Liu & Pecht, 2010). 
The Medical Devices Industry in Japan 
Japan is the second largest market for medical devices globally with an estimated 
net value of $23 billion in 2008. It is also the second largest market for U.S. exports of 
medical devices. The value of exports to this market in 2008 was valued at $3.5 billion 
(ITA, n.d.). Leading manufacturers in the country include Japan Hitachi, Toshiba, and 
Medical Corporation (Gross & Loh, 2006). Whereas Japan is the largest market for 
medical devices in Asia and has a big aging population, the harsh reimbursement and 
regulatory environment make this market difficult to penetrate for foreign manufacturers 
(Japan Pharmaceuticals and Medical Devices Agency (PMDA), 2006; Johnson et al., 
2007). According to Johnson et al., (2007), the market for medical devices in Japan is 
projected to drop by 0.9% up to 2013. The only growth is projected to come from devices 
that are used in the treatment of diseases associated with old age such as orthopedic 
implants and pacemakers. Besides the aging population, another factor that will 
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contribute to a growth in this particular segment is the small number of manufacturers 
making these devices and this will provide opportunities for manufacturers from US to 
capitalize on the market (Gross & Loh, 2006).  
Other large markets in Asia such as Taiwan and Korea also have the same 
bottlenecks. Australia has a relatively small market for medical devices but its regulatory 
system favors manufacturers and this has largely contributed to the growth of this sector 
in the country. Other countries such as Thailand, Malaysia, and Singapore have relatively 
well-developed markets for medical devices and the improving regulatory environment is 
seen as a boon for the medical device market in the years to come (Nakai & Yahiro, 
2004; Gross & Loh, 2006). 
The five biggest countries in terms of population (China, India, Pakistan, Brazil 
and Indonesia) make up almost 50% of the entire global population but account for just 
4.4% of the global medical device use (Gross & Loh, 2006; ITA, 2012). 
The Indian Medical Devices Market 
India is a country that also has a market that is increasingly growing. According 
to ITA (n.d.), the medical devices market in the country is growing by double digits every 
year. The attractiveness of the Indian market is due to the increased uptake in healthcare 
spending by a fast growing middle class and the private sector. There is a rising demand 
for high tech products and the per capita expenditure on healthcare is on an upward 
trajectory. India has not yet fully complied with developing requirements. The US is the 
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leading foreign supplier of medical devices in India (Economic Intelligence Unit, 2009; 
Torsekar, 2010). 
The Medical Devices Industry in Brazil 
Brazil has emerged as one of the fastest growing economies in the world and this 
has provided immense opportunities for the export of medical devices manufactured in 
the US. However, the global economic crisis has pushed the economy from the 8
th
 largest 
economy in the world to the 11
th
 largest. Medical device imports into Brazil have also 
been hurt by currency devaluations. Brazil’s medical device market is one of the largest 
in the world nevertheless (ITA, 2012). According to ITA (2012), this market is the 8
th
 
largest globally. Local companies supply close to 70% of medical devices with the rest 
being supplied by foreign companies. The US is the biggest foreign supplier of medical 
devices in Brazil and demand for foreign devices is mostly for high-tech imports (Brito, 
2004). 
The Medical Devices Industry in Canada 
Exports of medical equipment to Canada have expanded over the past 5 years and 
the trend is expected to continue largely because of the country’s highly developed and 
affluent market. Besides, healthcare in the country is for the most part bankrolled through 
the public service. However, the US is facing stiff competition from manufacturers in 
Japan and other European countries. Though stable, the Canadian market has relatively 
low yearly growth rates that do not exceed 5% (Johnson et al., 2007; Porter, 2012). 
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The Medical Devices Industry in Mexico 
Mexico forms the second largest market for medical equipment in Latin America 
after Brazil. Trade between the United States and Mexico has significantly increased 
since North American Free Trade Agreement between the United States, Canada, and 
Mexico (NAFTA) became effective (Office of the United States Trade Representative 
[USTR], 2014). U.S. companies dominate the Mexican market for medical devices. 
Another factor that has benefitted manufacturers of medical devices in America is the 
absence of a well-developed medical device industry in Mexico. This has opened up sales 
opportunities for U.S. firms (ITA, 2005; Johnson et al., 2007; Porter, 2012). 
Impacts of Medical Device Software 
Positive Impacts of Medical Devices 
Medical devices play a very important role in boosting the health and economic 
fortunes of millions of people around the world. Medical devices have greatly helped to 
boost health outcomes (Ceer, 2006; King, 2006). For instance, devices such as 
pacemakers, stents, and defibrillators are critical in reducing heart attack mortality. 
Mortality due to heart attacks fell by 40% between 1980 and 2000 and this decline is 
attributed to an increased use of cardiovascular medical devices. Estimates show that the 
devices have helped to reduce mortality due to cancer by an estimated 20% between 1980 
and 2000. The number of deaths due to stroke also reduced by 37% between the same 
period and this has been largely attributed to the increased use of well designed medical 
devices (Calfee & Sudduth, 2011).  
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Besides saving lives and improving the quality of life of the sick, medical devices 
also provide economic benefits to millions of people around the world. These devices 
improve the economic wellbeing of the employees and their families and the 
communities in which the firms manufacturing them are located (Ceer, 2006). In many 
areas, medical device companies have led to higher disposable incomes, which in turn 
have resulted in higher demand for consumables and other goods leading to the creation 
of more jobs. Other benefits that accrue from the medical device industry include 
multiplier economic effects associated with expenditure by the employees in the industry, 
procurement of services and goods for use as inputs by the firms in the industry, and 
revenues and earnings arising from the sales and marketing of medical devices (Nixt, 
2004; Pammolli et al., 2005; Porter, 2012). According to estimates, employees of medical 
device firms earn about $24 billion and spend close to $18 billion on consumer services 
and goods. These employees spending have multiplier effects on other sectors of the 
economy. The remaining $6 billion was spent on taxes, savings, and investments 
(Johnson et al., 2007). 
Calculations by the Lewin Group (2010) use the example of California to 
demonstrate the economic benefits associated with the medical devices industry. The 
state has about 84,000 employees working in the industry with a combined payroll of 
$5.3 billion. Sales of the devices in the state total to about $26.3 billion. Based on these 
figures, the Lewin Group determined that the job, payroll, and sales multipliers for the 
industry in California are 3.5, 2.3, and 2.2 respectively. This means that each job in the 
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medical devices industry in California generates 210,000 other new jobs, an extra $6.9 
billion in payroll, and an additional $31.6 billion in sales (US Census Bureau, 2009; 
Lewin Group, 2010). In Oklahoma, the jobs multiplier is 2.48. The job multiplier is 
between 2 to 2.4 in 13 states, between 2.5 to 2.9 in 14 states, between 3 to 3.4 in 8 states, 
between 1.5 to 1.9 in 1 states, and between 1 to 1.9 in 2 states.  
The highest multipliers in the medical device industry in the US are the electro-
medical and in-vitro diagnostics. The median job multipliers for these two sectors are 
2.99 and 2.95 respectively. Multipliers for surgical and medical instruments, irradiation, 
and surgical appliance and supplies sectors are 2.53, 2.50, and 2.46 respectively. The 
sectors that have the least job multipliers in the medical devices industry are dental 
equipment and supplies, ophthalmic, and dental laboratories which have median rates of 
2.23, 2.02 and 1.77 respectively (Johnson et al., 2007; US Census Bureau, 2009; Lewin 
Group, 2010). 
Negative Impacts of Medical Software  
Health and Safety Risks. Whereas medical devices are associated with many 
benefits, use of these devices can potentially endanger the lives of users by exposing 
them to various risks. These risks include the risk of device failure, hacking, breach of 
privacy and safety, and security risks. The following is a review of these majors risks. 
Device Failure. One of the most dangerous risks associated with use of software-
containing medical devices is the risk of device failure. This is a prevalent risk going by 
the number and rate of recalls done for software-containing medical devices. There has 
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been an increase in the rate and number of recalls of software-containing medical devices 
(Lee et al., 2006). According to Maisel et al. (2001) and Halperin et al. (2008), recall of 
medical devices is a big problem encumbering healthcare today. Recalls are usually done 
and advisories issued against particular medical devices due to product malfunctions or 
glitches. A study by Maison et al. (2001) showed that 41% of all recalls of medical 
devices by the FDA since 1990 were because of firmware malfunction. Wallace and 
Kuhn (2001) carried out a study of software-containing medical devices that were 
recalled between 1983 and 1997. They identified these recalls by interrogating FDA’s 
database of failures of medical devices. According to their findings, a total of 2,792 
medical devices with or without software were recalled between 1983 and 1991. Only 
165 (6%) of these recalls had computer software. For the entire duration (1983-1997), 
Wallace and Kuhn (2001) found out that there were 383 recalls of medical devices 
containing software. There was a progressive decline in the number of software recalls 
between 1994 and 1996. As found out, 11%, 10%, and 9% of the recalls were medical 
device software in 1994, 1995, and 1996 respectively. This decline was the result of the 
fast increase in the number of medical device software (Wallace & Kuhn, 2001).  
Wallace and Kuhn (2001) grouped the recalls according to the main function for 
which the medical devices were indicated. According to their findings, majority of the 
recalls were for radiology devices (30%) followed by cardiology (21%) and diagnostic 
devices (19%). Recalls for devices for general hospital, anesthesiology, and surgery 
constituted 10%, 10%, and 3% of the recalls respectively. High failure rates for radiology 
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and cardiology devices were the results of the relative complexity for their development 
(Wallace & Kuhn, 2001). 
Based on the problems displayed by the failed devices, Wallace and Kuhn (2001) 
were able to define 13 symptoms and classify the 383 recalls by their symptoms. 
According to their findings, most of the failures were due to software malfunction (29%) 
and behavior (22%). Others were because of failure of output (19%), service (10%), 
display (8%) input (4%) and response (3%). Failure due to data, quality, user instruction, 
timing, and system each constituted 1% of the total recalls (Wallace & Kuhn, 2001). 
According to Sandler et al. (2010), there were 23 recalls made by the FDA in the 
first half of 2010. All the recalls were for Class I medical devices and six of the defective 
devices were due to errors in the software (Sandler et al., 2010). Increased use of medical 
device software is associated with an increase in the frequency of fatal incidences and 
malicious attacks (Sandler et al., 2010). In a study on defects in medical devices spanning 
a 15-year period, Dolores and Kuhn (2001) noted that there was an increase in the 
incidence of recalls due to flawed software during the later years. Dolores and Kuhn 
(2001) attributed the increase in the incidence of recalls to the increase in the number of 
medical device software with time (Dolores & Kuhn, 2001). 
According to Dolores and Kuhn (2001), 2,792 defects in medical device software 
led to these devices recall between 1983 and 1997. Out of these defects, 383 were due to 
defective software while 21% of the recalls were due to faulty cardiovascular devices. 
Dolores and Kuhn (2001) also found out that 98% of the software defects could have 
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been uncovered through elementary testing techniques. There were nearly 56,000 adverse 
events reported from the use of infusion pumps between 2005 and 2009. These adverse 
events included death and injuries and most were due to flawed software. The total 
number of infusion pumps recalled during this period was 87 and the recalls were due to 
concerns about the safety of these devices. According to Hauser and Kallinen (2004), 212 
deaths resulted from the use of implantable cardioverter defibrillators (ICDs) in the 
United States between 1997and 2003. Inspections, specifications-based testing, flaw 
hypothesis penetration testing, and failure modes and effects analysis are techniques 
available to ensure the quality and reliability of software (Wallace & Kuhn, 2001). 
Risk of Hacking. Medical devices are increasingly becoming vulnerable to 
hackers (Peck, 2011). According to Peck (2011), medical devices expose their users to 
potential hacking attacks. There is a possibility of hackers intercepting communications 
between medical devices and other equipment and transmitting injurious data to the 
devices. Hackers can also steal confidential patient data (Peck, 2011).  
Leavitt (2010) demonstrated that it is possible to use computer and radio 
equipment to reprogram medical devices as well as gain access to patient data (Leavitt, 
2010). Solutions to prevent against hacking include encryption, use of patient-centered 
approaches, and zero power defenses (Peck, 2011). According to Geissler (2010), 
encryption is one of the ways to limit or prevent hacking of medical device software. 
Encryption can be useful against hacking since it can restrict unauthorized access as well 
as conceal the commands used by medical device software. The main problem associated 
67 
 
with this approach is that it can increase computing complexity thereby imposing 
additional system requirements. In particular, inadequate computing and battery power 
can hinder implementation of complex encryption algorithms (Geissler, 2010). 
Patient-centered techniques are available to prevent hackers from interfering with 
software-containing medical devices. Empowering patients can help to minimize or 
eliminate incidences of hacking. One of the ways this can happen is by encouraging 
patients to use strong passwords, which must be entered before access to the medical 
device software can be granted. To enable doctors gain access to the IMDs during 
emergencies, the passwords can be encrypted inside bracelets worn by the patients or 
tattooed as barcodes that can only be seen under ultraviolet light (Juels, 2006).  
According to Halperin et al. (2008a), zero power defense is being considered as 
an appropriate strategy for preventing hacking attacks since it does not impose additional 
resource requirements on the IMDs. The objective is to make the medical devices safe 
from hackers without utilizing more energy from the gadget’s battery. According to 
Geissler (2010), this approach involves the use of a computer to harvest energy and serve 
as a gateway device. Radio transmissions from people who need to access the medical 
device are used to power this gateway device. The gateway device thereafter initiates a 
challenge-response protocol requiring people to verify that they are authorized to make 
contact with the medical device. People who are unauthorized do not therefore use any of 
the device’s battery power as they are stopped by the verification process (Geissler, 
2010). 
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Privacy Issues. Use of software-containing medical devices can potentially 
expose the patient to breach of privacy. Medical device software can potentially place the 
users’ safety and privacy at risk since the conventional techniques for imparting safety 
such as redundancy and use of unique identifiers are ineffective against deliberate 
security and privacy attacks and failures. Moreover, knowledge about the safety and 
privacy of medical device software is still limited and this is largely due to the isolation 
of the devices from interoperable networks (Rieback et al., 2005). 
According to Halperin et al. (2008), there is limited knowledge on how the use of 
software-containing medical devices affects the privacy and security of users. This is 
largely due to the separation of medical devices from networks thereby limiting their 
inter-operation (Halperin et al 2008). The limited knowledge further compounds the 
observation that currently available methods for forestalling attacks such as use of unique 
IDs and redundancy are not fail-safe mechanisms for stopping unintentional attacks or 
providing security. In addition, medical devices deployment over the network has 
increased thereby creating new challenges associated with user security (Geissler, 2010). 
Halperin et al. (2008) and Geissler (2010) documented several privacy goals for medical 
device software and include device-existence privacy, device-type privacy, specific-ID 
privacy, bearer privacy, measurement and log privacy, and integrity of data. The 
following is a brief description of challenges associated with user security.  
Device-existence privacy. This privacy feature refers to the inability of 
unauthorized people to make out remotely the medical devices implanted in a patient. 
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This is because the unauthorized person may be an adversary such as a prospective 
worker who is keen on perpetuating discrimination against the patient or a member of a 
criminal group looking to sell some costly device (Geissler, 2010). 
Device type-privacy. According to Halperin et al. (2008), device-type privacy is 
an important feature that medical device software should have. This feature means that 
medical devices must not disclose their type to unauthorized persons even though it 
discloses its existence. This is important because patients with implantable devices may 
be unwilling to let others know that they have these devices for reasons such as to avoid 
stigma associated with their condition, to prevent other people from knowing that they 
have a terminal condition, or because the device may be too costly and may attract 
criminals on the prowl for such devices (Juels, 2006). 
Specific-device ID privacy. The goal of specific-device identification (ID) privacy 
is to stop unauthorized people from tracking individual medical devices using wireless 
techniques such as Bluetooth, 802.11 media access control (MAC) addresses, and Radio-
frequency identification (RFIDs). If this happens then the location privacy of the patient 
can become compromised (Juels, 2006). 
Bearer privacy. Bearer privacy is also an important feature of privacy in medical 
device software. Bearer privacy means that adversaries must not take advantage of the 
features of medical devices to pinpoint the identity of the patient or dig up patient-related 
information such as the patient’s medical history, demographic data, or medical history 
(Geissler, 2010). 
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Measurement and log privacy. Medical device software should be designed and 
configured such, that hackers cannot breach the privacy of the patient by accessing 
measurement or log data stored in the device. It should also be impossible for the 
adversary to dig up or intercept patient-related information that is being transmitted 
(Schneier & Kelsey, 1998). 
Integrity of data. Protection of patient safety and privacy also involves ensuring 
that the integrity of the data that is stored or being transmitted is not spurious. 
Consequently, medical device software should be designed in a way that prevents 
unauthorized people from interfering with previous measurements or log files, modifying 
the physiological features, or deleting and insertion of events. The demographic 
information and other data that has been stored should not be amenable to modification 
(Juels, 2006). 
Security Issues. One of the most important features of medical device software is 
safety. Safety means that the harm caused by the devices should be minimal or non-
existent while its benefits should be greater (Halperin et al., 2008). All medical devices 
have an inherent form of risks to the safety of their users. Device safety is usually 
determined through risk assessment studies. In the US, medical devices are classified into 
3 classes based on the risk that they portend to the health of the user. Other countries use 
different methods to classify medical devices based on their safety risks (WHO, 2003). 
According to Geissler (2010), one of the foremost challenges facing the 
development of effective and safe medical device software relates on how to balance 
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safety and effectiveness with security and privacy. With regard to safety, these devices 
should permit access to the data only by authorized persons. Measurement and storage of 
data should be highly accurate and authorized persons ought to be able to identify the 
device without much difficulty as well as configure the settings of the device. It should be 
possible to update the software and the operational history of the device ought to be 
auditable in the event of device failure. In addition, safety of medical device software 
includes the ability of the device to interact or coordinate with other devices and it should 
be efficient in terms of utilization of resources (Geissler, 2010). Security goals of medical 
device software include authorization, availability, device software settings, and 
identification and containment of adversaries (Juels, 2006). 
Authorization. The safety of medical device software largely depends on 
authorization. There are different levels of authorization and these include personal 
authorization, role-based authorization, and selection. Personal authorization refers to the 
ability of the system to allow only certain people to carry out some defined tasks. The 
device authentication scheme integrates the rights of different sets of people to perform 
the tasks. Role-based authentication allows people to perform particular tasks based on 
their roles and access to the system could be role-based. With regard to selection, the 
devices ought to be able to communicate with only intended devices. Authentication and 
authorization of medical device software are highly contextual processes. Consequently, 
the rules can be set to relax in emergencies in order to protect the patient from grievous 
harm arising from non-intervention due to the strict authorization rules. The devices 
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ought to have the capacity to ensure that the authorization rules are stringently enforced 
(Geissler, 2010). 
Availability. Availability is another important feature of medical device software 
security. It specifies the ability of the device to thwart attempts by adversaries to execute 
successful denial of service (DOS) attacks against the device (Halperin et al., 2008). 
Software and settings of the device. For safety purposes, only approved persons 
should be able to configure, modify, or carry out actions on the medical devices that 
would lead to alteration of behavior. Accordingly, settings configuration by the device 
manufacturers and physicians should be in such a way that patients cannot deliberately or 
accidentally place themselves in danger. For instance, the drug delivery system 
configuration should not enable patients to increase the dose of their morphine 
medication. Additionally, access by physicians to debug modes or audit logs should be 
restricted and the devices ought to receive only firmware updates (Forsstrom, 1997; Juels, 
2006). 
Adversaries. Adversaries are people or actions that can compromise the safety 
and privacy of patients using medical device software (Geissler, 2010). According to 
Halperin et al. (2008), adversaries can be classified as insiders, active adversaries, passive 
adversaries, or coordinated adversaries. Insiders may include patients, software 
developers, healthcare providers, and hardware engineers and can potentially sabotage 
the effective functioning of medical device software thus placing the patients using these 
devices under great risk. Passive adversaries can breach the safety and privacy of patients 
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using medical device software by listening in on signals that are being sent or received by 
the devices (Halperin et al., 2008). 
Besides listening in on transmissions, active adversaries can also set off malicious 
communications with peripheral equipment and other medical devices as well as cause 
interference with legitimate communications (Juels, 2006). Coordinated adversaries 
utilize collaboration between two or more adversaries in order to carry out an activity that 
can cause risks to the safety and privacy of patients using medical device software 
(Halperin et al., 2008). In performing attacks, adversaries may either use standard or 
custom equipment. Standard equipment are those that are commercially manufactured 
while custom equipment are those that are developed at home and used for active attacks 
and listening in (Geissler, 2010). 
While enhanced security is desirable for software-containing medical devices, it 
could also lead to reduced system performance and increase in costs. Enhanced security 
of software-containing medical devices can also necessitate the purchase of new 
equipment. For instance, implementation of security measures requiring two-way 
communication in medical devices based on unidirectional equipment would compel the 
users to acquire bidirectional equipment (Leavitt et al., 2010). Enhancement of security in 
software-containing medical devices is faced with challenges in coming up with solutions 
that do not only work but are also acceptable to patients themselves. 
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Directions in Enhancing the Safety of Medical Device Software.  
As noted before, safety and privacy issues are increasingly becoming important in the 
development of medical device software. Halperin et al. (2008), provide several research 
directions for minimizing or eliminating threats to safety and privacy in medical device 
software. These directions include use of fine-grained access control, open access with 
revocation and second-factor authentication, shifting of computation to external devices, 
authorization using secondary channels, use of secondary channels to let the patients 
know about their security status, and integration of accountability into the system 
(Halperin et al., 2008). These are briefly discussed in the sections that follow. 
Use of fine-grained Access Control.  
Fine-grained access control can help to resolve the conflict between predefined 
authorization and authentication rules and open access in the event of emergences. This 
approach resembles the Grey system where programmers examine the serial number, 
model, and primary-care center of the patient in an emergency and use the information 
obtained to get in touch with the manufacturer of the device and request access to 
specified functions for a particular duration of time. The manufacturer than evaluates the 
request and decides whether to give access rights to the programmer through issuance of 
a signed credential. The main feature of this approach is that the ultimate power on 
deciding which device interacts with a given device rests with the manufacturer. The 
main undoing of the approach is that it does not fully support specific-ID privacy and can 
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raise safety issues if the internet link between the manufacturer, emergency programmer, 
and primary care center is broken, cut off or slow (Bauer et al., 2005). 
Open Access with Revocation and Second-Factor Authentication.  
Another approach that is being considered for use in ensuring safety and privacy 
of patients using medical device software involves allowing unlimited access to medical 
devices and revoking or restricting access to these devices when they get stolen or lost. 
Access restriction or revocation might be done through the use of certificates that expire 
automatically. To make the system work properly, it would be difficult for one to regain 
the certificates without the right medical. Distribution of the certificates should be done 
in a hierarchical manner and they should be stored in safe places. The main drawback of 
this approach is that the devices are exposed to equipment that can be compromised for 
small periods and exposes the healthcare provider to DOS attacks due to the certificate 
distribution procedure. Additionally, the approach requires that the devices have a robust 
time notion (Halperin et al., 2008).  
Another way of implementing this approach in medical device software is to 
restrict access to the device through the use of tokens to authenticate the identity of 
authorized users. The main undoing of this approach is that it might limit interventions 
during emergencies. Integration of federated identity management systems in the devices 
can also help to overcome the safety and privacy concerns associated with the devices 
(Geissler, 2010). 
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Shifting of Computation to External Devices.  
Use of cryptography to initiate DOS attacks against the battery, processors, or 
communications of medical device software is a possible mechanism that can be used by 
adversaries to carry out actions that can compromise the safety and privacy of patients 
using medical devices. Adversaries can also utilize methods based on asymmetric 
cryptography to mount DOS attacks. These attacks can be minimized or eliminated by 
expanding the protocols and devices. This can however result into a bigger computing 
base that might render the system difficult to secure (Juels & Brainard, 1999; Juels et al., 
2005). 
Authorization using Secondary Channels.  
Secondary channels can be used to authorize access to the medical device 
software. Wands located close to the chest have been used to activate ICDs through near-
field communication. Once activated, the medical device can then be programmed by the 
healthcare provider for a greater duration of time. Alternatively, accelerometers 
integrated in medical devices can be used to halt communication whenever it becomes 
apparent that there is a considerable change in the patient’s environment. These 
approaches are effective at curtailing breaches to the patient’s security and privacy 
because they restrict lengthy exposure to situations that may compromise the safety and 
privacy of the patient. Research approaches also propose the use of encryption keys 
indented on medical-alert bracelets or cards to secure the communications between 
medical devices and the programmer. The main drawback of this method is that the 
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patient may be exposed to safety risks if the bracelet or card are forgotten or lost and 
there is need for emergency interventions (Halperin et al., 2008; Geissler, 2010). 
Use of secondary channels. 
Some of the currently available medical devices enhance the safety of the patient 
by issuing out audible alerts upon depletion of their battery. According to Halperin et al. 
(2008), secondary channels can be used to better notify the patients about the security 
status of their medical device software. These channels include environmental factors 
such as mobile phones, watches, and monitors located in the house. These channels can 
be used to transmit tactile, auditory, or visual information whenever there is a change in 
their environment. Whereas these alerts cannot by themselves stop malicious attacks, 
they can inform the patient about the threatening situation and thereby cause them to put 
in place protective measures (Halperin et al., 2008; Geissler, 2010). 
Integration of Accountability into the Medical Device Software System.  
Accountability measures can go a long way towards making medical device 
software safer and confidential. This can involve recording all the malicious activities 
and associating them with a particular person or event. The activities can be identified by 
reviewing the cryptographic audit log (Schneier & Kelsey, 1998; Halperin et al., 2008). 
Risks Associated with Off-label Use.  
According to David and Hyman (2007), off-label use of medical devices refers to 
the use of the device for reasons that are not listed as indications by regulatory authorities 
such as the EC and the FDA. It involves the use of medical devices for indications other 
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than those in the approved device labeling list of the EC and FDA. Off-label uses of these 
medical devices may include applications that are contraindicated or expressly forbidden 
thereby exposing the users to grave danger. According to Lee et al. (2006), medical 
devices are increasingly becoming networked and this has created challenges that make it 
difficult to make sure that there is uniformity in health safety. 
There are many ways in which the use of medical devices can be referred to be 
off-label use. Reuse of devices, which are designed and labeled for single use only, is one 
example of off-label use that is widely practiced by many people (David & Hyman, 
2007). The use of substances such as the human growth hormone and erythropoietin by 
athletes is an example of off-label drug use. Off-label use of medical devices may also be 
due to misapplication as a result of lack of knowledge, or flawed analysis. It may also be 
due to carelessness. In some instances, manufacturers may fail to obtain clearance from 
regulatory authorities due to the costly nature of clinical trials, sufficient prior familiarity 
with similar devices, or unprejudiced data that lend credence to labeling claims. Risks 
associated with off-label use include injuries, death, and incapacitation (David & Hyman, 
2007). 
Legislation of Medical Devices Software 
Increase in the number and rate of recalls and the risks associated with use of 
software-containing medical devices-brought into the fore the importance of legislation 
with regard to these devices. For a long time, the regulations governing the production 
and marketing of software for medical devices was lax and the Medical Devices 
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Directive had not officially classified software as a medical product. In addition, previous 
regulations were only ideal for those devices whose risk levels were comparatively low. 
Medical devices that were used for critically important physiological functions and 
whose failure could lead to serious harm or even death were not covered adequately by 
the regulations. However, all this has changed and a new system controlling software-
containing medical devices has been instituted. The system is the EN/IEC 62304 and is 
the world standard for managing the software development lifecycle. Although EN/IEC 
62304 standard has been embraced as a global benchmark for management of the 
software development lifecycle, implementation of the standard has been slow due to 
unintended consequences including its effect on costs to manufacturers of medical 
devices, the competitiveness of companies, and the effect on companies arising from 
requirements touching on training and hiring of employees (Hall, 2010). 
Regulation is done at the following levels: conception and development, 
manufacturing where good manufacturing practices (GMP) must be followed, packaging 
and labeling, advertising, sales, use, and disposal. Regulation involves the manufacturer 
of the device, the vendor, the user, the public, and the government. Regulation is done at 
3 levels namely pre-market review, product representation, and post market surveillance.  
Pre-Market Review 
Pre-market review is carried out on the medical device before it can be brought 
into the market. The objective is to ensure that only products that meet the regulatory 
requirements eventually get to the market. 
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Product Representation 
This involves the regulation of devices during the advertising and sales periods in 
order to ensure that vendors do not only operate from established premises but also fulfill 
their after-sale obligations and do not use advertisements that are either misleading or 
false. The objective is to protect the users from being exploited by insincere vendors.  
Post-Market Surveillance 
Post-market surveillance involves the continuous monitoring of products already 
approved to be in the market. The objective of post-market surveillance is to ensure that 
the safety and efficacy of the products being sold is maintained as time passes by. In the 
US, medical devices are highly regulated by the Food and Drug Administration (FDA). 
The FDA is responsible for ensuring that the health of members of the public is protected 
by ensuring that medical devices, drugs, cosmetics, radioactive products, food supply, 
and biological products are not only safe but are also effective and secure (David & 
Hyman, 2007). 
Standards for Quality Assurance of Medical Devices 
Quality systems refer to the resources, organizational structure, methods, 
processes, and tasks required in the execution of quality management (WHO, 2003). The 
ISO defines standards as accepted agreements that comprise of technical plans or other 
clear-cut principles that are meant to be used always as definitions of features, guidelines, 
or regulations to ensure that services, products, materials, and processes are suitable for 
their purpose. 
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Increasingly, generic standards that are universal standards that can be made use 
of by any company regardless of the products or services being produced or provided 
have gained prominence. Standards are of utmost importance in the medical devices 
industry for several reasons. First, they provide a benchmark that must be attained by a 
process, service or product thereby ensuring that the medical devices produced are of 
high quality. Secondly, they guarantee consumers that the features of services or products 
in the market are not only reliable but also consistent. Third, standards avail data that can 
be used to improve the trustworthiness, performance, and safety of processes, products, 
and services. Additionally, quality standards provide more choices to consumers by 
allowing the products of a particular company to be combined or replaced with those of a 
different company (WHO, 2003). 
In the medical device industry, standards that are largely used to regulate the 
quality of products are ISO 13485 and ISO 13488. Different countries make use of 
different quality systems as shown in the table below (WHO, 2003). 
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Table 1  
Quality Standards Used in Different Regions. 
Region / Country Standards Conformity Assessment 
Canada   
 ISO 13485, ISO 13488 
Third party (Conformity 
Assessment Bodies) 
Japan   
 
GMP#40 ordinance 
GMP#63 ordinance 
QS standard for medical devices #1128 
notice 
Government 
Australia   
 
ISO 13485 
ISO 13488 
Third party and 
government 
United States   
 QS (21 CFR part 820) Government 
EU   
 
ISO 13485 
ISO 13488 
Third party (notified 
bodies) 
Note. Source: World Health Organization (WHO), 2003. 
Standards may contain different types of specifications and these may be prescriptive, 
performance, design, or management specifications. Prescriptive specifications detail the 
desirable features in a product while performance specifications guarantee that a 
prescribed test such as the capacity of a battery is met. Design specifications stipulate the 
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particular technical or design features of a product whereas management specifications 
spell out the requirements for the procedures and methods firms establish. Standards may 
have different sets of specifications (WHO, 2003). Since medical devices manufactured 
in one country can be used by people in many other different countries, it is of critical 
importance that the quality standards used in different jurisdictions be harmonized in 
order to ensure the consistency of these devices and avoid endangering the health of 
patients (WHO, 2003). 
Harmonization of Quality Standards for Medical Devices.  
The GHTF comprised of Australia, the United States, Japan, Canada, and the EU. 
Pre-market approval involves the issuance of the Australian Register of Therapeutic 
Goods by the Therapeutic Goods Administration in Australia and the PMA or 510(k) by 
the FDA in US. A Device License is issued by the Therapeutic Products Directorate in 
Canada while the Pharmaceutical and Medical Safety Bureau of the Ministry of Health, 
Labor, and Welfare issues a Shounin in Japan for devices that have been granted pre-
market approval. In the EU, the manufacturer is given an EC certificate and is thereafter 
required to pin the compliance label (CE mark) on the devices for sale. The table below 
describes the tools and requirements applied in regulating the medical devices sectors in 
those countries: 
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Table 2  
Tools and Requirements Used in Regulation of Medical Devices in Different Countries. 
Region/ 
country 
Tool showing pre-market 
approval 
Requirements for placing device on market 
Australia ARTG number Enterprise identification (ENTID) 
US PMA or 510(k) Establishment registration 
Canada Device Letter Establishment license 
Japan Todokede (notification) or 
Shounin (approval) 
Yunyu Hanbai-Gyo or import license, 
Seizo-Gyo or manufacturer license, and 
Hanbai Todoke or sales notification 
EU Compliance label (CE mark) Registration of responsible person 
Source: WHO (2003) 
Conformity Assessment.  
Conformity assessment refers to the procedures, methods, and processes that are 
carried out in order to ascertain whether a particular product adhere to the specifications 
of a certain standard. Conformity assessment can be done using any of 4 recognized 
methods. Direct testing is the most commonly used method to determine conformity to 
quality standards. Other methods are auditing, accreditation, or registration. Firms that 
meet the management standards receive a registration certificates from Management 
Registration agencies. The following table shows the organizations responsible for 
ensuring that medical device software comply with quality standards in different 
countries as well as globally.  
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Table 3  
Different Standards Organization. 
Region/Country Standards Body 
Canada  
 Standards Council of Canada (SCC) 
European Union  
 
European Committee for Electrotechnical 
Standardization (CENELEC) 
European Telecommunication Standards Institute 
(ETSI) 
Comité Européen de Normalisation (CEN) 
United Kingdom  
 Medicines and Healthcare products Regulatory 
Agency (MHRA) 
Germany  
 The Act on Medical Devices(Medical Devices Act) 
(Medizinproduktegesetz - MPG) 
US  
 American National Standards Institute (ANSI) 
International Standards Organizations 
Organization Domain Standards 
International 
Organization for 
Standardization (ISO) 
 ISO 13485, ISO13488 
International 
Electrotechnical 
Commission(IEC) 
Electrical and electronics 
engineering 
IEC 60601-1, IEC 
61010-1, 
IEC 60601-2, IEC 
62304(2006) 
International 
Telecommunication 
Union (ITU). 
Telecommunications  
Source: WHO (2003) 
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Voluntary Standards.  
Voluntary standards refer to standards that have been developed and ratified 
based on broad participation and compromise by all stakeholders. Voluntary standards 
are useful because they involve the participation of many experts from diverse fields and 
who have access to cutting edge technologies and other resources present in industry and 
other professional bodies. Such standards are also beneficial since they enable the 
government to overcome its weaknesses such as limited resources and come up with 
extensive and well-thought out specifications for products and services. In addition, they 
enable accredited third parties to conform to standards besides harmonizing different 
regulations in different nations. Voluntary standards help in technology transfer to less 
developed nations because standards are updated without much difficulty as new 
technologies are adopted. Voluntary standards provide manufacturers with the flexibility 
to select suitable standards or comply with regulations (WHO, 2003). 
According to the GHTF (2012), following “Essential Principles of Safety and 
Performance of Medical Devices” are instrumental when developing standards in order to 
ensure that they comply with the. New medical devices standards should also be based on 
internationally accepted standards and regulatory authorities are required to make 
available a system for identifying international standards so that manufacturers are 
provided with a means of proving that they have complied with the aforementioned 
essential principles. However, full application of an international standard is not 
mandatory so long as the firms can demonstrate compliance to the essential requirements 
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of the standard. Additionally, GHTF required that international standards be used to 
harmonize different regulations but still provides room for the use of regional or national 
standards in order to demonstrate compliance.  
Product Standards.  
The EN/IEC/62304 is a harmonized standard for the design of medical device 
software. The US and EU have adopted this standard. Since this is a harmonized 
standard, manufacturers using the standard are able to comply with the requirements of 
MDD 93/42/EEC and the M5 (2007/47/EEC) amendment. The standard requires that 
medical device software manufacturers assigned safety classes to the medical device 
software. Medical device software can be classified as Class A, Class B, or Class C (IEC 
& ISO, 2006). Class A devices are those that have no potential of causing an injury or 
damage to health while Class B devices can potentially cause an injury that is not serious. 
Class C represents medical device software that can possible cause serious injury or even 
death of the patient (IEC & ISO, 2006). In this context, serious injury is defined as an 
illness or injury that can threaten one’s life, can cause a body structure or function to be 
permanently impaired, or occasions an intervention that is surgical or medical in nature 
and which is necessary in order to stop a body structure or function from becoming 
permanently impaired. Permanent injury means that a body structure or function has been 
damaged or impaired in a permanent manner (Hall, 2010). 
After classification of the software into the appropriate class, the next step as 
specified in the EN/IEC/62304 is to decompose the software into items and units. A 
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software item refers to a component of a computer program that can be identified. On the 
other hand, software units are indivisible software items. The units and items can be 
typifies using an architectural diagram and this can also be used to relegate the safety 
classification of certain parts of the software so long as they are separable or can be 
segregated. Segregation can involve using different processors to execute software items. 
This means that it is possible to break up safety-critical software into items. The items 
may be classified differently (Hall, 2010). 
Other product standards used in the design of medical devices are IEC 60601-1, 
which is a standard for medical electrical equipment safety, IEC 61010-1, which contains 
specifications for electrical equipment safety requirements, and IEC 60601-2, which has 
specific requirements for medical electrical equipment safety.  
Management Environment Standards.  
The International Organization for Standardization (ISO) has provided several 
standards for medical devices. Standards for the management of the environments for the 
manufacture of medical devices include ISO 13485, ISO 13488, ISO 14971, and EN/IEC 
62304: 2006. The latter standard has harmonized all the other standards for software-
containing medical devices. The United States and the EU have both adopted the 
standard. Adoption of EN/IEC 62304: 2006 by manufacturers ensures that they comply 
with the requirements for software development as contained in MDD 93/42/EEC and 
MDD 2007/47/EC. This standard enforces strict guidelines for medical device software 
and classifies software as a medical product (Hall, 2010). The ANSI/AAMI/IEC 
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62304:2006 standard, which is indistinguishable from the EN/IEC 62304: 2006 variants 
is also adopted in the United States (Hall, 2010). Standards for medical device software 
life cycle processes include ISO/IEC 90003: 2004 and the IEC 60601 series.  
EN ISO 14971 was developed by the International Organization for Standards 
(ISO) and seeks to provide guidance to manufacturers on conducting analysis, evaluation, 
and control of risks. This is important in risk management especially when designing, 
developing, manufacturing, and monitoring the safety and functionality of medical 
devices after they have been sold (WHO, 2003).  
On August 30, 2012, the updated “EN ISO 14971:2012 standard was published as 
harmonized to the Medical Device Directive (MDD) 93/42/EEC, and became effective 
immediately without a transition period. Three annexes ZA, ZB, and ZC were added to 
be used by Notified Bodies to assess compliance with the Essential Requirements of the 
Medical Device Directive (MDD) 93/42/EEC. There has been no change to the normative 
text of the standard. 
The Food and Drug Administration (FDA) and Regulation in the US 
The Food, Drug, and Cosmetic Act granted FDA limited powers to regulate 
medical devices in 1938. The agency can confiscate devices that have been adulterated 
and misbranded as well as prosecute the companies responsible for producing the 
products. The authority of the agency to exert control over medical devices became 
increasingly lame as technological advances took place resulting in devices that are not 
only complex and advanced but also which placed the health and safety of individuals at 
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significant risk. Consequently, FDA requested more regulatory authority over medical 
devices. Subsequently, the Bureau of Radiological Health received congressional 
authority over radiological devices such as x-rays and merged with the FDA in 1971.  
Due to a number of scandals associated with medical devices, there was a public 
outcry demanding a strict regulation of the medical devices industry. This outcry led to 
the formulation of the Medical Device Amendments in 1976 that gave the FDA more 
authority to control the way the devices are designed, labeled, marketed, produced and 
distributed. The new regulation also gave rise to the formation of a classification system, 
which specified the process for registering and approving new medical devices. The FDA 
formed expert advisory committees made up of medical specialists to help examine the 
devices as well as to advise on policy matters. The FDA’s regulatory systems include the 
classification, device approval, and reclassification systems (FDA, 2011; FDA 2012, 
FDA, 2012b). 
Regulatory Systems. The FDA classifies medical devices based on their class 
and category. Classification by class involves grouping medical devices into 3 groups 
referred to as Class I, Class II, and Class III. Class I products have a simple design, are 
not strictly regulated and are not associated with significant risks to the safety or health of 
users. Class II products are more complex in design, but could pose minimal risks to the 
users. Class III products are highly advanced devices are very tightly regulated and can 
cause significant health and safety risks to users. Medical devices are also classified 
based on codes that reflect the medical specialty of the product and contain two letters. 
91 
 
The specialties relate to advisory committees that supervise the device regulation. They 
also include product codes, which relate to the function and features of the devices and 
which consist of three letters. 
System for Approval of Devices. Pre-market notification or pre-market approval 
(PMA) process is required for FDA clearance to market. Class I medical devices does not 
require approval as they are associated with little or no risk to the safety and health of 
consumers. On the other hand, Class II medical devices require submission of a pre-
notification for FDA clearance to market. In this process, the manufacturers are required 
to fill 510(k) for new products or whenever they carry out significant alterations on the 
labeling and design of existing devices. This process requires that companies demonstrate 
that there is “substantial equivalence” between their product and other products in the 
same category, which were manufactured earlier or specified standards formulated by the 
FDA for that particular category. Demonstration of “substantial equivalence” usually 
involves the presentation to the FDA of aspects of the device’s design and testing 
information (FDA, 2011; FDA 2012, FDA, 2012b). 
For Class II devices, manufacturers must present their devices for approval 
through the PMA process. This particular process requires that manufacturers provide 
copious amounts of materials that support the safety and efficacy of the device. Such 
materials may include data from clinical tests demonstrating that the devices are both 
effective and safe. There are two types of PMA, one original and the other 
supplementary. The original PMA is filled anytime a new medical device is being 
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launched while supplements are filled whenever changes are made in the design, 
manufacturing process, manufacturing location, and labeling (FDA, 2011; FDA 2012, 
FDA, 2012b). 
Reclassification System. Over the years, there have been many changes made in 
the classification of medical devices by the FDA and this has led to the reclassification of 
hundreds of medical devices. Most of the reclassifications have involved the movement 
of Class III medical devices to either Class I or Class II hence the replacement of PMA 
requirements with 510(k) requirements. Reclassifications are carried out through 
Congressional mandates, petitions made to the FDA by concerned parties, and by FDA 
through the agency’s own initiative. Before reclassifications occur, the FDA seeks advice 
from the concerned advisory committee and other specialists. The agency also broadcasts 
the proposed rules for reclassifications a couple of months prior to the reclassification in 
order to enable the public to make their contributions to the proposed reclassification 
(FDA, 2011; FDA 2012, FDA, 2012b). 
The Center for Devices and Radiological Health (CDRH) is the division of the 
FDA that regulates manufacturers of medical devices in the United States (Bartoo, 2005). 
In 2009, CDRH received nearly $43 billion from the $325 billion allocated to FDA (ITA, 
n.d.). The CDRH carry out premarket review of medical device software in order to 
determine the efficacy and safety of the devices. The review of the device includes 
evaluating artifacts for the software development life cycle in order to make out the 
suitability of the device’s quality assurance features. CDRH also performs post market 
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surveillance after the device has been placed in the market. Market surveillance involves 
evaluating the performance of the device. Whenever reports about grievous harm or 
deaths due to the device are received, CDRH carries out a health-hazard evaluation. This 
evaluation may result in a full-scale investigation referred as forensic analysis to 
determine the cause of the malfunction or failure. Depending on the outcomes obtained, 
the center can decide to either recall the devices or compel the manufacturer to institute 
corrective measures (Jetley, Iyer, & Jones, 2006).  
According to Jetley, Iyer, and Jones (2006), these processes by CDRH are usually 
effective for the processes involved in production of the devices. However, they are not 
adequate in evaluating software. This is because most manufacturers do not use the 
model-based approach when developing their software. Rather, they develop their 
software based on the product requirements. As a result, it is not possible to detect some 
errors and bugs during the premarket assessment stage because model-checking methods 
or white-box testing techniques cannot be applied to the software. In addition, 
determining the source of software defects during forensic analysis is a very difficult 
undertaking. This is because the defects are usually non-deterministic and are largely 
system-dependent thereby making their reproduction a difficult if impossible task. 
Review of the software’s source code is thus the only way to identify the defects and this 
is a laborious and difficult task because third parties usually perform the reviews and they 
often lack prior understanding of the software (Jetley, Iyer, & Jones, 2006).  
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The FDA has recently embarked on a drive to grow the number of electronic 
submissions for approval. The FDA launched in May 2008 the Sentinel Initiative to 
create a national electronic system that would enable FDA to look for safety data on 
medical devices approved by FDA in existing databases. In addition, the agency seeks to 
streamline existing good manufacturing practices (GMP) in order to forestall 
inconsistencies arising out of ambiguities in the GMP requirements that could lead to 
health and safety risks (ITA, n.d.).  
Other initiatives by the FDA geared towards tightening the regulation of medical 
devices include re-examination of the 510(k) process. The 510(k) is a process that allows 
the FDA to determine substantial equivalence evaluation for premarket notification 
(510(k)) submissions. The intend of the re-examination is to get rid of ambiguous and 
unclear requirements as well as decide if restrictions should be placed on the kinds of 
products that can be subjected to the 510(k) clearance procedure (ITA, n.d.). 
Based on Congress’ request, the Government Accountability Office (GAO) 
carried out a study on the 510(k) process. According to the recommendations made by 
GAO, the FDA should establish regulations for a small set of PMA devices that get into 
the market via the 510(k) process. Re-evaluation or down-classification of the devices 
should follow the strict PMA procedure for class III products. Based on this directive, the 
FDA conducted a reevaluation of a type of artificial hip joints, pedicle screw spinal 
systems, external counter-pulsating devices, intra-aortic balloon and control systems, and 
implanted blood access devices. The FDA ordered manufacturers to send data about their 
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class III devices on the efficacy and safety of the devices prior to the amendment (FDA, 
2011; FDA 2012, FDA, 2012b). 
To further strengthen the regulation of medical devices, the FDA collaborated 
with other stakeholders in order to put in place a Unique Device Identifier (UDI) system 
for medical devices. The system is expected simplify the process used to recall products, 
reduce medical errors, enhance the reporting of adverse events, and improve the post-
market surveillance of medical devices. Further, the FDA made it compulsory for 
manufacturers of medical devices to submit electronic copies of adverse event reports 
(AERs) to CDRH. This is expected to cut costs and enable CDRH to carry out safety 
reviews faster since the previous method involved submission of paper reports that were 
then fed into the Manufacturer and User Facility Device Experience (MAUDE) database 
(ITA, n.d.; FDA, 2011; FDA 2012, FDA, 2012b). 
The Medical Devices Directive (MDD 93/42/EEC) 
The Medical Devices Directive 93/42/EEC is the main directive regulating the 
medical devices industry in the EU and is the benchmark standard for medical devices all 
over the world. Other directives include Directive 90/385/EC, which regulates active 
IMDs and Directive 98/79/EC, which regulates in-vitro diagnostic devices. The MDD 
93/42/EEC aims at ensuring that medical devices manufactured and used in the EU are 
not only effective but are also safe (EC, 1993). It comprises of 23 articles, which specify 
the regulations that medical devices must meet. 
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Amendments to MDD 93/42/EEC 
Amendment M5 (2007/47/EC) came into operation in 21
st
 March, 2010 and 
introduces changes to the MDD 93/42/EEC. Amendments of the MDD 2007/47/EEC 
include the following changes. First, standalone software is specifically included in the 
definition of medical devices. Secondly, the amendments require providing the proof of 
the clinical efficacy for Class I devices and all other devices. The amendments do not 
exclude medical devices that also happen to be machines as described by the Machinery 
Directive (2006/42/EC) from assessment of their efficacy and safety. In addition, MDD 
93/42/EEC was amended to state that the Personal Protective Equipment Directive 
89/686/EEC must be used to evaluate medical devices, which offer protection to the user 
or operator. Moreover, the amendments make it mandatory for all customized medical 
devices to undergo post market surveillance. It is also required that the patient for whom 
the device was customized should be given particular information.  
Other amendments state that manufacturers are required to appoint Authorized 
Representatives to act on their behalf if they are not located in the EU. Additionally, 
trending has been included as part of the post market surveillance processes and the list 
of incidents reportable to the Medicines and Healthcare products Regulatory Agency 
(MHRA) have been expanded to include birth defects, congenital abnormalities, and fetal 
distress and death. MHRA is the UK government agency, which is responsible for 
ensuring that drugs and medical devices sold in the UK are safe and effective. The 
amendments also require that information about the technical factors and characteristics 
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identified as hazards that can cause risks upon reuse of the medical device should be 
clearly indicated and accompany single use devices and that manufacturers must ensure 
that Declaration of Conformity and Instructions for Use are controlled documents in the 
quality management system of the manufacturer. 
Other inclusions are that processes that outline the post market surveillance 
activities related to the device must be included in the quality management system for 
most devices, the technical file must contain data from clinical evaluations, and that the 
notified body ought to monitor third party subcontractors carefully. In the new rules, 
reclassifications occur continuously and all stakeholders are therefore required to keep 
themselves updated. Finally, the EC requires that new devices comply with the most 
recent standards since the harmonization of standards is a continuous process 
(Conformance, 2012). 
Legislation of Medical Devices in Developing Countries 
Developing countries cannot sustainably grow their medical devices industries 
unless they adopt and enforce standards for risk management, regulatory approval, and 
quality. They also need to harmonize their local standards so that they attain world best 
practices established on the guidelines set by the Global Harmonization Task Force 
(GHTF) (ITA, n.d.). The GHTF was a task force that comprised of industry players and 
regulators. It was a voluntary body that comprises of Australia, Japan, Canada, the United 
States, and the EU. Its main objective was to streamline and harmonize regulations. 
Developing countries such as Brazil, South Africa, Chile, and Mexico participated in the 
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GHTF through the Latin American Harmonization Working Party (LAHWP) while 
China, Vietnam, Indonesia, Malaysia, and Thailand participated through the Asian 
Harmonization Working Party (AHWP) (ITA, n.d.). 
Legislative weaknesses 
One of the biggest weaknesses of the regulations governing medical devices is 
that approval is very costly. Before Class III products can get PMA approvals, 
manufacturers are required to submit copious amounts of materials that can prove that the 
devices are safe and effective. Detailed data from clinical tests are some of the 
information required. The clinical tests are very expensive to conduct. Class II products 
also require huge amounts of money to push through the PMA process although the cost 
is not as large as that for Class III products. This is because the regulations for Class II 
devices are not as strict and the company is only required to demonstrate “substantial 
equivalence” between its devices and other devices of the same category, which exist in 
the market (Lee et al., 2006). 
Secondly, approval takes a lot of time. The PMA approval process often requires 
the submission and resubmission of material and this usually takes a lot of time. (Lee et 
al., 2006). Thirdly, some of the provisions are very difficult to enforce. According to 
Donawa (2010), enforcement of the legislation for medical devices in Europe is not 
always effective. Enforcement occurs through market surveillance program, which enable 
the authorities to detect firms, and devices that are not up to standard and take the 
appropriate action to protect the consumers form these companies and products. 
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Conformity assessment and post market surveillance are also difficult to conduct and 
unscrupulous traders can find loopholes.  
Another weakness associated with the regulations is that source code for the 
medical device software remains the exclusive property of the manufacturers. The 
legislation covering these devices does not regulate source code. Therefore, patients and 
doctors do not have access to the medical device source code and cannot test the security 
of these devices. However, manufacturers have the option of submitting their source 
codes to FDA for analysis by its specialists in order to uncover any flaws before 
premarket review. This requirement is nevertheless optional and not compulsory (Sandler 
et al., 2010).  
The regulations have also failed to protect users and members of the public 
effectively. In a precedent set in 2008 in the Riegel vs Medtronic Inc., the United States 
Supreme Court ruled that patients injured by medical devices sanctioned by FDA and 
recalled in 2005 were ineligible to pursue compensation from the manufacturers. The 
court removed the product liability lawsuits that were the only protection for people using 
IMDs thus exposing them to potential harm. This is an example of an area in which the 
legislation does not effectively safeguard the interests of patients using medical device 
software (Sandler et al., 2010). Another weakness is that the regulations do not have 
adequate safeguards to protect users against threats to their privacy (Leavitt, 2010). Other 
weaknesses of the regulations include lack of standardization in the security properties of 
medical devices and ambiguities in the requirements for clinical evaluation.  
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Additionally, the regulations create entry barriers that lock out small companies 
that cannot afford to go through the approval process (Higgs, 1995). They increase the 
sunk costs and since sunk costs are the main determinant of the economies of scale, the 
number of companies capable of returning profits in a particular market is limited by high 
sunk costs. There is a correlation between high sunk costs on one hand and lessened 
competition and fewer companies on the other hand (Sutton, 1991; Nixt, 2004). A study 
by Nixt (2004) shows that reduction in sunk costs lead to the increase by more than 100% 
of the number of companies entering the market each year. It is also associated with an 
80% rise in the rate of new products launched into the market every year. The increases 
are not short lived; rather, they are long-term and take effect instantly. Nixt (2004) also 
found out that reductions in sunk costs have considerable effects on the rate at which 
medical devices are patented. One of the possible effects of sunk costs on the rate of 
patenting is that it can affect the value of patent protection and hence the tendency of 
companies to seek for patent protection. It was found out that reclassification by FDA 
does not only lead to a reduction in the rate of patenting but also enhances the quality of 
patents given. This implies that high sunk costs lead to an improvement in innovation 
(Nixt, 2004). 
Nixt (2004) also investigate the effect of sunk costs on the entry of firms in the 
medical devices industry. A key factor of the medical devices market is the repeated 
entry resulting from the innovations taking place in the industry. The results of the study 
indicate that fewer new companies enter into the medical devices market when the sunk 
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costs are high and vice versa with a decline in the sunk costs. The same situation obtains 
with incumbent companies (Nixt, 2004). The findings suggest that entry barriers are 
critically important factors in the long-term success of firms in the medical devices 
industry. Since these entry barriers are largely determined by the existing regulations, the 
inescapable conclusion is that the success of new or incumbent firms or that of products 
entering a market depends on the regulations governing these companies and products. 
The literature suggests that the FDA regulations create entry barriers that hinder the entry 
of new firms (Nixt, 2004). Finally, the regulations have limited innovation. 
Future Outlook of Medical Devices Software 
According to Halperin et al. (2008), the future of medical devices is bright. High 
demand for these devices is expected to persist in the coming year due to factors such as 
the aging baby-boomer generation and the emergence of novel therapies. Aging of the 
baby-boomer generations bound to increase the demand and use of medical devices as 
they increasingly seek geriatric care. Emergence of novel therapies for chronic ailments 
such as sexual dysfunctions, anorgasmia, and juvenile diabetes continue to increase the 
demand for medical devices. Technological advancements that will aid the increased use 
of software-containing medical devices and medical devices will increase in complexity. 
The outlook for the medical device software also shows that there will be an increase in 
the miniaturization of medical devices leading to a decrease in the size of software-
containing devices (Halperin et al., 2008). 
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According to Hegde and Raheja (2010), one of the factors that will power the 
growth of the medical devices market is increased healthcare spending. According to 
estimates, healthcare spending in the United States stood at $2.4 trillion in 2008 and was 
forecast to stand at $3.1 trillion in 2012 and $4.3 trillion by 2016. Healthcare expenditure 
is forecast to constitute a fifth of America’s GDP by 2017 (Keehan et al., 2008). 
According to Chase (2004), beneficiaries of Medicare are projected to exceed 75 million 
people by 2030. Increased healthcare expenditure will lead to an increase in the 
consumption of medical device software (Hegde & Raheja, 2010). 
Favorable demographics in the United States and other major markets for medical 
device software will also play a role in enhancing the use of these devices. According to 
Gibbs (1994), there’s a doubling in the quantity of software present in consumer products 
every 2 to 3 years and this will also aid the growth of the industry to a larger extent. 
Increased inter-communication between medical devices through high-bandwidth and 
long-range wireless links – for instance, IMDs can now support the transfer of telemetry 
for remote monitoring using wireless means and at higher bandwidths and longer read 
ranges (Halperin et al., 2008). The US healthcare system is largely ineffective, costly, and 
is encumbered by an acute shortage of healthcare providers and an increase in the 
population of senior citizens. This provides a backdrop for the increased use of medical 
devices (Lee et al., 2006).  
The 2005 High Confidence Medical Device Software and Systems (HCMDSS) 
workshop identified several critical issues to the future development of software-
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containing medical devices. These issues include certification and validation, 
environmental concerns due to climate change, integration of medical devices, modeling 
and simulation of patients, and embedding of networked system infrastructure in a real-
time manner. Validation and certification are required before legislative authorities can 
grant manufacturers of medical devices the go ahead to market their devices.  
According to Lee et al. (2006), the certification is about to reach a limit due to the 
increasing complexity of the devices and their overreliance on embedded software to 
attain important functionality. Current validation and certification processes not only 
highly inflate the costs of medical devices but also increase the time to market and 
enhance the likelihood of device failure leading to higher recall rates and liability costs 
(Lee et al., 2006). There is need to review the current validation and certification 
processes to ensure that they not only protect the consumers of the products but also do 
not unjustifiably increase manufacturing costs and time. 
Integration of medical device systems will shape the medical devices industry to 
no small extent. Currently available medical devices are not highly distributed and have 
poor safety, privacy, extensibility, robustness, mobility, and interoperability 
characteristics. In addition, there is a disconnect between treatment and diagnostic 
systems that needs to be addressed for them to work together effectively. (Lee et al., 
2006). Modeling and simulation of patients is another factor that will have a bearing on 
the future outlook of medical device software. Software containing medical devices are 
more and more effective because of the increased use of simulation and modeling.  
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Embedding of networked system infrastructure in a real-time manner will help to 
enhance the role and effectiveness of medical device software. The outlook of software-
containing medical devices is that they will comprise of persistent networked systems 
that provide safe, dependable, cost-effective, high-quality, confidential, and personalized 
healthcare (Lee et al., 2006).  
Regarding global warming and climate change, environmental concerns are 
increasingly shaping the direction of medical device software. Future medical devices 
will need to be made of environmentally friendly materials (Woo & Woo, 2010). These 
concerns have led to the discontinued use of chlorofluorocarbon (CFC) in cleaning the 
medical devices as well as that of lead in the assembly of electronic instruments. More 
and more medical devices are manufactured using metallocenes and polyolefins such as 
cyclic olefin copolymers (COC) and cyclic olefin polymers (COP) in place of Polyvinyl 
chloride (PVC). In addition, sterilization using ethylene oxide gas has considerably 
reduced and replaced with ionizing radiation (Woo & Woo, 2010). Health concerns about 
these materials are also influencing the selection of materials for manufacturing medical 
devices. Concerns about the health risks posed by the use of PVC and di (2-ethylhexyl) 
phthalate (DHEP) led to their elimination in the manufacture of medical devices (Woo & 
Woo, 2010).There is also concern that the continued use of bisphenol A (BPA) in the 
manufacture of medical devices could pose health risks to consumers. This is borne out 
of the observation that BPA can imitate some hormones resulting in detrimental effects 
on expectant women and their children (Woo & Woo, 2010). 
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Emerging technologies such as nanotechnology drive the growth of medical 
device software. Innovation, increased uptake and improvements of technology, and 
biomaterials are also important factors as are micro-electro-mechanical systems (MEMS) 
and improvements in manufacturing processes. Trends in lifestyle will also have an 
impact on the future outlook of medical device software. Lifestyle changes are one of the 
main contributors to the growth of the medical device software market. For instance, 
people with sedentary lifestyles have a higher risk of obesity and diabetes mellitus and 
this determines demand for insulin pumps. More and more people perform sports and 
outdoor activities. These activities are bound to lead to body injuries and necessitate use 
of medical devices such as prosthetics.  
Design issues such as increased use of computer-aided design (CAD) and 
computer-aided manufacturing (CAM) coupled with better technology will make medical 
devices more compatible with a larger subset of the population and this has not only 
widened the consumer base but also reduced the age threshold for their use. Other 
important factors that will determine the future outlook of medical device software are 
new product development, establishment and growth of public health insurance, 
demographics especially aging populations, rising levels of income in developing nations 
and harmonization of legislative requirements and standards worldwide (ITA, n.d.). 
Chapter Summary 
The medical device market has expanded exponentially over the past decade. The 
US has the largest market for medical devices globally followed by the EU and Japan. 
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However, markets in countries such as China, India, and Brazil have continued to exhibit 
robust growth and they will become very important markets in future. Factors that will 
drive growth in many markets include expanding health insurance schemes, 
demographics, increased healthcare expenditure and harmonization of regulations, 
changing lifestyles, and better economic conditions among others. There are many 
positive impacts of medical device software such as improved health and economic 
fortunes. However, these devices expose users to many health and safety risks and can 
render them susceptible to loss of privacy as well as lead to deaths and injuries due to 
device failure.  
The objectives of standards are to ensure that the medical devices are not only 
effective but are also safe. The MDD 93/42/EEC is an example of a regulation 
formulated specifically for this purpose. There is still a high rate of software recall due to 
device failure. The regulations have also increased the sunk costs and the approval time 
to market medical devices. There is need to determine the exact impact that the MDD 
93/42/EEC has had on medical device software and to address any regulatory and 
legislative weaknesses. This will not only enhance the efficacy and safety of medical 
device software but also make the medical industry more competitive. Arising from this 
literature review, very few sources discussed the impact of the Directive on medical 
device software, and the impact to firm competitiveness remains to be ascertained. The 
next chapter will present the methodology of investigating the research questions and 
hypotheses postulated from chapter 1. 
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Chapter 3: Research Methodology 
Introduction 
This study involved examining the impact of the amendments to the MDD 
93/42/EEC on the U.S. medical device software industry. The purpose of the study was to 
evaluate impact of the changes in the MDD 93/42/EEC on the net income and share 
prices of the compliant firms; the training cost for each EN/IEC/62304 compliant 
software year; project cost for each EN/IEC/62304; and the recall rate of devices 
manufactured by firms in the United States. This chapter includes the research methods 
used to conduct the study. This chapter outlines the nature of the study, its 
appropriateness to the research, and the population, sampling, and data collection criteria. 
This chapter also contains measures used for ensuring the reliability and validity of the 
study, evidence of trustworthiness, a description of the data analysis methods, ethics, and 
data management methods. The research questions and hypotheses formulated were as 
follows: 
1. Research Question 1: What is the impact of changes to the MDD to the net 
income of medical device software firms in the United States? 
H10-Null Hypothesis: There has not been a decrease in the net income of medical 
device software firms in the United States due to changes to the MDD. 
H1a-Alternative Hypothesis: Changes to the MDD have led to a significant 
decrease in the net income of medical device software firms in the United States. 
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2. Research Question 2: What is the impact of changes to the MDD on the training 
costs for each EN/IEC/62304 compliant software year of medical device software 
firms in the United States? 
H20-Null Hypothesis: Changes to the MDD have not significantly reduced the 
training costs for each EN/IEC/62304 compliant software year of medical device 
software firms in the United States. 
H2a-Alternative Hypothesis: Changes to the MDD have significantly reduced 
the training costs for each EN/IEC/62304 compliant software year of medical 
device software firms in the United States. 
3. Research Question 3: What is the impact of changes to the MDD on the project 
costs of medical device software firms in the United States? 
H30-Null Hypothesis: There has not been a significant decrease in the project 
costs for each EN/IEC/62304 compliant software year of medical device software 
firms in the United States due to changes to the MDD. 
H3a-Alternative Hypothesis: Changes to the MDD have led to a significant 
decrease in the project costs for each EN/IEC/62304 compliant software year of 
medical device software firms in the United States. 
4. Research Question 4: What is the impact of changes to the MDD on the recall rate 
of medical device software firms in the United States? 
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H40-Null Hypothesis: There has not been a significant decrease in the recall rate 
of medical device software manufactured by firms in the United States due to 
changes to the MDD. 
H4a-Alternative Hypothesis: Changes to the MDD have led to a significant 
increase in the recall rate of medical device software manufactured by firms in the 
United States. 
Research Design and Rationale 
The nature of this study was a mixed methodology of qualitative study and 
quantitative techniques. The main objective of conducting a qualitative study was to 
understand and decipher subjective meaning from the point of views of the participants of 
the study. The quantitative techniques involved testing closed ended questions under a 
multivariate analysis framework. The significance of means from the participants was 
suitable to accept or reject the given alternate hypotheses and their null statements 
(Tabachnick & Fidell, 2001).  
Appropriateness of the study method chosen 
The qualitative technique involved systematic literature review, interviews and 
case study for the following reasons: (a) the qualitative method enables researchers to 
discover the problems under investigation (Bryman & Bell, 2011), and (b) this approach 
was preferred since the technique leads to the discovery of feasible solutions for the 
problems at hand (Coffey & Atkinson, 1996). The method does not only allow the 
researchers to devise novel concepts and ideas related to the issues under investigation 
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but also enable the analysis of lots of information (Bryman & Bell, 2011). In addition, 
compared to other methods, it was relatively cost-effective. Moreover, the method allows 
rapid turnaround time and the outcomes can be obtained within a short time (Dawson, 
2013). The qualitative method was suitable since it enables the gathering of large 
amounts of background information quickly and without much difficulty (Coffey & 
Atkinson, 1996). 
The quantitative method was suitable for its simple correlation, descriptive and 
Analysis of Variance (ANOVA) capabilities of the given factors and hypotheses 
(Tabachnick & Fidell, 2001). The simple correlation measured the sampled firms 
performance attributes before and after the implementation of the EU MDD such as net 
income, stock values, project costs and impact on revenue and employee numbers. The 
descriptive analysis was suitable to evaluate the demographic and operational key 
performance indicators of the various firms whose representatives participated in the 
survey. The ANOVA was appropriate for testing the hypotheses significance against 
p=0.05 (SPSS Inc., 2008).  
Rationale for Selection of the Mixed Method  
The mixed method design was suitable for this study due to the following 
considerations:  
1. I was able to explore the issues under study using both qualitative or narrative and 
quantitative or numerical forms thereby enabling a systematic and complete 
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appreciation of the research problem and expansion of the breadth and scope of 
the investigation (Borkan, 2004) 
2. The mixed method study approach allowed the collection of useful primary data 
on the impacts of the MDD 93/42/EEC directive on medical device software 
which would otherwise be impossible if other methods such as meta-analysis 
were used due to the scarcity of current and conclusive data  
3. In mixed method studies, researchers have recourse to different feasible 
alternatives (Zikmund, 2010). The main objective of this study was to determine 
the impact of the EU Medical Device Directive on medical device software and 
hence infer possible solutions to solve identified problems. I used of the mixed 
method approach not only to identify the problems and drawbacks associated with 
the MDD 93/42/EEC but also to propose viable alternatives that could be used to 
redress these problems. From the foregoing therefore, it is evident that the mixed 
method was a more useful approach than either the explanatory or the descriptive 
approach for this particular study. 
4. The mixed method approach allowed the outcomes and questions of one method 
to be recasted with those of the other method thus enabling the discovery of novel 
perspectives, contradictions, and paradoxes (Zikmund, 2010) 
5. Exploratory research is advantageous when mixed method studies are conducted. 
I was able to build theory as well as obtain a profound understanding of the issues 
I investigated. In particular, mixed method studies are beneficial during the early 
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phases of research. The use of the mixed method approach helped formulate 
theories on the impact of the EU Medical Device Directive on medical device 
software and hence provided a comprehensive and well-supported framework on 
the research topic.  
6. A major goal of this study was to identify problems associated with the EU 
Medical Device Directive on medical device software. Studies conducted using 
the mixed method approach have been instrumental in deciphering problems 
facing important regulations and directives in the medical field. Therefore, I was 
confident that the correct use of the mixed method approach in this study would 
similarly enable the identification of any problems associated with the EU 
Medical Device Directive on medical device software.  
7. The mixed method approach promotes the creation of new novel ideas. This study 
sought to come up with new ideas about the role, place, impact and possible 
effects of the EU Medical Device Directive on medical device software. The 
mixed method technique was also preferred because it enhances 
complementarities, validity and reliability of the study (Green et al., 1989). 
Program Evaluation 
Summative evaluation was suitable to determine the impact of EN/IEC/62304 of 
Medical Software. Summative evaluation is a method of assessing the value of a program 
against its specification. It provides information on the capability of the program to meet 
the expectation of performance. Singleton and Straits (2010) describe two types of 
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summative evaluation used in this study: (a) Effect assessment evaluated whether the 
Medical Device Directive was achieving its intended effects and (b) efficiency 
assessment evaluated the cost and benefit values of the Directive. Summative evaluation 
included descriptive statistics. Considering that significance in summative evaluations is 
not an expression of randomness, the issue of randomness was not an important aspect of 
the measure, since the concern was for the impact of EN/IEC/62304 on firm 
performance.  
Role of the researcher 
Denzin and Lincoln (2003) consider the research as a human instrument of data 
collection. The role of the researcher in this study necessitates the identification of 
personal values, including any assumptions and biases, any expectations and experiences 
at the outset of the study (Greenbank, 2003). The researcher is a Biomedical Engineer 
with decades of experiences in the medical devices manufacturing industry. He is a 
current member of the American Society of Quality Assurance (ASQ) and has extensive 
experience in the European Medical Device Directive 93/42/EEC as well the U.S. Code 
of Federal Regulations for medical devices (Title 21 CFR part 820). 
I believe that my professional experience provides firsthand knowledge, and 
sensitivity to the topic examined in this study. Although I made every effort to ensure 
objectivity, personal bias may have shape the way I viewed and understood the data 
collected and their interpretation.  
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The interview participants were purposefully selected because of their unique 
expertise in their respective fields. I did not have supervisory or instructor relationships 
involving power over the participants. The interviewees worked for different firms. I 
conducted the study using combination of questionnaires and structured interviewing 
techniques; asking the participants open-ended questions about their unique expertise 
with the research topic. I reduced researcher bias by administrating the survey 
anonymously using SurveyMonkey.com. Based on the ethics review, as part of this study, 
I assigned the study participants pseudonyms and the data collection occurred in total 
confidentiality.  
Population 
The target population included employees at selected medical device 
manufacturing companies. My preliminary investigation established that there were at 
least 265 firms in the medical device industry with business interest reaching the EU 
regions. I conducted interviews with managers at the following firms: Organization X 
and Organization Z. Organization X employs about 250 employees, and Organization Z 
employs about 85 employees. References to these organizations as Organization X and 
Organization Z are for purposes of confidentiality. Each of these companies was listed 
either in the New York Stock Exchange or NASDAQ or in terms of size, their market 
capitalization ran into millions of dollars. The study involved qualitative case studies of 
five medical device companies that have been in operation since the publication of the 
EN/IEC/62304 standard in 2007. 
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Sampling Methods and Procedures 
For both the survey and interviews, the sampling frame consisted of senior and 
middle level managers of the companies listed in the preceding section. This study 
included a concurrent mixed method study and involved administering questionnaires to 
a convenient sample of professionals from companies in the medical device software 
industry. The population size consisted of 256 potential respondents targeting at least 1 in 
each firm. I used the purposive sampling technique to select respondents for the study. I 
selected the respondents in a non-random fashion based on the qualities that I deemed 
were suitable for attaining the ends of the study. The method was suitable since I was 
able to select respondents well versed with the issues under investigation. In particular, 
the purposive sampling technique allowed the selection of respondents based on their 
easy availability and more importantly because their experiences and perspectives 
provided useful information critical in answering the research questions (Saunders et al., 
2009). 
Since the study survey was administered online, I adopted convenient sampling of 
the respective firms’ managers. Eventually, I managed to get interviews from two 
managers of the cited firms and while the survey managed to get feedback from 56 firm 
representatives. This is equivalent to 21.87% response rate. According to Kaplowitz et 
al., (2004), this response rate is admissible for an online survey first due to the 
geographical dispersion of the respondent and second due to difficulties of contacting the 
respondents. For years, observers assumed that higher response rates guaranty more 
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accurate survey results (Aday, 1996; Rea & Parker, 1997). However, very few studies 
have documented the consequences of lower response rates. A study by Visser, Krosnick, 
Marquette and Curtin (1996) indicated that surveys with lower response rates (closed to 
20%) yielded more accurate results than did surveys with 60 or 70% response rates.
 
A 
study by Curtin et al. (2000) on the effect of lower response rates found no effect of 
excluding respondents who initially refused to cooperate on estimates of the Index of 
Consumer Sentiment using monthly samples of hundreds of respondents. On the other 
hand, a low response rate is likely to give rise to sampling bias. Holbrook et al. (2005) 
found that surveys with much lower response rates decreased local representativeness 
within the demographic range examined, but not significantly. Data saturation was not 
addressed in this study. Due to resource constraints, the sample respondents for 
qualitative data capture was done purposively. The following criteria were suitable to 
ascertain the eligibility of participants in the study: 
Inclusion criteria 
1. Study participants were willing to take part in the study 
2. They must have worked in the medical devices software field for a period not 
less than 5 years 
3. Their company must have released a EN/IEC/62304 compliant software since 
the publication of the standard in 2007 
4. They must be able to speak and write in English 
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Data Collection Methods 
Primary Data 
I collected primary data using surveys, in-depth interviews, and case study and 
systematic literature review (Saunders, et al., 2009). 
Survey Instruments. I used survey instruments since they allow me to collect 
information in an inexpensive manner and without much difficulty. The study involved 
collecting primary data using SurveyMonkey.com. This method was ideal for 
administering the surveys because of a variety of reasons including its low cost especially 
where the target population resides in remote or distant geographical areas and the ease of 
administration to large populations. Use of the web surveys enabled instant transmission 
and reception of the questionnaires. Web surveys allowed enforcement of anonymity. No 
staff time was required with this method (Kaplowitz, et al., 2004). The questionnaire was 
designed using tools provided in the website and is attached as shown in the appendix. 
The survey questions probed the effectiveness Medical Devices Directive MDD 
93/42/EEC, the impact of the MDD 93/42/EEC on medical devices costs and firms 
revenues. Other questions focused on process improvement of conformity assessment and 
the legal impact of the MDD 93/42/EEC. 
In-Depth Interviews. The study involved performing in-depth interviews. These were 
open-ended, detailed, discovery-oriented and unstructured data collection tools (Guion, 
2006), According to Zikmund (2010), in-depth interviews are qualitative research 
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methods that allow a one-on-one discussions. The main objective of the in-depth 
interviews was to understand the impact of EU Medical Devices Directive on medical 
device software by assessing the answers provided by the respondents when questioned 
(Zikmund, 2010). The chief characteristic of in-depth interviews was the use of open-
ended questions in which the respondents provided responses to the questions that I 
posed in an open and free manner (Zikmund, 2010). In-depth interviews consisted of 
seven steps namely thematization, designing, interviewing, and transcription. Others were 
analysis, verification, and reporting (Kvale, 1996 cited in Guion 2006 p.2).  
I adopted good interviewing skills in order to ensure that the responses obtained 
were accurate. I prepared an exhaustive interview guide comprising of a list of questions 
and follow-ups in order to keep interviewees from digressing. The guide also helped to 
provide a summary of the question, ensured that questions followed a sequential order, 
and ensured consistency in during the interviews. I used reasonably acceptable standards 
and formats during the preparation of the interview guide and I utilized a detailed face 
sheet to log in the date, demographic data of the participants, time of the interviews, and 
interview location. I also made use of good interviewing practices like patience, 
flexibility, and active listening to ensure optimum process and quality responses 
obtained. I used audiotapes to record the interviews after obtaining permission from the 
respondents. The objective was to store information for future reference as well as to 
enhance the interview precision.  
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The interview questions assessed the impact of EN/IEC/62304 on organization, 
and explored ways in which EN/IEC/62304 has been effective in enhancing the safety of 
medical devices, and whether or not medical device software produced under the 
guidance of EN/IEC/62304 provides firms with a competitive advantage. 
Case Studies. I reviewed cases of financial performance of purposively selected 
companies in the medical device manufacturing industry, which are Artventive Medical 
Group Inc., Varian Medical, Mindray Medical, Abiomed and CryoLife. The purposive 
sample relied on the assurance that these medical device companies have embedded 
software and export products to EU markets. I retrieved case study information was from 
Securities and Exchange Commission (SEC) and Yahoo Financial data, both which are 
free access for public viewing. The justification of case studies was that method used 
collation first-hand information from medical devices software firms in the United States 
on the impact of EU medical Directive on these devices. Net income, shares stock price 
trends and the cost of implementation of the standard in terms of R&D served as the basis 
to examine participating firms’ competitiveness after the implementation of the changes 
in the MDD 93/42/EEC. According to Yin (2009), case studies are appropriate when 
there are structured data and information about organizations or system whose variable 
comparison is under investigation. 
Secondary Data.  
According to Saunders, et al. (2009) use of different sources of secondary enables 
researchers to address successive gaps raised by every other. I developed and used the 
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systematic literature review method to gather literatures, theories and positions of various 
issues in the study such as MDD 93/42/EEC, medical device industry and various 
Standard Operating Procedures (SOP) which assign labels on medical devices as mark of 
quality and certification. Systematic literature review provided evidence about trends and 
acquires higher reliability if corroborated by different sources (Hiladgo, et al., 2011). 
Systematic Literature review provided information about policy, laws, practices and the 
impact to stakeholders (Evidence for Policy and Practice Information and Co-ordinating 
Centre, 2007). Systematic literature review is appropriate for studying robust supply 
chains such as envisaged in the medical device industry of interest in this research 
(Colicchia & Strozzi, 2012). The secondary data I collected included the net income for 
each company under study and the percent changes in training cost for each 
EN/IEC/62304 compliant software year. Secondary data also included the percent 
changes in project cost for each EN/IEC/62304 compliant software year and the percent 
changes in net income for each EN/IEC/62304 compliant software year. These data were 
obtained from company reports, Hoovers database and Yahoo Finance. Secondary data 
were also collected from the internet, peer-reviewed articles, premium content databases 
such as the IEEE, online vendors, books, market research reports, government reports and 
white papers, books, market research reports, standard reference works, and libraries.  
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Validity and Reliability 
Validity is a measure used to determine how accurately a particular tool assesses 
what it is supposed to assess (Zikmund, 2010). It indicates the degree to which collected 
data is a reflection of reality and therefore determines how useful a particular outcome is. 
Threats to Validity 
The convenience method of sampling and the use of archival data potentially 
limited a generalization of the findings (Creswell, 1998). The overall strategy was a 
mixed purposeful sampling composed of convenience sampling and purposive sampling. 
While these types of sampling techniques use small sample sizes, the goal was 
credibility, not representativeness. The respondents were from firms within a certain 
geographical region, which may have led to selection bias with a possible negative effect 
on validity. A low response rate is likely to give rise to sampling bias. 
Due to the different level of experience of the respondents, the selection 
maturation effect could have threatened the validity of the study. To reduce this threat, 
one of the inclusion criteria for the study was that participants must have worked in the 
medical devices software field for a period not less than 5 years. Data collected from 
participants during the interviews, and survey included opinions that could have also 
threatened the credibility of the study.  
Issue of Trustworthiness 
Guba (1981) proposed four constructs for judging the trustworthiness of 
qualitative research: credibility, transferability, dependability and confirmability. In 
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addressing credibility, I used data triangulation: collecting both quantitative and 
qualitative data from both primary and secondary sources. Trustworthiness of 
interpretations was enhanced through triangulation of quantitative financial data on the 
performance of the five medical device companies, in depth interviews with two 
experience managers in regulatory affairs and quality assurance. Member checking was 
included as a validity strategy. I conducted a follow-up meeting to give them the 
opportunity to verify the transcripts. On the issue of reflectivity, Creswell (1998) believes 
that all researchers have personal biases that can influence their interpretation of data. I 
believe that my professional experience provides firsthand knowledge, and sensitivity to 
the topic examined in this study. Personal bias may have influenced my interpretation of 
the data collected. 
To allow transferability, specific criteria were defined (P. 117) to ascertain the 
eligibility of participants in the study. In addition to being a U. S. medical device 
companies marketing products in the EU, and the detail description on the research 
methods, these criteria provide sufficient details for a reader to be able to decide whether 
the findings can justifiably be applied to the other contexts or settings.  
In addressing the issue of dependability, I used triangulation and audit trail. I 
provided a detail report of the research design and study results. The meeting of the 
dependability criterion should enable a research to repeat the study in the future.  
Finally, to achieve confirmability, the findings of this study are the result of the 
experiences and opinions of the participants. The findings emerged from data collected 
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from literature reviews, interviews and case study of five U.S. medical device companies. 
I have provided evidence in Chapter 4 on procedures I used in this study to increase 
trustworthiness of the research. 
Minimization of Bias 
Questionnaire bias was reduced by administering the questionnaires to people 
meeting the inclusion criteria, and standardization of the questionnaire. Learner bias was 
avoided by randomizing the order of questions asked. Researcher bias was reduced by 
administrating the survey anonymously using SurveyMonkey.com. The data collection 
occurred in total confidentiality. 
Research Strategy and Time Frame 
The entire study took place over a period of 12 months. Following the review of 
literature, the design of questionnaires was done and participants for the study recruited 
thereafter. Administration of questionnaires, and in-depth interviews were conducted 
subsequently. Completed questionnaires were collected and data verification and 
transformation thereafter performed. The data were then analyzed and the final report 
compiled. The following convergence table was used to present results of the 
triangulation. 
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Table 4  
Convergence Table for Presenting Triangulation Results 
Research question Results 
Comparison / 
convergence 
 Quantitative Qualitative  
What is the impact of changes to 
the MDD 93/42/EEC on medical 
device software? 
Summary Summary 
Summary of whether 
the results converged or 
failed to converge 
What is the impact of the MDD 
93/42/EEC on Europeans medical 
device manufacturer’s 
competitiveness? 
Summary Summary 
Summary of whether 
the results converged or 
failed to converge 
 
Data Analysis 
Qualitative Data Analysis  
The qualitative data analysis was done using thematic descriptions along the study 
questions and hypothesis and summative evaluation (Coffey and Atkinson, 1996). In the 
case studies, descriptive statistics involved univariate analysis in which measures of 
central tendency, namely the mean and mode, were computed and displayed graphically 
(Saunders, et al., and 2009). The interviews were analyzed thematically with relevance to 
the research questions (Gillham, 2005). The secondary data and information were 
analyzed by summative evaluation to document whether EN/IEC/62304 is meeting its 
objectives, and whether there are any unintended consequences. Summative evaluation 
involves making judgments about the efficacy of a program at its conclusion (Bryman & 
Bell, 2011). It provides information on EN/IEC/62304 's efficacy and its ability to do 
what it was designed to do.  
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Quantitative data analysis 
The quantitative financial data analysis were analyzed using excel to extrapolate 
the trends and measures from central tendencies (Saunders, et al., 2009). Additionally, I 
tested the hypotheses by data entry into SPSS tool, which is versatile in univariate and 
multivariate correlations (SPSS Inc., 2008). The ANOVA method was preferred to test 
the data along the Five Point Likert scale for their significance on the benchmark of 
p=0.05 (Tabachnic & Fidell, 2001).  
Table 5  
Quantitative Data Analysis. 
Hypotheses 
Dependent 
variable 
Independent 
variable 
H10: Changes to the MDD 93/42/EEC have led 
to a decrease in the net income of medical 
device software firms in the US 
Net income for 
the firms in 
2011 
Average net income 
for the firms (2005-
2009) 
H20: Changes to the MDD 93/42/EEC have led 
to a decrease in the training costs for each 
EN/IEC/62304 compliant software year of 
medical device software firms in the US. 
Training costs 
for the firms in 
2011 
Average training 
costs for the firms 
(2005-2009) 
H30: Changes to the MDD 93/42/EEC have led 
to a decrease in the project costs for each 
EN/IEC/62304 compliant software year of 
medical device software firms in the US. 
Project costs 
for the firms in 
2011 
Average project 
costs for the firms 
(2005-2009) 
H40: Changes to the MDD 93/42/EEC have led 
to an increase in the recall rate of medical device 
software manufactured by firms in the US. 
Average 
percent recall 
rate (2011) 
Average percent 
recall rate (2005-
2009) 
 
Constant comparison was at the core of the data analysis. A convergence table 
was used to present results of the triangulation (p. 124). 
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Ethical Considerations 
A letter of participation was email to the heads of the Quality Assurance 
department of participant firms (see Appendix G). I subsequently sent an email with the 
consent form (Appendix H) to the participants after I received a positive response to the 
letter of participation. 
Ethical considerations were taken into account in order to comply with the 
demands of good research and to protect the privacy and rights of the participants 
(Saunders, et al., 2009). Privacy was enhanced by use of unique codes instead of the 
participants’ names. Permission was obtained from the university’s Institutional Review 
Board (IRB) before commencement of the study and full disclosure was made to all 
participants in order to comply with ethical requirements. The IRB approval number for 
the current study issued by Walden University is 09-20-13-0109393 and expired on 
September 19, 2014 (see Appendix E). 
In addition, collection of data through interviews was also done in an ethical 
manner. From the outset, I acknowledged and respected the respondents’ right to privacy 
and therefore avoided asking questions that overstepped the limits of personal privacy 
(Trochim, 2001). 
I also took steps to safeguard the respondents’ anonymity and sought informed 
consent prior to the administration of the questionnaires. This involved explaining the 
purpose of the study to the respondents and giving them a clear description of the aims 
and objectives before requesting for permission to take part in the study. I also informed 
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the respondents that they could opt to discontinue the study at any time. I carried out the 
interviews openly without any concealment or dishonesty and I adhered to the letter the 
code of ethics guiding research from the National Institutes of Health (NIH) Office of 
Extramural Research (Certification Number: 853619). I used safe filing cabinet and 
strong password to store data ensured that the privacy of the participants was 
safeguarded. Privacy of the respondents will also be guaranteed by destroying the data 60 
months after completion of the study through shredding or formatting the hard disk. The 
nature of the data gathering process did not require a formal procedure for exiting the 
study. All participants were thank for participating in the study. 
Data Entry and Management 
Quantitative data entry was through typing and scanning of financial data into a 
Microsoft Excel spreadsheet to extrapolate the individual company performance then 
comparison is conducted across the firms. Data validation was done to ensure that no 
questions have been skipped and that all important demographic and background 
information has been supplied. I contacted the participants for clarification to correct 
incomplete questionnaires. In line with good research practices, I made use of a codebook 
to store pertinent information about the research and the collected data. Each anonymous 
interview respondent was accorded their wish as prerequisite for participating in the 
study.  
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Summary  
This chapter has outlined the research strategy, which was comprised of mixed 
qualitative methods of systematic literature review, interviews, online survey and case 
studies. I adopted convenient sampling to get interviews from two managers and while 56 
firm representatives participated in the online survey. I conducted the case study of 
ArtVentive Medical Group Inc., Varian Medical, Mindray Medical, Abiomed and 
CryoLife companies. The chapter has defined each strategy and justified choices of each 
method. The chapter has also defined the data and information analysis methods suitable 
for triangulation of these three methods to ensure the outcomes are replicable and 
validated. I have outlined ethical factors that had impact on the study. The next chapter 
will provide interview, case study and literature findings followed by analysis and 
interpretation along the research questions and hypothesis. 
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Chapter 4: Results, Data Analysis, and Discussion 
Introduction 
The main objective for this study was to determine the impact of the amendments 
to the MDD 93/42/EEC on the U.S. medical device software industry. The purpose of the 
study was to evaluate the impact of the changes in the MDD 93/42/EEC on the net 
income and share prices of the compliant firms, the training cost for each EN/IEC/62304 
compliant software year, project cost for each EN/IEC/62304, and the recall rate of 
devices manufactured by firms in the United States. This chapter is organized around the 
research questions identified in chapter 1, the methodology defined in chapter 3, the 
interview findings followed by case study results, analysis, and discussion along the 
research questions. The chapter also contains a brief recapitulation of the latest proposed 
amendments in the MDD 93/42/EEC on cost, safety, quality, and reliability aspects. The 
final section contains a summary of the results pertaining to each research question. 
Settings 
The nature of this study was a concurrent mixed method study involving both 
quantitative and qualitative techniques. The qualitative phase involved systematic 
literature review, interviews and case study of five medical devices companies selected 
by purposive sampling. The study involved recording interviews on tape and collecting 
surveys using surveymonkey.com. Each of the interview items answers are sub-questions 
from the main research questions. I adopted convenient sampling to get telephone 
interviews from two managers and while 56 firm representatives participated in the 
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online survey. This is equivalent to 21.87% response rate. The survey participants 
represented several different organizations. The quantitative phase involved the collection 
of financial data on the performance of the five medical device companies. There were no 
known current personal or organizational conditions that influenced participants or their 
experiences that may have affected the study results. The same was true of the 
participants in the quantitative phase. 
Demographics 
I gathered survey results from 56 respondents via mail (71% male and 29% 
female). Study participants were limited to individual who have worked in the medical 
devices software field for a period not less than 5 years. The study also involved 
submitting the questionnaire and survey to two managers with experience in the medical 
device industry working at Company X and Company Z. The first participant was the 
manager of quality assurance and regulatory affairs at Organization X (MOX), and the 
second was the senior director of clinical affairs working at Organization Z (DOZ). MOX 
had been working in the medical device industry for 21 years. DOZ had 18 years of 
experience in clinical affairs management. 
Data Collection 
This study had four main questions and hypotheses addressed by surveys, in-
depth interviews, a case study of five U.S. medical device manufacturers purposively 
selected and systematic literature review. Permission was obtained from the university’s 
Institutional Review Board (IRB) before commencement of the study and full disclosure 
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was made to all participants in order to comply with ethical requirements. The IRB 
approval number for the current study issued by Walden University is 09-20-13-0109393/ 
I gathered survey results from 56 respondents via mail. The study also involved 
submitting the questionnaire and survey to two managers with experience in the medical 
device industry. These managers worked for two different medical devices manufacturers 
located in the San Francisco Bay Area. Interviews lasted one hour, with a planned ninety 
minutes minimum time. The interviews were tape-recorded and I transcribed from the 
audio recording taken. Primary data were collected using SurveyMonkey.com. The 
survey questions probed the effectiveness Medical Devices Directive MDD 93/42/EEC, 
the impact of the MDD 93/42/EEC on medical devices costs and firms revenues. Other 
questions focused on process improvement of conformity assessment and the legal 
impact of the MDD 93/42/EEC. The study involved performing in-depth interviews. The 
main objective of the in-depth interviews was to understand the impact of EU Medical 
Devices Directive on medical device software by assessing the answers provided by the 
respondents when questioned (Zikmund, 2010). I used audiotapes to record the 
interviews after obtaining permission from the respondents. The objective was to store 
information for future reference as well as to enhance the interview precision. I reviewed 
cases of financial performance of purposively selected companies in the medical device 
manufacturing industry, which are ArtVentive Medical Group Inc., Varian Medical, 
Mindray Medical, Abiomed and CryoLife. The purposive sample relied on the assurance 
that these medical device companies have embedded software and export products to EU 
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markets. The entire study took place over a period of 4 months. There were no variations 
from the data collection plan presented in Chapter 3, and no unusual circumstances 
occurred. 
Research Questions 
This section includes data from surveys and survey, market capitalization for each 
company under study, mean changes in stock company performance for each 
EN/IEC/62304 compliant software year, mean changes in project cost of R&D for each 
EN/IEC/62304 compliant software year, and mean changes in net income for each 
EN/IEC/62304 compliant software year. The investigation for each research question 
involved administering qualitative telephone-administered surveys to the various 
companies affected by the MDD 93/42/EEC amendments. The targeted population 
consisted of medical equipment companies. To determine the impact of the MDD 
93/42/EEC on the safety and reliability of software systems, and the impact on training 
and employee recruitment, the research questions and hypotheses formulated were as 
follows: 
Research Question 1: What is the impact of changes to the MDD to the net 
income of medical device software firms in the United States? 
H10: There has not been a decrease in the net income of medical device software 
firms in the United States due to changes to the MDD. 
H1a: Changes to the MDD have led to a significant decrease in the net income of 
medical device software firms in the United States. 
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Research Question 2: What is the impact of changes to the MDD on the training 
costs for each EN/IEC/62304 compliant software year of medical device software firms 
in the United States? 
H20: Changes to the MDD have not significantly reduced the training costs for 
each EN/IEC/62304 compliant software year of medical device software firms in the 
United States. 
H2a: Changes to the MDD have significantly reduced the training costs for each 
EN/IEC/62304 compliant software year of medical device software firms in the United 
States. 
Research Question 3: What is the impact of changes to the MDD on the project 
costs of medical device software firms in the United States? 
H30: There has not been a significant decrease in the project costs for each 
EN/IEC/62304 compliant software year of medical device software firms in the United 
States due to changes to the MDD. 
H3a: Changes to the MDD have led to a significant decrease in the project costs 
for each EN/IEC/62304 compliant software year of medical device software firms in the 
United States. 
Research Question 4: What is the impact of changes to the MDD on the recall rate 
of medical device software firms in the United States? 
H40: There has not been a significant decrease in the recall rate of medical device 
software manufactured by firms in the United States due to changes to the MDD. 
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H4a: Changes to the MDD have led to a significant increase in the recall rate of 
medical device software manufactured by firms in the United States. 
Interview Results  
The study involved submitting the questionnaire and survey to two managers with 
experience in the medical device industry working at Company X and Company Z 
because these individuals indicated during my initial phone call that they were the 
persons to review and approve my request to conduct the research study. During the 
phone calls, the managers requested that I e-mail them in advance all documents 
associated with the research, including the questionnaire. After reviewing the documents, 
they indicated that they would be the sole participants. References to these organizations 
as Organization X and Organization Z are for purposes of confidentiality. 
The two participants completed a 60-minute survey online and two interviews 
took place during 60-minute phone calls. The first participant was the manager of quality 
assurance and regulatory affairs at Organization X (MOX), and the second was the senior 
director of clinical affairs working at Organization Z (DOZ). The study involved 
triangulating the interview data by conducting case studies of financial data, stocks, and 
R&D competitiveness of selected companies.  
My first contact was with MOX. MOX was the manager of quality assurance and 
regulatory affairs at Organization X, a company that manufactures medical therapy 
apparatus software. MOX had been working in the medical device industry for 21 years. 
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Organization X has approximately 250 employees worldwide. This interview took place 
on December 12, 2013, at 10:30 p.m. 
The second participant, DOZ, was the senior director of clinical affairs working at 
Organization Z. Organization Z is a medical device company specializing in the 
manufacturing of wound healing technologies. DOZ had 18 years of experience in 
clinical affairs management. This survey took place on December 10, 2013, at 7:35 p.m. 
Organization Z has approximately 85 employees worldwide. 
As previously stated, the purpose of the study was to evaluate the impact of the 
changes in the EU MDD 93/42/EEC on medical software and firm competiveness. The 
two interviews captured various areas where medical device software is applicable. The 
interviews and surveys indicated various departments existed within the medical device 
companies, including hardware engineering, software engineering, project management, 
regulatory affairs, operations, manufacturing, and others. Each department has close 
relations to the overall software product and standardization, hence the importance of 
capturing their supply chain value systems.  
The interviews captured various demographic factors that may have a direct or 
indirect impact on the employee characteristics and organizational structure. Both 
interview participants were males, aged between 36 and 55 years. Both respondents had 
been with their current employer less than 10 years. 
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Research Question 1 
Research Question 1 was as follows: What is the impact of changes to the MDD 
to the net income of medical device software firms in the United States? MOX indicated 
that the value of Organization X’s exports to Europe from March 24, 2011, to March 24, 
2012, exceeded US$1 million. DOZ did not disclose information on the value of the 
company’s export to Europe between March 24, 2011, and March 24, 2012. DOZ had no 
opinion regarding whether the amendments had a significant impact on competitiveness 
of the company. MOX reported that leaders of Organization X implemented 
EN/EN/IEC/62304 in early 2013 using a third-party consultant to speed up the software 
life cycle, and the organization has benefited from various competitive advantages such 
as validated performance and reliability compared to other types of devices measurable in 
financial metrics. 
The survey on the impact on European market-share changes since March 24, 
2011, indicated 50% have not changed while 50% decreased. Neither respondent 
indicated the percentage change by increase or reduction of the European market share 
since March 24, 2011. The question whether medical device software produced under the 
guidance of EN/IEC/62304 provides firms with a competitive advantage had affirmative 
responses. MOX confirmed, “It will provide competitive advantage, because it is a 
harmonized standard. That means the scientific community is behind it.” MOX reiterated 
that EN/IEC/62304 is useful in the “safety and efficacy” of the medical device that was a 
troubled link from product standards.  
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Research Question 2 
Research Question 2 was as follows: What is the impact of changes to the MDD 
on the training costs for each EN/IEC/62304 compliant software year of medical device 
software firms in the United States? MOX commented, “We have implemented 62304 
fully, we are practicing fully. All our procedures have been revised, and people have been 
trained. We have spent $100,000 on training. We have about 265 associates globally.” 
MOX stated that the number of new employees increased by 10% since March 24, 
2011,while the number of old employees decreased by 15% since March 24, 2011. DOZ 
did not disclose any data associated with changes to the MDD 93/42/EEC on the training 
costs. When asked what organizational leaders could do to increase the implementation 
speed of EN/IEC/62304 and employee retention, MOX responded that the company had 
“invested nearly $100,000 on training.” 
I commented that EN/IEC/62304 outlines the software development life cycle by 
defining the majority of verification activities, which has an impact on training needs at 
various stages of best practice such as software devices planning, requirement analysis, 
implementation and verification, integration, and software release at different phases 
within the organizations. In terms of demonstrating compliance with these standards, 
DOZ commented, “Again right now, everybody is going through a learning curve. It is an 
excellent process, well-structured.” MOX noted that the entire workforce has received 
training on the EN/IEC 62304 standard for efficiency and competitiveness in operations. 
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Research Question 3 
Research Question 3 was as follows: What is the impact of changes to the MDD 
on the project costs of medical device software firms in the United States? The survey 
finding on the costliness of the MDD 92/42/EEC approval process was that MOX and 
DOZ indicated Class I and Class IIa devices were 100% and 50% not costly, respectively, 
and both participants indicated Class IIb and Class III were 100% costly. The findings on 
the effects of the amendments on the cost of approval were split, with MOX indicating 
“increased costs” while DOZ indicated “do not know.” With regard to the question about 
the duration of the approval process for medical devices, both respondents indicated a 
“long time more than 90 days.” 
During the probe regarding any effects of the implementation of EN/IEC/62304 
on software costs and employee training, MOX indicated a concern about the cost of 
compliance, stating, “If you are selling a product to the EU, you are required to comply 
with 62304; otherwise, you might not be able to sell the product.” MOX noted that sales 
fluctuations affect company labor planning. Consequently, regarding the impact of 
EN/IEC/62304 on changes of the number of employees since March 24, 2011, MOX 
indicated a 50% increase while DOZ indicated a 50% reduction. There was mixed 
feedback about the changes on employee numbers. 
Research Question 4 
Research Question 4 was as follows: What is the impact of changes to the MDD 
on the recall rate of medical device software firms in the United States? A review of FDA 
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data between 2002 and 2010 revealed recalls for approximately 1.5 million software-
based medical devices. That 8-year period had more than twice the number of software 
device recalls compared to the previous 8-year period. DOZ indicated there were no 
recalls of devices after June 30, 2004. However, the survey responses identified various 
areas with potential causes of product recall such as initial software malfunction, 
behavior failure, failure of output, service failure, delay failure, input failure, response 
failure, failure due to data, user instruction failure, timing failure, system failure, quality 
failure, and others. During the interviews, MOX attributed the previous high percentages 
of software recall to poor risk analysis, which was “inconclusive during the development, 
verification, and validation stages instead of a complete life cycle.” MOX emphasized 
that risk analysis should start at the initial phase and cover supply chain, manufacturing, 
design transfer, software integration, and transfer to manufacturing before aligning with 
the post market surveillance operations.  
Probing the occurrence of any unintended consequences associated with the 
implementation of EN/IEC/62304, MOX stated, “So far, we have not seen any adverse 
event report.” Similarly, with regard to the survey question on whether any of the 
organizations had any recalls after March 21, 2010, both respondents indicated none, as 
the same types of potential causes for device recall apply, as indicated in the previous 
questions. 
MOX did not comment on what could be done to improve the process of 
conformity assessment. However, with regard to what could be done to improve the 
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designation and monitoring of notified bodies, MOX called for random observers’ 
participation during audits. With regard to what could be done to make the clinical 
evaluation requirements clearer, MOX called on the establishment of requirements and 
usability studies. When indicating what could be done to improve the process of 
conformity assessment, DOZ called for reducing clinical data requirements. DOZ was not 
sure which actions would improve the designation and monitoring of notified bodies and 
was uncertain on how to make the clinical evaluation requirements clearer.  
The survey question on what could be done to improve process conformity 
assessment did not receive any feedback from MOX and DOZ. According to the FDA, 
software validation is imperative for software in medical devices and applications, 
whether during the production stage or during the launch of the devices for quality 
purposes. The intention for EN/IEC/62304 was to make medical device software 
validation safer. The interviewees agreed with this goal because achieving various 
documentation standards serves to address previous product safety gaps and reduce 
recalls. 
The survey question on what could be done to improve the designation and 
monitoring of the notified bodies did not receive feedback from the respondents. The 
EN/IEC/62304 introduction is useful for classifying software into A, B, and C categories. 
MOX indicated a concern regarding the possibility that designers under classify medical 
device software to avoid meeting the stringent documentation requirements. To that 
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effect, the MOX recommended, “The process should be applied the same to all classes, 
so that you have a standard practice. Otherwise, people may slip.” 
MOX reaffirmed the need to validate medical devices to “ensure accuracy, 
reliability, consistent . . . performance” and minimize recalls. A general belief is that the 
EN/IEC/62304 has met expectations in enhancing the safety of medical devices. DOZ 
noted, “Classification of software highlights the defects and the software damages that 
may occur in future.” I further highlighted the importance of keen audits to capture 
problems not discovered during manufacture that have a likelihood of causing product 
recall and that warrant additional classification procedures. With regard to what could be 
done to make the clinical evaluation requirements clearer to reduce recalls and whether 
medical devices produced under the EN/IEC/62304 are much safer during use, MOX 
responded that safety is in “the complete software design development documentation, 
the software architecture, the risk analysis, the V&V [verification and validation].” 
The question on how to improve the process of post market surveillance to reduce 
device recalls received mixed feedback. I stated, “Although EN/IEC 62304 standard has 
been embraced as a global benchmark for management of the software development 
lifecycle, implementation of the standard has been slow.” In probing the causes of the 
slow adoption especially post market surveillance, the interviewees responded that 
misunderstanding the standard and the lack of availability of the template were 
hindrances. Basing the argument on company experience, MOX added that people do not 
know “what should go in the design and development software document.” 
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The question on whether the approval process aimed at reducing device recall is 
transparent received 100% agreement from both interviewees. The question on how to 
improve the transparency of the approval process to reduce device recalls did not receive 
any feedback from the respondents. The interviewees agreed that the approval process 
was already transparent enough.  
The question on whether the organization has a specific work instruction or SOP 
for EN/IEC/62304 received an affirmative response from MOX, who added, “We have a 
procedure for software development life cycle, and we revised it last year to comply with 
62304.” MOX expressed concerns with SOUP [software of unknown provenance]: “We 
do not have a procedure on how to manage SOUP. That is one area where regulatory 
agencies will look into,” and this can be a potential problem leading to product recalls.  
The International Electrotechnical Commission introduced EN/IEC/62304 to 
medical device manufacturers to address some of the major concerns such as rampant 
product recall and lack of documented procedures when changes in software designs take 
place. I noted [“to the participants”], “The FDA and the EU have observed an increase 
use of off-the-shelf software (SOUP) in automated medical devices prior to the 
introduction of EN/IEC/62304.” MOX underscored the need for documented processes to 
be part of the design process in all activities to create a significance level of 
accountability during product recall. MOX added, “The software design document, 
SDDs, must clearly document what off-the-shelf commercial software we are using.” 
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The topic of one survey question was the effectiveness of MDD 93/42/EEC 
enhancing the efficacy of medical devices, and both respondents indicated that Class I, 
IIa, IIb, and III devices were “100% effective” in managing potential product recalls. In 
response to the survey question on the effectiveness of the MDD 93/42/EEC enhancing 
the safety of medical devices responsible for various recalls, respondents indicated Class 
I devices are “100% very effective,” Class IIa devices are “50% very effective” and 
“50% effective,” Class IIb devices are “100% effective,” and Class III devices are “100% 
effective.” MOX acknowledged that EN/IEC/62304 was a good standard for the medical 
device industry to reign in the problems leading to product recall. MOX added, “The only 
thing is that we need guidance and more, . . . for example, sample templates. If the 
standard is requiring a software architecture document, they should be guidance at the 
minimum what the content of the software architecture should be” 
Case Studies on the Financial, Stocks, and Research and Development 
Competitiveness of Selected Companies 
This section contains an analysis of the case studies of five medical device 
companies that have been in operation since the publication of the EN/IEC/62304 
standard in 2007. The companies, selected by purposive sampling, are ArtVentive 
Medical Group, Varian Medical Systems, Mindray Medical, Abiomed, and CryoLife. 
These companies export medical software devices to Europe and other continents. The 
data in this section include the company size, net income, closing share prices from Q4-
2009 to Q3-2013, and EN/IEC/62304 standard R&D expenditures. I could not access data 
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for each of the five companies on training costs for each EN/IEC/62304 compliant 
software year or on project cost for each EN/IEC/62304 compliant software year. 
However, I assumed that these figures were a percentage of expenditures for each 
EN/IEC/62304 compliant year in research and staff development. The section contains a 
summative evaluation of net percent changes for data category per year since 2009. The 
following is a brief description about each of the five case study companies.  
ArtVentive Medical Group 
ArtVentive Medical Group has a market capitalization of $48.87 million 
(ArtVentive Medical Group, 2013). The company manufactures medical devices with a 
focus on endoluminal occlusion devices (EOS). Since listing in the New York Stock 
Exchange, the company files their accounts according to SEC regulations (ArtVentive 
Medical Group, 2013). 
ArtVentive leaders pursue manufacturing innovations and intellectual property 
rights to introduce and market their medical devices. ArtVentive devices have an 
exceptional performance in invasive medical diagnoses and procedures that target various 
health problems that were previously a challenge to many practitioners. The ArtVentive 
medical devices have high industry demand, including women’s health care, surface and 
neurological problems, and cardiovascular diagnosis. Among the various 
accomplishments is the subsidiary incorporation of ArtVentive Women’s Health Group. 
Other than manufacturing medical devices for human health care, ArtVentive leaders 
have diversified into animal health as well, and the products conform to Directive 
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93/42/EEC and the FDA, among other standards. The company leaders adhere to 
regulations and procedures for raising equity for expansion and research; hence, in 2001, 
the safety and operational standards achieved the EOS device classification (ArtVentive 
Medical Group , 2013). 
In terms of financial performance, the company has been facing some liquidity 
problems because the investment into research and the cost of compliance to 
EN/IEC/62304 are expensive. Thus, ArtVentive leadership has been struggling to balance 
the company balance sheet to profitability. In Q3-2013, ArtVentive had negative capital 
of -$17,748 in the balance sheet and a yearly total deficit of $6,998,014. As a remedial 
step, ArtVentive leaders had elaborate plans to raise more capital via equity finance to 
ease the operational pressures and ensure the company remained competitive for the next 
year. It is possible for ArtVentive to revive from the current financial problems as long as 
the company leaders obtain timely financial capital partners, improve the research 
efficiency, and innovate more medical device products that can compete with existing 
market offers in price, quality, and efficacy. Consequently, ArtVentive management 
recently announced that they would seek more equity finance via public and private 
expression of interest for offers.  
An independent audit report by Anderson Bradshaw PPLC published with 
Mergent (2013) indicated that ArtVentive’s performance from 2011 to 2013 conformed 
to rules and regulations in the United States. The report had various concerns because 
ArtVentive was making a loss since the company’s inception. The report further 
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indicated that ArtVentive could be having some internal operations problems that were 
preventing the achievement of financial performance goals (Mergent, 2013). 
Data analysis revealed ArtVentive’s financial performance problems were an 
indication of management issues. The decline in net income was a red flag that 
management needed to address; otherwise, the company would fail to attract potential 
strategic investors for a merger or an acquisition due to its uncertainty trends. Analysis 
indicated that the stock’s performance gained marginally from 2009 to 2011 before 
worsening in 2012, which indicated that public investors were wary about the company’s 
stocks with marginal trading in prospects.  
Varian Medical Systems 
The headquarters for Varian Medical Systems is in Palo Alto, California. The 
company is a leading medical device software manufacturer targeting cancer therapy, 
radiology, radiosurgery, proton therapy, and brachytherapy (Varian Medical Systems, 
2013). Varian also manufactures data software for cancer care in clinics and major 
hospitals around the world, including Europe. The company manufactures X-ray tubes 
and other hardware for imaging and diagnostic operations. Varian is a leading venture in 
scientific innovations that solve many cancer problems in the medical industry (Varian 
Medical Systems, 2013). Varian Medical Systems was initially Varian Associates, 
founded by Russell H. Varian, Sigurd F. Varian, William Webster Hansen, and Edward 
Ginzton in 1940 (Varian Medical Systems, 2013).  
147 
 
One of the greatest Varian software innovations is the noninvasive stereotactic 
ablative body radiotherapy suitable alternative to surgery in lung cancer called 
TrueBeam. This technology is useful for targeting patients with lung cancer at the early 
stages. Various studies on the effectiveness of this medical software have consistently 
shown that the technology is useful for increasing the survival rate of patients and 
reducing their healing time because of the noninvasive techniques compared to the 
normal open surgery approaches (Varian Medical Systems, 2013). 
In a study of 3,771 patients involving 45 research associates, 3,201 patients 
indicated a longer survival by at least 2 years when targeted by TrueBeam. The study also 
showed that complete healing occurred in approximately 70% of the patients, including 
the ability to manage 91% of tumors. This finding was better than the 68% survival rate 
of 2,038 patients for whom health care professionals managed their cancer infections 
using traditional surgical methods (Varian Medical Systems, 2013). 
The noninvasive stereotactic ablative body radiotherapy as a suitable alternative 
to surgery for lung cancer has thus proved to be a major breakthrough in modern cancer 
management where there is the lowest need for an operation as the patients are at primary 
stages. Moreover, the Varian cancer-treating device, TrueBeam, is useful for reducing the 
side effects that some patients’ experiences due to the procedures of managing such 
ailments as administered by oncologists in open surgery methods. Researchers from 
Harley Street and University College Hospital London conducted the study involving 
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Varian Medical Systems and used patients with radio surgery and conventional methods 
as controls (Varian Medical Systems, 2013).  
According to analysts at Market Grader (2013), Varian’s performance in Q3-2013 
was below expectations, as reflected in its revenue growth at $770.43 million compared 
to $755.86 million in 2013, which reflected a 1.93% change in growth as opposed to 
projections of nearly 4% growth. Sales were worth $2.94 billion in Q3-2013 and were 
24.77% better than Q3-2011. To improve the company’s revenue performance, analysts 
at Market Grader (2013) recommended that Varian cut cost in various operational areas 
such as shortening the research life cycles. Additionally, the analysts at Market Grader 
(2013) speculated that Varian stock earnings could go either way in Q4-2013, with the 
Q3-2013 price being 19 times the listing share price, which indicates that Varian stocks 
have been increasing in value 8.97% annually. Overall, the analysts at Market Grader 
(2013) viewed Varian’s financial trends as promising and demonstrating stable business 
performance. 
Data analysis indicated Varian Medical System financial trends were increasing 
every quarter and year. Therefore, Varian leaders must keep an eye on the operating 
expenses as they research and launch more products. Data analysis further indicated that 
the stock’s diluted value has been strong year on year, and the company leaders need to 
maintain the positive market outlook that will sustain investor confidence for future 
performance.  
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Mindray Medical International 
Mindray Medical is a Chinese-owned but New York Stock Exchange listed firm 
that manufactures various medical devices and software targeting human and animal 
medicine practice (Mindray Medical International, 2013). The company began in 1991 
and has over 6,000 employees. Mindray has three major operational divisions: Patient 
Monitoring & Life Support, In-Vitro Diagnostic Products, and Medical Imaging Systems. 
Some of Mindray’s Medical device products include patient monitors, ECG machines, 
pulse oximeters, telemetry, ultrasound systems, anesthesia delivery systems, hematology 
analyzers, chemistry analyzers, regents, and veterinary equipment. Most of Mindray’s 
device manufacturing takes place at Shenzhen, China, with satellite stations around the 
world, including New Jersey (Mindray Medical, 2013). 
The Patient Monitoring & Life Support Department manufactures multiparameter 
patient monitors, biotelemetry systems, anesthesia delivery systems, defibrillators, ECG 
machines, pulse oximeters, hospital beds, and other support structures. Market research 
analysts at Frost & Sullivan recognized Mindray Medical in 2007 for the innovations in 
Patient Monitoring & Life Support with the Global Excellence Award following an audit. 
In 2008, Mindray Medical acquired the Datascope Corporation at $2009 million to 
improve their market share in China. The In-Vitro Department of Mindray Medical is 
responsible for data management from various human body fluid tests. This department 
also works on various laboratory analyses that blend manual and automatic tests 
(Mindray Medical, 2013). 
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According to Jayson (2013), Mindray Medical International has not been 
performing according to investors’ expectations and investors did not expect performance 
to improve during Q4-2013. Various indications that Mindray would have another low 
quarterly earnings were the poor performance of accounts receivable and revenue. These 
performances could have a role in the Mindray stocks. Jayson (2013) indicated concern 
about Mindray debts and slow-moving inventory, as some of the factors affected the 
company’s financial performance. Mindray leaders might have been remiss in collecting 
money owed to the firm or lining up for strategic changes such as acquisition. Similarly, 
it was possible that Mindray device prices had a problem that needed urgent attention to 
increase the revenue growth track.  
Data analysis indicated that Mindray leaders must increase revenue targets and 
assign sales staff to report targets to ensure timely action by the senior management. 
Moreover, Mindray leaders would need to improve the current average inventory period 
from 64.4 days, including the quarterly figure of 59.7 days. The analysis revealed that 
Mindray leaders must overhaul the business model to a more stable approach that will 
ensure sales attain quarterly targets. Income and stocks data were below expectations 
because since 2012, revenue increased by only 10.5% while the debt owed increased by 
20.6% (Jayson, 2013). Mindray leaders might also increase their accounting surveillance 
to ensure investors have the correct information. 
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Abiomed 
Abiomed is a company that manufactures medical devices for circulatory system 
and medical care in the category of acute heart failure management. The company 
launched in 1981 with headquarters at Danvers, Massachusetts, and appears on the 
NASDAQ. Abiomed market capitalization is $1.067 billion (Abiomed, 2013). Abiomed 
products include, the Impella 2.5 catheter, a percutaneous micro heart pump with 
integrated motor and sensors for use in interventional cardiology; and Impella 5.0 
catheter and Impella LD, which are percutaneous micro heart pumps with integrated 
motors and sensors for use primarily in the heart surgery suite. The company also 
manufactures and sells the AB5000 circulatory support system and the BVS 5000 
biventricular support system for temporary support of acute heart failure patients in 
profound shock, including patients suffering from cardiogenic shock after a heart attack, 
post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers AbioCor 
implantable replacement heart, a self-contained artificial heart for end-stage biventricular 
heart failure patients. (Abiomed, 2013).  
On August 1, 2013, Abiomed leaders reported revenues of $42.7 million for Q1-
2014, which is 10% more than the same period in the previous year of $38.8 million. 
Nevertheless, the company still register a loss of $1.7 million, which was equivalent to 
$0.04 per diluted share but an improvement from the previous year at $3.1 million, and 
$0.80 per diluted share in Q1-2013. The improved performance of Abiomed is from the 
increased global sales of Impella, which the company expected to rise to $38.7 million or 
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12% revenue compared to Q1-2013 from $34.7 million. Overall, the Impella sales in the 
United States alone were up by 7%, equivalent to $35.4 million, compared to $33.0 
million in Q1-2013 (Abiomed 2013). 
The use of Impella by U.S. patients rose by 12% in Q4-2013. In the same period, 
at least 27 medical clinics bought the Impella device, thus reaching 775 units sold in Q4-
2013. Furthermore, 66 clinics acquired the Impella CP, to increase the Q4-2013 sales to 
172, which indicated that the distributions of Impella 2.5 and CP are 2.4 units per clinic 
and not much different from Q1-2013 (Abiomed 2013).  
Market analysts at Zacks (2013a) noted that Abiomed would continue its positive 
performance buoyed by the new products development and device trials at clinics despite 
the poor performance in the 4 years preceding 2014. Market analysts at Zacks (2013a) 
justified their assessment of Abiomed with caution following the decline in stock 
earnings by nearly 76.9% by Q4-2013 compared to a 13% decline in Q4-2012. 
Furthermore, the analysts at Zacks (2013a) appreciated Abiomed’s net income growth by 
nearly 19%, which was within the projections, and continued the 4-year income trends in 
double digits, supported by the increased demand of the Impella device in successive 
financial quarters.  
Demand for the Impella device is likely to increase in 2014, as the leaders of 
many hospitals adopt the heart pump devices that are applicable in many remedial cases 
of heart failure. Nevertheless, Abiomed’s operational expenditures decreased by nearly 
5%, whereas approximately 8% of expenses were for legal services, compliance 
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submissions, and supply chain development, including R&D. Overall, the increasing 
operational costs have had pull-down effects on Abiomed’s bottom line prospects, and 
analysts are watching the trend (Seiffert, 2013). 
Data analysis indicated that Abiomed leaders have managed to stabilize 
expenditures on R&D each year, and Abiomed’s net income has been improving. Thus, 
Abiomed is efficient in resource use in successive years as the returns on investment 
improve. Analysis also indicated that Abiomed’s stock performance is flat, despite the 
improving net income, which indicates that investors have stable demand for Abiomed 
stock. 
CryoLife 
CryoLife is a company that manufactures and distributes medical devices for 
cardiovascular and vascular transplant operations and that trades at the New York Stock 
Exchange (CryoLife, 2013). CryoLife has a market capitalization of $298.75 million and 
has several subsidiary companies, including Natus Medical, Cryosure, Heart 
International, AngioDynamics, Accuray, Teleflex, Echo Therapeutics, and MAKO 
Surgical. The average CryoLife enterprise value in the past 5 years was $146.74 million 
(CryoLife, 2013). 
CryoLife operates and specializes in preservation and logistics of human tissues 
for various transplant needs other than manufacturing medical devices for sales to 
hospitals. Some of the devices are the CryoValve SG pulmonary valve and the CryoPatch 
SG pulmonary cardiac patch tissue; the management of each involves using CryoLife 
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SynerGraft Technology. In mid-2011, CryoLife bought Hemosphere, which sells 
Hemodialysis Reliable Outflow, a technology for grafting final stages of renal diseases. 
In Europe, the company sells medical software devices via CryoLife Europa (CryoLife, 
2013). 
CryoLife has many other products and devices sold around the world, including 
Europe. SynerGraft Technologies is among CryoLife’s patented products for aiding 
medical implants of biological cells and organs. This technology limits a cell’s pathogen-
causing cells while vital tissues are healing. Therefore, the SynerGraft Technologies aid 
in the lowing cases of human leukocyte antigen Class I and II antibodies which 
pulmonary tissue growths. The application of this technology reduces chances of a 
patient requiring a heart transplant. The device is useful for monitoring the advances of 
panel reactive antibodies, whose excessive presence in the body can lead to emergency 
operational risks to the patient (CryoLife, 2013).  
According to market analysts at Zacks (2013b), CryoLife’s improved 
performance on revenues was due to the Q3-2013 growth surpassing expectations. 
Specifically, the CryoLife revenue for Q3-2013 improved to $18.8 million compared to 
Q3-2012 at $16.9 million. The gross income was up by 81% in Q3-2013 compared to 
82% in Q3-2012. The higher sales of revascularization devices and laser devices, whose 
revenues rose by 14.3% at $2.4 million in the Q3-2013, accounted for these positive 
trends. Moreover, the shortage of some alternative medical device shipments increased 
demand for CryoLife devices. Also during Q3-2013 period, the preservation devices sales 
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increased by 6.1% to 17.4 million, which led to better margins by 46% compared to 45% 
in Q3-2012. Specifically, vascular device sales increased by 8% due to new service fees 
occasioned by the shortfall of substitute shipments used for vascular grafts (Zacks, 
2013b). 
CryoLife’s share price rose by nearly 50% in Q3-2012, by which was $0.12 
compared to an $0.08 increase in Q3-2012. This trend beat Zacks Research Market 
predicted 43.8% increase. The CryoLife net income increased by 11% to $3.2 million in 
Q3-2013 compared to an increase of 6% to $1.5 million in Q3-2012. The CryoLife 
revenues also had an impressive performance, increasing by 8% to $36.3 million in Q3-
2013 from $33.4 million in Q3-2012. This growth was due to strong sales of BioGlue and 
revascularization devices (Zacks, 2013b). 
Data analysis revealed that CryoLife’s increasing investment in R&D would 
improve the company’s performance. Analysis further indicated that the trends in 
investments in R&D are matching the net income growth. This implies that CryoLife 
management is efficient in resource management.  
Survey Results and Hypothesis Tests 
From the possible working population of 256 organizations in the medical device 
industry with business interests within the EU region, I gathered survey results from 56 
respondents via mail (71% male and 29% female). I evaluated the respondents’ 
experiences in the medical device industry and established the outcomes seen in Figure 2. 
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Figure 2. Gender versus experiences in the medical device industry. 
The cross-gender analysis indicated that the high durations of services or 
attachment to the medical device industry has fewer respondents while the males had 
more experience than the females. The analysis also involved evaluating the professional 
spread for the combined genders, which revealed that 31% were in software sales or 
marketing management, 24% were in finance and accounts management, 21% were 
designer engineers, 14% were in operations management, and 10% were in other 
unspecified positions. The findings on the current job titles appear in Figure 3.  
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Figure 3. Professional roles of the respondents. 
In terms of efficacy, the study involved evaluating the effectiveness of various 
devices along their classifications after the introduction of Directive 93/42/EEC. I found 
that only Class I devices had some incidences of not being effective at all at 5%. 
Additionally, Class IIb devices had the highest efficacy rate of performance at 73%, 
followed closely by Class IIa at 64%, Class III devices at 63%, and Class I at 46%. 
Figure 4 contains these findings. 
158 
 
 
Figure 4. Device efficacy along class types for implementation of Directive 93/42/EEC. 
In terms of safety, the study involved evaluating the different device classes 
following the implementation of Directive 93/42/EEC. The findings indicated that only 
Class I devices registered incidences of not being effective at all (4%). Class III devices 
had the highest safety rating of 75% being very effective, followed by Class IIa at 64%, 
Class IIb devices at 61%, and Class I at 54%. Figure 5 contains the findings.  
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Figure 5. Device safety long class types for implementation of Directive 93/42/EEC. 
Following the implementation of Directive 93/42/EEC, cost implications were 
likely. I surveyed the respondents on the cost impact and found that the highest cost 
reduction was with Class III devices at 5%. The most maintained low cost from previous 
period was 9%, also with Class I devices. The highest percentage of cases with no cost 
effects was Class III devices at 5%. The most maintained high cost from previous period 
was with Class I devices at 25%. Finally, the most increased cost was with Class IIa 
devices at 77%. Figure 6 contains these findings. 
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Figure 6. Cost impact after the implementation of Directive 93/42/EEC. 
The study involved investigating the average time it takes for software devices to 
receive approval before their release to the market. Forty-five percent of the respondents 
noted that it takes more than 180 days, which is a long time. Additionally, 36% of the 
respondents observed that it takes 90 to 180 days. Sixteen percent stated it takes 45 to 90 
days, and 4% stated it took less than 45 days. Figure 7 contains these findings.  
 
Figure 7. Duration for approval of software after the implementation of Directive 93/42/EEC. 
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The market surveillance involved evaluating the number of product recalls after 
June 30, 2004, and after June 30, 2010. The greatest improvement in terms of reduced 
recalls is with device input failures at 71.4%, while the least is others at 20%. These 
findings indicated that the medical software industry still has at least 20% product recalls, 
even after the implementation of Directive 93/42/EEC. The total number of recalls from 
among the sampled respondents dropped from 78 after June 30, 2004, to 35 after March 
21, 2010. Nevertheless, even if there was a reduction in recall incidence, software 
malfunctions still had the highest frequencies among the other types of failures cited in 
the survey. Table 6 and Figure 8 contain data on the reduction of product recalls before 
and after the implementation of the Amendment M5 (2007/47/EC). 
Table 6  
Medical Device Malfunction and Failure Tabulations After June 30, 2004, and After March 21, 2010 
 
Type of 
malfunction/failure 
Number of recalls 
after June 30, 2004 
Number of recalls 
after March 21, 2010 
% 
reduction 
No recall 78 35 38.1 
Software malfunction 13 8 23.8 
Behavior failure 3 2 20.0 
Failure of output 5 3 25.0 
Service failure 4 2 33.3 
Display failure 9 2 63.6 
Input failure 6 1 71.4 
Response failure 7 3 40.0 
Failure due to data 5 1 66.7 
User instruction failure 4 3 14.3 
Timing failure 5 1 66.7 
System failure 6 2 50.0 
Quality failure 5 3 25.0 
Other 6 4 20.0 
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Figure 8. Medical device malfunction and failure trends after June 30, 2004, and after March 21, 2010. 
Finally, the study involved surveying the impact of Directive 93/42/EEC on 
various firms’ market values and the number of employees. First, Figure 9 contains the 
outcomes of market values for medical device organizations that range in size. Second, 
on the changes I established a fluctuating trend, as shown in Figure 10, where the 
percentages represent the company’s share of the European market changed since March 
24, 2011, and the number of employees changed since March 24, 2011. 
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Figure 9. Value of respondents affiliated company. 
 
Figure 10. Changes in company market share versus number of employees. 
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Participants responded to a variety of open-ended questions regarding how enable 
better conformity assessment. I asked the respondents how to improve process 
conformity assessment. The responses indicated that regular updates and communications 
are necessary to reach the industry players to ensure all read from the same script. 
Moreover, I established that the leaders of each firm strengthen their internal assessment 
frequency and quality to conform to new medical device regulations. Adhering to third-
party audits to ascertain conformity to Directive 93/42/EEC was a common view held by 
the respondents.  
The study involved investigating what need to be done to improve the designation 
and monitoring of notified bodies. I found that the notified bodies require close 
supervision to ensure achievement of their mandates within Directive 93/42/EEC. 
Additionally, I found that stipulation and strict follow-up on monitoring schedules, 
supported by some random checks, is a common approach considered by MDD bodies. 
Overall, I established that the monitoring bodies must speed up their approval stages to 
reduce the number of product recalls.  
I evaluated what I can do to make clinical requirements clearer, and I found that 
the stakeholders in the implementation differ on the interpretation of some articles of 
Directive 93/42/EEC. However, when language or communication barriers lead to issues, 
there are common online platforms to seek clarity within a short time. Additionally, there 
are routine meetings and workshops where leaders of the member countries and 
165 
 
industries converge to discuss and clear any sticky points on the clinical implementation 
of Directive 93/42/EEC.  
An investigation of how to improve the process of post market surveillance 
revealed that most firms tend to rely on surveys and feedback from hospitals and end 
users on the performance of their devices. Most firms have additional internal checks and 
balances to verify the quality of the medical devices just before and after operations on 
patients. A lot of work will be necessary to strengthen post market surveillance, including 
clustering supervisions in different medical device classes and enforcing sanctions for 
any contraventions.  
Within the inquiry of whether the process of approving medical devices is 
transparent, a majority of the respondents concurred and there were few dissenting views. 
Dissenting views arose regarding delays in approving medical devices. Moreover, some 
respondents cited additional standard requirements that go beyond the stipulations in 
Directive 93/42/EEC as potential causes for concern about the transparency of the entire 
approval process.  
An investigation into how to improve the transparency of the entire approval 
process revealed that most respondents would like the time frame allocated for approving 
various medical device classes adhered to strictly to inspire confidence among the 
medical device industry players. The respondents indicated they want adequate time to 
comply whenever there are new amendments in the articles of Directive 93/42/EEC 
because some changes have serious implications on the firms’ mass production strategies 
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and operations. Transparency can greatly improve when all the approval standards are 
properly communicate, interpret, and translate for international purposes.  
I evaluated the respondents’ view on the impact of Directive 93/42/EEC on 
market competition and established a level playing ground had taken shape. Some 
respondents noted that the impact was negative because the cost of compliance reflected 
on the firms’ bottom line. Other respondents were uncertain of the impact because the 
leaders of their firms had yet to release vital reports and findings following the 
implementation of Directive 93/42/EEC.  
Analysis of Data and Hypotheses Discussion 
This study had four main questions and hypotheses addressed by a detailed 
literature review, interviews, and a case study of five companies purposively selected 
from the category of medical device manufacturers with product exported to European 
markets, among other destinations. This section contains a discussion on each research 
question in light of the qualitative findings of the above sources using ANOVA tests of 
the hypotheses. In testing H1a using ANOVA, at a 95% confidence level and gathering 
data from 56 respondents, the mean was 4.0, which indicated they agreed with the 
statement, “Changes to the EU MDD have led to a significant increase in the net income 
of medical device software firms in the US” Additionally, the SD of 0.89 indicated that 
the responses were closely clustered in support of H1a, as shown in Table 7. When testing 
H2a, the mean was 1.61, which fell in the range of disagree to neutral, and the SD was 
0.91. The H3a tests had a mean of 1.45, which was also in the range of disagree to 
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neutral, with an SD of 0.60. Finally, the H4a tests had a mean of 3.98, which fell within 
the range of neutral to agree, with an SD of 1.07. Table 7 contains these findings.  
Table 7  
Descriptive H1a-H4a Alternative Hypotheses 
     95% CI   
Variable n M SD SE LL UL Min Max 
H1a 
Male 40 3.83 0.90 0.14 3.54 4.11 2.00 5.00 
Female 16 4.44 0.73 0.18 4.05 4.83 3.00 5.00 
Total 56 4.00 0.89 0.12 3.76 4.24 2.00 5.00 
H2a 
Male 40 1.60 0.84 0.13 1.33 1.87 1.00 4.00 
Female 16 1.63 1.09 0.27 1.05 2.20 1.00 5.00 
Total 56 1.61 0.91 0.12 1.36 1.85 1.00 5.00 
H3a 
Male 40 1.45 0.60 0.09 1.26 1.64 1.00 3.00 
Female 16 1.44 0.63 0.16 1.10 1.77 1.00 3.00 
Total 56 1.45 0.60 0.08 1.29 1.61 1.00 3.00 
H4a 
Male 40 3.93 1.14 0.18 3.56 4.29 1.00 5.00 
Female 16 4.13 0.89 0.22 3.65 4.60 2.00 5.00 
Total 56 3.98 1.07 0.14 3.70 4.27 1.00 5.00 
 
Table 8 contains the results of the ANOVA tests of the hypotheses, at a 95% 
confidence level and gathering data from 56 respondents. The following sections provide 
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a discussion on each research question in light of the qualitative findings using ANOVA 
tests of the hypotheses. 
Table 8  
ANOVA H1a-H4a Alternative Hypotheses 
Variation SS df MS F Sig. 
H1a      
Between groups 4.287 1 4.287 5.830 .019 
Within groups 39.713 54 .735   
Total 44.000 55    
H2a      
Between groups .007 1 .007 .009 .927 
Within groups 45.350 54 .840   
Total 45.357 55    
H3a      
Between groups .002 1 .002 .005 .945 
Within groups 19.838 54 .367   
Total 19.839 55    
H4a      
Between groups .457 1 .457 .395 .532 
Within groups 62.525 54 1.158   
Total 62.982 55    
 
MDD and Net Income for Company  
Research Question 1: What is the impact of changes to the MDD to the net 
income of medical device software firms in the United States? 
H10: There has not been a decrease in the net income of medical device software 
firms in the United States due to changes to the MDD. 
169 
 
H1a: Changes to the MDD have led to a significant decrease in the net income of 
medical device software firms in the United States. 
The first competitiveness factor ranked among the five medical device 
manufacturing companies was net income in millions of dollars. According to the 
literature reviewed, projected U.S. firm sales of medical devices were $102.4 in 2009, 
$107.1 in 2010, $112.1 in 2011, $117.4 in 2012, and $122.8 in 2013. By meeting the 
MDD essential requirements, U.S. firms were able to compete and sell more products to 
the EU markets. Compliance to the MDD promotes the innovation and the 
competitiveness of this sector by meeting the essential requirements: before firm leaders 
can market a medical device in the EU, the product must meet the essential requirements 
in Annex 1 of the MDD, as well as the standards related to the device class (U.S. 
Department of Commerce, 2008). From the case studies, ArtVenture Medical had the 
lowest mean income growth per annum ($-1.3779 million), while Varian had the highest 
mean growth ($374.974 million), as indicated Table 9 and Figure 11.  
Table 9  
Last Five Years Net Income for the Five Companies ($ Million) 
Year 
ArtVentive 
Medical Group 
Varian Medical 
Mindray 
Medical 
Abiomed CryoLife 
2009 -0.0287 329.0000 139.1800 -28.4530 8.6790 
2010 -1.0733 378.1300 155.4700 -10.9580 3.9440 
2011 -2.6076 392.6800 166.6300   -2.8440 7.3710 
2012 -0.8579 432.0900 180.2200  13.8390 7.9460 
2013
a
 -2.3221 342.9700 149.5300    3.0780 7.1460 
Mean -1.3779 374.9740 158.2060   -5.0676 7.0172 
a
As of September 2013. 
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Figure 11. Net income trends for the five companies. 
The second competitiveness factor ranked among the five medical device 
manufacturing companies was the diluted stock price figures in millions of dollars by the 
respective companies. After the presentation of the brief case studies of the five 
companies, I compared their diluted stocks prices over the same 5-year period. The SEC 
data showed that Varian Medical was the best performing, with a low of $0.63, a high of 
$1.0790, and mean of 0.8318. Additionally, the SEC data showed that ArtVentive was 
the lowest performing, with low of $-0.0002, a high of $0.02, and a mean of 0.0083 over 
the 5-year period. Overall, the income from stock share sales showed an upward trend, as 
demonstrated by the case study of the five companies shown in Table 10.  
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Table 10  
Closing Diluted Stock Price Figures per Year 
Year 
ArtVentive 
Medical Group 
Varian 
Medical 
Mindray 
Medical 
Abiomed CryoLife 
2009 -0.0002 0.6300 0.3279 -0.1200 0.0831 
2010 -0.0030 0.8000 0.3475 -0.0200 0.0755 
2011 -0.0116 0.7900 0.3945 0.0700 0.0673 
2012 -0.0068 0.8600 0.4633 0.0700 0.0753 
2013
a
 -0.0200 1.0790 0.2500 0.0300 0.1100 
Mean -0.0083 0.8318 0.3566 0.0060 0.0822 
a 
As of September 2013. 
 
Figure 12. Stock movement from 2009 to 2013. 
In a further demonstration of the impact of the MDD 93/42/EEC on income 
streams and sustainability, the literature reviewed showed that medical devices that can 
aid in the diagnosis of diseases or the administration of certain hospital procedures have 
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existed in the early 19
th
 century (Zaykoski, 2011). However, the emphasis was on 
software-embedded devices and the performance increase from the last decade with the 
introduction of the MDD 93/42/EEC. Some of the medical procedures where the 
software-embedded devices have become competitive and made a strong impact are 
neurosurgery of brain tissues for persons with Parkinson’s disease, cardiovascular 
implants for persons with heart valve complications, and general data collaboration with 
related diagnostic needs and recommendations (Lewin Group, 2008). 
Other areas where medical device software has evolved are tumor localization, 
therapy, and treatment procedures with early detection being possible, hence increasing 
survival rates. Some medical device software is capable of guiding doctors to administer 
medicine to specific organs. However, developing the device software does not occur in 
isolation, because R&D firms are finding new uses and integration with biological tissue 
makers, robots, tissue implants, fluid and superficial dressings, or monitoring the 
ingestion of drugs (Lewin Group, 2008). 
The most common type of medical device software is the noninvasive type, where 
surgeons are able to observe the body organs and tissues using an endoscopic procedure. 
This technology combines the diagnosis and surgery together or may require a patient to 
swallow some tablets embedded with tiny tracking devices (Higgins et al., 2003). As the 
tablet moves down the digestive system, the doctor can make conclusive observations 
and diagnose the problem. Other medical device software has been successful in aiding 
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diagnosis of internal tumors, abnormal growths, and Crohn’s disease (Lewin Group, 
2008). 
Despite all the technology-driven advances in medical devices, the finding from 
this study indicated that Directive 93/42/EEC has turned around the medical device 
software export-trading environment in many ways. First, many U.S. medical device 
manufacturing companies have been exporting their product around the world. However, 
the implementation of Directive 93/42/EEC to the European markets will result in the 
leaders of these companies realigning their product to conform to certain safety and 
efficacy standards (Panesar-Walawege et al., 2010). Directive 93/42/EEC has enhanced 
the technology of medical device software to improve their performance and to reduce 
failure rates and recall incidences (Higgins et al., 2003). In return, the EU market 
promises high-value financial returns to the U.S. medical device manufacturers. Data 
analysis revealed that medical device exports to the EU in 2008, just after the 
introduction of Directive 93/42/EEC, were $13.8 billion. The key EU markets for 
medical devices with software are Germany, Italy, France, and the United Kingdom 
(Episcom, 2008). 
After surveying the 56 participants, I evaluated their data to test H1a. I found that 
most of the responses were distributed toward the right side of the figure, which is a 
preliminary indication of support for the test statement. Figure 13 contains the 
distribution of responses during the survey. 
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Figure 13. Alternative hypothesis H1a.  
As shown in Table 8, the mean sum of squares within gender groups was 39.713, 
while between gender groups it was 4.287. Because the mean between gender groups was 
above the p = .05 level of determination of significance, it was not possible to support 
H10; therefore, it was possible to uphold H1a. Thus, the data indicated support for H1a 
(Changes to the MDD have led to a significant decrease in the net income of medical 
device software firms in the United States) but not for H10 (There has not been a decrease 
in the net income of medical device software firms in the United States due to changes to 
the MDD). 
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MDD and Training Needs 
Research Question 2: What is the impact of changes to the MDD on the training 
costs for each EN/IEC/62304 -compliant software year of medical device software firms 
in the United States? 
H20: Changes to the MDD have not significantly reduced the training costs for 
each EN/IEC/62304 -compliant software year of medical device software firms in the 
United States. 
H2a: Changes to the MDD have significantly reduced the training costs for each 
EN/IEC/62304 -compliant software year of medical device software firms in the United 
States. 
Every year, leaders of medical device firms take their staff to various trainings. 
Respondents MOX and DOZ indicated that their companies spent approximately 
$100,000 per year on training of small teams. Research also showed that 73% of all the 
medical device firms in the United States had less than 20 workers each (U.S. Bureau of 
the Census, 2007) who required training. Another 15% of the firms had more than 100 
workers who required training. In the United States, the locations of medical device 
manufacturers are throughout the nation. However, the most high-technology-oriented 
medical device firms, including software technology applicants, are in California, 
Florida, New York, Pennsylvania, Michigan, Massachusetts, Illinois, Minnesota, and 
Georgia (U.S. Bureau of the Census, 2007). Each of these high-technology firms requires 
matching trainings among the staff to deliver according to key performance indicators.  
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A review of the literature revealed that just before the MDD 93/42/EEC 
enforcement, the U.S. medical device exports data from NAICS was valued at $98 billion 
following an annual growth rate of 6% (Lewin Group, 2008). The wage rewards of most 
of the well-trained employees in the medical device manufacturers were 15% higher than 
the other nonmedical manufacturing sectors (Lewin Group, 2008). Additionally, the 
industry had over 365,000 workers in 2007 in the United States, with a mean yearly 
income of $60,000. The growth of the medical device industry in the United States is due 
to various technological and training advances in related sectors such as biotechnology, 
software development, microelectronics, instrumentation, and communication (U.S. 
Bureau of the Census, 2007). The export value indicated that these companies could 
afford to invest significant resources into staff training to meet the MDD 93/42/EEC 
standards. 
The adoption of the MDD 93/42/EEC by U.S. medical device manufacturing 
companies has dual competitiveness at domestic and international levels that requires 
adequate staff training. At the domestic level, the leaders of medical companies have 
opportunities to improve the quality and innovativeness of their device software beyond 
the FDA and ISO certification benchmarks by training their employee (Lewin Group, 
2008). Furthermore, the MDD 93/42/EEC creates competitiveness among U.S. 
companies as the staff members receive training to keep abreast of emerging technology 
standards regulating raw materials, software design processes, and technological 
scalability. The medical devices market is global, and firms with skilled and trained 
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employees can meet MDD 93/42/EEC requirements and compete more effectively in the 
EU market (U.S. Department of Commerce, 2008). 
I evaluated the data from the survey of the 56 participants to test the H2a 
hypothesis statement. I found that the distribution of most of the responses was toward 
the left side of the curve, which is a preliminary indication of a lack of support for the test 
statement. Figure 14 contains the distribution of responses during the survey testing the 
hypothesis statement. 
 
Figure 14. H2a alternative hypothesis. 
As shown in Table 8, the mean sum of squares within gender groups was 45.350, 
while between gender groups it was 0.007. Because the mean between gender groups is 
below the p = .05 level of determination of significance, there was no evidence to support 
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the alternate hypothesis H2a, and instead the data upheld the null H20. Therefore, H20 
(Changes to the MDD have not significantly reduced the training costs for each 
EN/IEC/62304 -compliant software year of medical device software firms in the United 
States) received support, and findings supported the rejection of H2a (Changes to the 
MDD have significantly reduced the training costs for each EN/IEC/62304 -compliant 
software year of medical device software firms in the United States).  
MDD and Project Cost of Medical Device 
Research Question 3: What is the impact of changes to the MDD on the project 
costs of medical device software firms in the United States? 
H30: There has not been a significant decrease in the project costs for each 
EN/IEC/62304 compliant software year of medical device software firms in the United 
States due to changes to the MDD. 
H3a: Changes to the MDD have led to a significant decrease in the project costs 
for each EN/IEC/62304 compliant software year of medical device software firms in the 
United States. 
The MDD 93/42/EEC guides the leaders of U.S. companies to increase their 
investment in R&D. Medical device manufacturers may spend twice as much investment 
on R&D compared to other sectors (Lewin Group, 2008). Leaders in the U.S. medical 
device industry strive to deliver best quality products from their range of innovations and 
technologies (Denger et al., 2007). The case studies further established that leaders of 
most medical device manufacturing companies invest substantial resources in research 
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and development to standardize their products. There were approximately 5,300 
manufacturers of medical devices in the United States in 2007, most classified as SMEs 
(ITA, n.d.).  
Directive 93/42/EEC has opened new software market opportunities to companies 
that invest heavily in R&D because the safety (Panesar-Walawege et al., 2010) and 
efficacy standards outlined in the EN/IEC 62304 have emerged as a global standard for 
the software development life cycle and have achieved global harmony (Damian & 
Moitra, 2006). Device software companies that conform can receive reimbursement of 
tariffs, while noncompliant manufacturers pay higher tariffs or cannot enter the EU 
market.  
Directive 93/42/EEC has improved the competitiveness of project costs of 
medical device software by making the requirements more transparent for firms selling in 
the EU. This applies where there are at least two different manufacturers of a medical 
software device with the same function in a volatile medical industry (Denger et al., 
2007). Previous reports on dumping low-priced medical devices at the behest of safety 
and efficacy have reduced significantly with the introduction of Directive 93/42/EEC to 
all medical device manufacturers.  
Directive 93/42/EEC has improved the harmonization of project costs with 
foreign regulations such as the FDA because past competition resulted in conflicting 
standards. Summary discrimination of a product without probing its quality and safety 
standards as envisaged in the EN/IEC 62304 and as a global standard for the software 
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development life cycle is catastrophic to medical device manufacturers (Panesar-
Walawege et al., 2010). In the worst case scenario, such unfair competition can escalate 
project costs and lead to businesses winding up operations, while others could struggle 
with financial debts due to a lack of attractive partnerships, as was evident in some of the 
case studies (Damian & Moitra, 2006). The comparison of expenditures by each case 
study company for EN/IEC/62304 compliance per year indicated that ArtVentive had the 
lowest mean at $0.8101 million, and Varian had the highest mean at $166.3660 million, 
as illustrated in Table 11 and Figure 15.  
Table 11  
Expenditure for Each EN/IEC/62304 Compliant Software Year in R&D ($ Million) 
Year 
ArtVentive Medical 
Group 
Varian 
Medical 
Mindray 
Medical 
Abiomed CryoLife 
2009 0.0000 148.7900 58.3800 26.2970 5.2470 
2010 0.7043 156.8600 74.6400 26.6220 5.9230 
2011 1.6307 175.9900 82.0200 26.7660 6.8990 
2012 0.3982 189.1000 104.3100 26.0610 7.2570 
2013
a
 1.3172 161.0900 86.4700 21.8300 5.9760 
Mean 0.8101 166.3660 81.1640 25.5152 6.2604 
a
 As of September 2013. 
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Figure 15. EN/IEC/62304 software compliance expenditure trends. 
From the survey of the 56 participants, I evaluated their data to test the H3a 
hypothesis statement. Most of the responses were distributed toward the left side of the 
curve, which is a preliminary indication of a lack of support for the test statement. Figure 
16 represents the distribution of responses during the survey testing the hypothesis 
statement. 
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Figure 16. H3a alternative hypothesis. 
As shown in Table 8, the mean sum of squares within gender groups was 19.838, 
and it was 0.002 between gender groups. Because the mean between gender groups is 
below the p = .05 level of determination of significance, the data did not support alternate 
hypothesis H3a and instead upheld the null H30. The findings revealed support for H30 
(There has not been a significant decrease in the project costs for each EN/IEC/62304 
compliant software year of medical device software firms in the United States due to 
changes to the MDD) but rejected H3a (Changes to the MDD have led to a significant 
decrease in the project costs for each EN/IEC/62304 compliant software year of medical 
device software firms in the United States). 
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MDD Impact on Medical Device Recall Rate 
Research Question 4: What is the impact of changes to the MDD on the recall rate 
of medical device software firms in the United States? 
H40: There has not been a significant decrease in the recall rate of medical device 
software manufactured by firms in the United States due to changes to the MDD. 
 H4a: Changes to the MDD have led to a significant increase in the recall rate of 
medical device software manufactured by firms in the United States. 
During the interviews, I highlighted FDA data that between 2002 and 2010, 
recalls occurred for approximately 1.5 million software-based medical devices. I also 
indicated that the 8-year period had more than double the number of software device 
recalls compared to the previous 8-year period. Directive 93/42/EEC repositioned 
medical device software in a more transparent manner not envisioned earlier because 
manufacturing standards, procedures, tests, validation, and accountability have all 
improved (Lee et al., 2006) to reduce the device recall statistics. Additionally, the recent 
amendment to Directive 93/42/EEC by the introduction of M5 (2007/47/EC) tightened 
the medical device software specifications by requiring medical device manufacturers to 
provide additional documentation to prove compliance with further safety and efficacy 
standards. This amendment further empowered oversight authorities to take firm action 
against nonconforming companies and their products (European Council, 2007).  
The review of literature revealed that Directive 93/42/EEC has enlightened the 
medical device industry on procedures for conforming to international regulations to 
184 
 
reduce incidences of device recall. Therefore, new entrants into the medical device 
manufacturing sector targeting the EU markets have competitive standards to aid their 
business missions and visions. Directive 93/42/EEC applies equally among the device 
manufacturers targeting the EU markets, which indicates that disputes will resolve 
amicably and the sanctions for violation of applicable rules and regulations will not 
prejudice some companies more than is necessary. 
Reviewed literature showed that Directive 93/42/EEC has helped SMEs in the 
medical device manufacturing to catch up with larger organizations because the same 
quality standards apply. Therefore, the entrants can compete for commercial market share 
from a qualitative accreditation and recognition, which translates to quantitative metrics 
such as revenue growth after acquiring strategic capital partners (McCaffery, Taylor, & 
Coleman, 2007) and a decrease in device recall among the SME firms.  
I evaluated the data from the surveys of the 56 participants to test H4a. The 
distribution of most of the responses was more toward the right side of the chart, which 
was a preliminary indication of support for the test statement. Figure 17 contains the 
distribution of responses during the survey testing of the hypothesis statement. 
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Figure 17. H4a alternative hypothesis. 
As shown in Table 8, the mean sum of squares within gender groups was 62.525, 
and it was 0.457 between gender groups. Because the mean between gender groups was 
above the p = .05 level of determination of significance, the data did not support the null 
hypothesis H40 and instead upheld H4a. Therefore, the findings indicated support for H4a 
(Changes to the MDD have led to a significant increase in the recall rate of medical 
device software manufactured by firms in the United States) but rejected H40  (There has 
not been a significant decrease in the recall rate of medical device software manufactured 
by firms in the United States due to changes to the MDD).  
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Proposed MDD Revisions and the Impact on Medical Device Manufacturers on 
Safety, Reliability, Quality, and Cost 
Major revisions to the MDD 93/42/EEC from the original draft that served the 
medical industry for 2 decades are likely. The European Commission published the 
points for review in safety, reliability, quality, and cost on September 26, 2012. The first 
focus of the review is better “communication on safe, effective and innovative medical 
devices and in vitro diagnostic medical devices for the benefit of patients, consumers and 
healthcare professionals” (Andersson, 2012, the second focus is proposed rules for the 
medical devices, and the third focus is new regulations for in vitro diagnostic devices 
(Andersson, 2012). 
Further, the reviews on the medical device regulations will cover active 
implantable MDD (under 90/385/EEC) and the MDD 93/42/ECC. The most important 
proposal is for medical device manufacturers to enforce regulations more than the MDD 
93/42/EEC, as applicable within the EU. A concern is the entrenchment of directives in 
each country in the national laws, which normally occurs in nonuniform timelines from 
one country to the next. Therefore, the European Commission will address the statements 
by medical device manufacturers whose country of origin is lagging behind on the 
entrenchment of respective regulations as an excuse to be able to export products to 
Europe at lax standards. Previously, the flexibilities on the medical device transportation 
directives from different nations into Europe were able to circumvent the regulations, 
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which exposed the product users to additional safety and reliability concerns (Andersson, 
2012). 
On the aspects of device safety, the proposed changes seek to widen the 
regulatory boundaries outside the EU borders as follows: 
 Medical devices embedded with software and designed with nonviable human 
tissues or their products after various alterations, including those applicable 
for therapeutic care, must undergo additional safety checks.  
 Specific implantable devices that are not targeting medical operations but pose 
similar risks to the category of medical devices, even if for noncorrective 
procedures, must undergo additional safety checks and approval.  
 All medical devices previously manufactured for single use but having a 
potential of reuse after the medic conducts certain clinical procedures must 
have adequate indications, and hospital leaders will take organizational 
responsibility during such reprocessing occasions.  
 Medical devices whose part replacement is likely to compromise their original 
manufacturer’s operational designs shall still be accredited under the CE 
making process, with all obligations of safety therein to the original 
manufacturers (Andersson, 2012). 
On the aspects of reliability, the MDD 93/42/EEC revisions will target procedural 
matters where the Medical Device Coordination Group (MDCG) will be an oversight 
body with members and leadership drawn from the EU nations. The most striking 
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mandate for the group is the evaluation of risks for innovative medical devices to adhere 
to certain standards after series of scrutiny. The MDCG must inform the MDD 
93/42/EEC commission whenever a company innovates a Class III device and declare all 
the details, even if doing so infringes on the intellectual property rights of the company. 
Failing to make this declaration could lead to no certification, yet the product details will 
still have leaked to public via the procedural scrutiny. This process of notification takes 
28 days before the MDCG reports back in 60 days, in which the first half these days may 
have calls for more clarity on the product details. Indeed, this revision is likely to 
heighten bureaucracy likened to the MDD 93/42/EEC procedures (Andersson, 2012). 
Under the quality issues targeted in the latest MDD 93/42/EEC reviews, Article 
13 contained a proposal that at least one qualified person must be available in each 
company to lead compliance with the regulations. Article 13 further indicated that the 
qualified person must have specified academic achievement and not less than five years 
of experience in the medical device industry. Furthermore, the qualified person must 
ensure the positive release of products conforming to the batch standards. The qualified 
person is responsible for all the technical data entries and due diligence for presentation 
in current and future audits of the documents. The qualified person keeps abreast of the 
medical device technical and industry developments and ensures the MDD 93/42/EECs 
are implemented to the fullest. The qualified person is responsible for carrying out all 
investigations during recalls and other device incidences that fall within the MDD 
93/42/EEC Point 4.1 Annex XIV (Andersson, 2012). 
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Under the cost aspects, the MDD 93/42/EEC revisions indicate pharmaceutical 
firms will follow guidelines of common technical specifications to price products as the 
Directive assumes they conform to standard safety and reliability requirements intended 
by the manufacturers. Therefore, the cost of a noncomplying device is not likely to be 
lower than market rates to move inventory even when their quality and performance are 
in doubt. Nevertheless, the revisions are somewhat uncertain about the fundamental cost 
issues of the medical devices because the wordings are ambiguous (Andersson, 2012). 
Evidence of Trustworthiness 
Member checking 
Creswell and Miller (2000) describe member checking, reflexivity, triangulation, 
and audit trails as some of the most often used procedures to increase trustworthiness in 
qualitative inquiry. Trustworthiness of interpretations was enhanced through triangulation 
of quantitative financial data on the performance of the five medical device companies, in 
depth interviews with two experience managers in regulatory affairs and quality 
assurance. After initial interviews with the managers, I conducted a follow-up meeting to 
give them the opportunity to verify the transcripts. The meetings permit each manager to 
read the transcripts from the interview to ensure the accuracy and credibility. Keeping 
careful documentation of all components of the study and maintaining audiotapes for five 
years is also part of constructing an audit trail. When considering trustworthiness, the 
purpose of member checking was not to generalize findings, instead the goal was 
accuracy and credibility. 
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Reflectivity 
On the issue of reflectivity, Creswell (1998) believes that all researchers have 
personal biases that can influence their interpretation of data. I believe that my 
professional experience provides firsthand knowledge, and sensitivity to the topic 
examined in this study. My extensive experience with software medical device 
manufacturing, preconceived belief or assumptions may have had a significant influence 
on the development of the research and the engagement of the participants. Although I 
made every effort to ensure objectivity, personal bias may have influenced my 
interpretation of the data collected. The interview participants were purposefully selected 
because of their unique expertise in their respective fields. I conducted the study using 
combination of questionnaires and structured interviewing techniques; asking the 
participants open-ended questions about their unique expertise with the research topic.  
Triangulation 
Triangulation refers to the simultaneous use of different methods and data in order 
to obtain different perspectives on a particular issue (Olsen, 2004). These perspectives 
include credibility, transferability, dependability, conformability and inter or intra coder 
reliability. In this study, triangulation involved the use of systematic literature reviews, 
interviews and case study of ArtVentive Medical Group Inc., Varian Medical, Mindray 
Medical, Abiomed and CryoLife. Triangulation also involved collection of quantitative 
financial data on the performance of the five medical device companies mentioned in the 
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sampling section and this was compared to the secondary sources of data obtained using 
the interviews and strategic literature reviews (SLR).  
The influence of transcribing. 
I opted for a complete transcription to ensure nothing of importance was 
overlooked. The transcription occurred after the completion of the interviews. The 
process involved listening to audio records and writing transcript. I listened the tape 
recording multiple times to verify the accuracy of transcription. Member checking was 
included as a validity strategy to allow the interviewees to review the transcripts to ensure 
an accurate transcription of their beliefs. Participants found no inaccuracies in the 
transcripts during the follow-up interview. 
Transferability 
Transferability is often a challenge in qualitative research. It refers to the degree 
to which a qualitative researcher can generalize or transfer the results of the research to 
other settings. I assumed that the findings from the case studies and the views expressed 
by the interviewees would provide a generalization of the medical device industry status. 
Therefore, the challenges and successes of the companies complying with the changes in 
MDD 93/42/EEC are shared and replicable with a fair degree of confidence. 
Dependability 
The idea of dependability highlights how the researcher’s observations are tied to 
the context or setting of the study. In addressing the issue of dependability, my 
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dissertation provides a detail report of the research design and study results. This should 
allow future researchers to repeat the study, and to develop a thorough understanding of 
the methods and to gain or similar the same results. 
Confirmability 
Confirmability refers to the degree to which others could corroborate the findings 
of a study. The findings of this study are the result of the experiences and opinions of the 
participants. I used triangulation to address the issue of confirmability and to reduce the 
effect of investigator bias. In this study, triangulation involved the use of systematic 
literature reviews, interviews and case study of five medical device companies. 
Threats to Reliability 
Zikmund (2010) defines reliability as a measure of the degree to which the results 
that have been obtained are consistent and devoid of flaws. Hence, for the quantitative 
data, the Cronbach Alpha of 0.7 was used to determine the data validity. There are three 
main aspects of reliability and these are consistency, ability to be replicated, and accuracy 
(Golafshani, 2003). In this study, methods to ensure validity and reliability included 
minimization of bias, and triangulation to achieve convergence validity (Sekaran & 
Roger, 2010). The qualitative data were evaluated for content and construct validity, 
whereby, repetitive themes from the interviews and case study were sought (Kirk & 
Miller, 1986). 
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Minimization of Bias 
Questionnaire bias was reduced by administering the questionnaires only to the 
right people, standardization of the questionnaire, and avoidance of jargon. The questions 
were also kept short and clear with no redundancies and appropriate formatting was used. 
Learner bias was avoided by randomizing the order of questions asked. Due to the 
sensitivity of the content of the survey, the data collection occurred in total 
confidentiality. Thus, respondents were not actively concerned about their information 
being disclosed. I reduced the threats to credibility by obtaining consent from the 
participants. I reduce the researcher bias by administrating the survey anonymously using 
SurveyMonkey.com. The data that were obtained were therefore abstracted. This enabled 
an evaluation of the research homogeneity and enhanced both the repeatability and 
validity of the study. 
Chapter Summary 
This chapter has contained findings from literature, interviews, and a brief survey 
before analyzing and discussing each along the provided research questions and 
hypotheses as follows. 
The findings indicated support for H1a (Changes to the MDD have led to a 
significant decrease in the net income of medical device software firms in the United 
States) but rejected H10. The case study of the five companies and the literature review 
established firms’ income increased after complying with the MDD. Even though the 
194 
 
income growth is not uniform across the sampled medical device manufacturing firms, 
there is a trend of general statistical growth.  
The findings indicated support for H20 (Changes to the MDD have not 
significantly reduced the training costs for each EN/IEC/62304 -compliant software year 
of medical device software firms in the United States) but rejected H2a. The literature 
sources and interview findings indicated that the training cost have significantly 
increased as leaders of firms seek compliance with the EN/IEC/62304. The study 
established that the training needs are at the quality and operational levels.  
The findings indicated support for H30 (There has not been a significant decrease 
in the project costs for each EN/IEC/62304 compliant software year of medical device 
software firms in the United States due to changes to the MDD) but rejected H3a. The 
graphical plots of the year-on-year expenditures in R&D showed a steady increase in the 
project costs. Moreover, these costs were likely to increase further with the 
implementation of the latest proposal to the MDD for 2012-2013.  
The findings indicated support for H4a (Changes to the MDD have led to a 
significant increase in the recall rate of medical device software manufactured by firms in 
the United States) while rejecting H40. The MDD has increased the surveillance and 
internal audits of the medical device manufacturing systems to minimize device recalls 
and failure incidences that put the lives of the users in danger. Additionally, compliance 
to the MDD has created widespread commitment among the medical device 
manufacturers to improve device quality and communication among the stakeholders. 
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This chapter also included a review on the progress of the proposed MDD 
Revisions (2012-2013) and the impact on medical device manufacturers regarding safety, 
reliability, quality, and cost. The reviews are targeting improved communication between 
the commission and the respective medical device manufacturers, which have previously 
experienced some lapses, leading to the penetration of uncertified or unreliable devices in 
the markets. The aim of the reviews is to increase device software reliability by 
increasing the verification procedures under the supervision of MDCG. Another aim of 
the reviews is to improve the safety of medical devices embedded with software by 
proposing a raft of new measures to make the manufacturers more accountable. Under the 
review of Article 13, the proposal targeted better device quality by requiring every 
organization to have a senior qualified and experienced staff member to address all the 
issues from compliance, internal audits, and recall management. Article 13 requires that 
medical device manufacturers appoint at least one qualified person to lead compliance 
with the regulations. Finally, the review will serve to address the aspect of cost after the 
respective device manufacturers adhere to the common technical specifications. The next 
chapter contains the conclusions of the research questions and hypotheses, limitations, 
implications of social change, and recommendations for practices and future studies.  
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Chapter 5: Summary, Recommendations, and Conclusion 
Introduction 
The purpose of the study was to evaluate the impact of the changes in the MDD 
93/42/EEC on the net income and share prices of compliant firms, the training cost for 
each EN/IEC/62304 compliant software year, project cost for each EN/IEC/62304, and 
the recall rate of devices manufactured by firms in the United States. This chapter, in 
consideration of the overall study limitations, contains a recapitulation each of the issues 
before a proceeding to discussion on the recommendations and the social change arising 
from EN/IEC/62304 compliance.  
This study was conducted to fill a gap in the scholarly literature. The findings of 
this study represent the first time the impact of the changes in the MDD 93/42/EEC on 
medical device software and U.S. medical device companies’ performances has been 
evaluated. The following main themes emerged from the study: (a) the Medical Devices 
Directive 93/42/EEC (MDD) with amendment M5 (2007/47/EC) have realigned device 
software manufacturing practices and incorporated other safety standards and (b) U.S. 
medical device companies have gained both domestic and global competitiveness in 
improving product safety, increasing sales revenue, and achieving stable stock 
performance. The conclusion of this chapter contains a recommendation to the EU 
Commission Services on how to update their best practices for enforcing conformance. 
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Interpretation of Findings 
The first purpose of the study was to evaluate the impact of MDD 93/42/EEC on 
the device manufacturers’ competitiveness benchmarked on the net income and share 
prices. The results of the research indicated overwhelming competitive advantages for the 
complying device manufacturers, including special certification and quality marks on the 
products preferred by hospitals and clinics. Additionally, medical devices that comply 
with the MDD 93/42/EEC have fewer product recalls, which often cause immense 
income losses to the device manufacturers, aside from the requirement of extra software 
checks and surveillance (Rakitin, 2006).  
The findings from this study also indicated that manufactures of medical software 
devices have positive income returns that improved after they complied with the MDD 
93/42/EEC. The same competitive advantages reflect on stable stock performances. 
Device recall cases highlighted in the press create public sentiments that can reflect in the 
stock market (Rakitin, 2006). However, the findings did not reveal any correlation 
between the increased revenues of U.S. firms in the EU and their compliance with the 
MDD 93/42/EEC.  
The need to reduce operational costs arises because compliance to the MDD 
93/42/EEC amendment targeting software safety and efficacy is a costly venture before a 
firm receives certification or accreditation to export to European markets (Panesar-
Walawege et al., 2010). The cost factor is mostly in the due diligence and massive 
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documentation procedures. Thus, as medical device manufacturing companies’ 
automated operations increased, the numbers of manual laborers decreased accordingly.  
The second purpose was to evaluate the impact of changes of the MDD 
93/42/EEC on the training cost for each EN/IEC/62304 compliant software year. The 
findings indicated the changes of the MDD 93/42/EEC have led to redefining the training 
needs for innovations, prototyping, design, testing, validation, and release processes (Lee 
et al., 2006; McCaffery et al., 2010). The extensive literature reviews revealed the 
process of MDD 93/42/EEC has retraced the staff training process to ensure better 
efficacy and accountability from the respective manufacturers (McCaffery & Dorling, 
2009).  
The literature review and interviews established that Amendment M5 
(2007/47/EC) had created new needs for retraining medical device manufacturers and 
practitioners to improve the success rates of the respective software-embedded devices 
(European Council, 2007). The interview responses included the extended training costs 
that the respective medical device manufacturers factor in their R&D going forward. The 
findings further indicated the need to train medical device manufacturers and users on 
FDA regulations and ISO 62304 requirements. This globally recognized standard is the 
benchmark for software development and testing (Damian & Moitra, 2006); hence, 
exporters to the EU region who conform are progressing toward Directive 2007/47/EC. 
The other impact of introducing the MDD 93/42/EEC is demand for skilled or 
specialized employees. The MDD 93/42/EEC amendment calls for recruiting staff 
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members who can provide the company with skills and productivity that will propel 
profitability (Sobelman, 2008). This case study revealed that some firms had struggles 
with internal organization, especially after acquisitions or mergers where staff members 
come in with different performance cultures. The synergy of skills such as software 
design and development is crucial for medical device manufacturers to nurture for 
research sustainability and better returns on investments (McCaughey et al., 2010). 
The third purpose of the study was to examine the impact of the MDD 93/42/EEC 
changes on the project cost for each EN/IEC/62304 . There was evidence that fixed costs 
of compliance with the MDD 93/42/EEC run into millions of dollars every year across 
the medical device industry. On the variable costs, this study involved examining the 
impact of the MDD 93/42/EEC on the employee recruitment trends with evidence 
collated from the interviewees. In many medical device manufacturing firms, the MDD 
93/42/EEC has led company leaders to restructure reorganization. 
According to the extensive literature sources and interviews, the introduction of 
the MDD 93/42/EEC has had mixed consequences for recruiting employees because 
leaders seek those with top skills, and their compensation has cost implications on the 
project for each EN/IEC/62304 compliance software release. Leaders lay off many 
workers as they pursue efficiency and cost-cutting goals (McCaffery, 2010). However, 
some of the people who lost their job will often find new positions in related medical 
device companies.  
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Finally, this study involved evaluating the impact of changes in the MDD 
93/42/EEC on the recall rate of devices manufactured by firms in the United States. The 
number of device recall before 2010 was approximately 1.5 million. However, the MDD 
93/42/EEC is according the manufacturing firms competitive edge over their other 
segment players apart from elimination of unreliable or unsafe products in the market that 
often trigger recall, which indicates that the MDD 93/42/EEC has provided extra 
surveillance needs and operations in the medical industry. The fact that certain medical 
devices with software embedded have the mark of quality assurance provides the 
manufacturers with advantages of better pricing and higher revenue returns because the 
MDD 93/42/EEC requires extra research and documentation to the specific proportion of 
redesigned device software. For example, if internal audits of a medical device company 
reveal 20% of the software requires a redesign, the leaders will test and recertify only that 
portion of the software, which indicates that the R&D will be rational and modest, and 
the device products will continue to be priced competitively in the markets (Sobelman, 
2008). 
Limitations of the Study 
A description of the limitations of the study is described in chapter 1. This 
includes the difficulty in making generalizations from the research methodology, the 
small sample size, the validity and reliability of the quantitative instrument. Qualitative 
research was suitable for this study; however, the results obtained from qualitative studies 
are not generalizable to entire populations (Maylor & Blackmon, 2005). When 
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considering the study findings, a primary limitation of this study was the potential 
limitation of purposive sampling. The potential disadvantage was the possibility to focus. 
The study included stringent inclusion and exclusion criteria to select the respondents, 
which has led to a limited sample size. Another limitation of this study was the potential 
for selection bias and response bias. Chapter 1 also outlined a strategy to address these 
limitations. The quantitative research included descriptive statistics, correlation, and data 
coding for analysis of variance, which was not only useful in testing the four hypotheses, 
but also to mitigate against the generalization limitation. The survey administration was 
anonymous to help reduce such a bias.  
When considering trustworthiness, I used Guba’s four criteria: credibility, 
transferability, dependability and confirmability. The basis of the responses collected 
from the survey was the opinions of the interviewees. These opinions constituted a threat 
to the overall credibility of the study. I used triangulation to address the issue of 
confirmability and to increase the validity and the reliability of the study results.  
Based upon the results of this study, I may have failed to reject or confirm some 
hypotheses. A plausible explanation for the lack of significant results lies in the small 
sample size. Any deviation will probably be due to the small sample size and resulting 
low statistical power of the study. Because of the lack of existing research in this area, the 
sample size further limited this study. The small sample size resulted from the inability to 
recruit additional participants, following the study modification detailed in Chapter 3, 
from already limited participant firms. 
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Recommendations 
This study provided a basis for future research studying the impact of the 
European Medical Device Directives on medical device manufacturers. I conducted this 
study to fill a gap in the scholarly literature. Based upon the findings of this study and 
considering the limitations and scope of the study, suggestions for future research are as 
follows. 
First, future researchers should investigate how medical device manufactures 
complying with the MDD 93/42/EEC can improve their market time deliveries, shorten 
the R&D life cycle, increase the device software revenue, and streamline the 
manufacturing predictability timelines. This is a call to improve future competitiveness. 
The compliance criteria were slowing down many operations among the medical device 
manufacturers who pursue industry innovations at the same time. Additionally, some 
medical device manufacturers tend to view the MDD 93/42/EEC as a bureaucratic system 
that imposes additional cost on their vision for lean operational management.  
Secondly, future researchers should indicate how medical device manufacturers 
could assess their current business operations to increase compliance with the MDD 
93/42/EEC while maintaining pace with medical industry innovations. New medical 
device software designs that pursue business and compliance goals tend to emphasize one 
aspect while the other suffers from lack of flexible adaptations to standards. Researchers 
should address the MDD 93/42/EEC standards and software designs rigidities that cloud 
management’s judgment on the best way forward. Since the MDD 93/42/EEC came into 
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effect, the leaders of many companies have been struggling to implement of efficiency 
practices such as timesavings and addressing market feedback on time. Moreover, even 
though the MDD 93/42/EEC amendment calls for companies to focus on testing the 
revised designs toward a relaunch process after a recall, future studies need to guide the 
scale of validation to save operational time and resources.  
Thirdly, future researchers should show how medical device manufacturers could 
be consistent in organizational governance. In the past, as the medical device 
manufacturers went through their usual business in compliance with the MDD 
93/42/EEC has seen blur of role such as who to review software, what bugs to eliminate , 
when to relaunch, and how to communicate safety and reliability changes to the medical 
industry is appropriate. Even though the MDD 93/42/EEC represents an attempt to 
formalize staffing and operational procedures, the findings in this study revealed that the 
diversity of medical device software creates unique challenges for each company. 
Therefore, software design projects that appear to be in regulatory compliance with the 
MDD 93/42/EEC can actually be struggling with business contingency measures.  
Fourth, future researchers should investigate how medical device manufacturers 
can take advantage of the open software design platforms to speed up their strategic 
plans. Even though many originators patent their software, the medical industry continues 
to establish collaborations that benefit from prior MDD 93/42/EEC compliance to shorten 
life cycles for other up-and-coming companies, especially the SMEs. Future researchers 
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should establish how the rest of the medical industry device manufacturers could increase 
collaboration in project, portfolio, documentation, and quality management.  
Finally, future researchers should come up with a universal methodology of 
complying to the MDD 93/42/EEC, where medical device manufacturers can refine 
aspects of product improvement and operational sequencing with the new product 
development, management, team responsibility, organizational systems, and software 
designs. These researchers should also address objectives such as goal-setting strategies. 
Future researchers should further explore a framework within which medical device 
manufacturers anywhere in the world could comply, to support marketing of compliant 
products, scheduling new product dates, efficiency, and improving life-cycle durations.  
Implications of Social Change From MDD 93/42/EEC Compliance 
This study has implications for positive social change. The findings of this study 
indicated that the changes in the MDD 93/42/EEC have a positive impact on the safety 
and reliability of software embedded medical devices. I sought to generate knowledge to 
contribute to a direct understanding of the phenomenon. As software embedded medical 
devices have been diversifying, the need to regulate their safety during applications 
became urgent owing to the increasing number of hazards and recalls (Rakitin, 2006). 
Members of the Council on medical devices of the European Commission believe that a 
consistent and coherent implementation of the MDD 93/42/EEC with Amendment M5 
(2007/47/EC) is necessary to ensure the protection of human health (European Council, 
2007). As a result, EN/IEC 62304 emerged as a global standard for the software 
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development life cycle. Medical device manufacturers failing to abide by the stipulated 
standards could lose their ability to access the respective markets, especially in the EU 
where the medical devices directive applies (Damian & Moitra, 2006). The implication 
for social change is to inform medical device manufacturers of the consequences of 
failure to comply with the standard. I indicated that most medical device manufacturers 
that comply or are in the process toward complying with the MDD 93/42/EEC 
amendments have less internal autonomy regarding how the operations run because the 
standard contains details of process flows to minimize risks and hazards on the products 
(Sobelman, 2008).  
From a social change perspective, the MDD 93/42/EEC has made medical device 
manufacturers more consistent in practices of software material designs and made them 
repeat the high-quality production of equipment that meets high-performance 
expectations. The MDD 93/42/EEC has led medical device manufacturers to improve 
their product maturity time-to-market lags because of established standard operational 
procedures. The MDD 93/42/EEC has increased the frequency of audits that medical 
device manufacturers must accomplish to ensure compliance. Compliance with the MDD 
93/42/EEC has improved the business results of many companies with products recalled 
following hazardous events. Moreover, any medical device manufacturer wishing to 
export to the EU has improved the software product quality under a consistent process. 
The outcome is resilient business performance in European markets, even when the 
economic environment is facing tough times (Sobelman, 2008). 
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The implication for social change included the evaluation of the changes in the 
MDD 93/42/EEC designed to make medical device safe and effective. MDD 93/42/EEC 
compliance has created high-performing device software manufacturers who have 
embraced a methodological standard as an organizational culture. Therefore, the medical 
device manufacturers have fortified their internal management policies to synchronize 
with industry innovations classes and times. The MDD 93/42/EEC has realigned the 
social technological links and methodology for medical device manufacturers because 
they share experiences and inventions to drive the industry forward. Moreover, the MDD 
93/42/EEC compliance has reshaped the social accountability of medical device 
manufacturers to show more care for human health and maintain high standards over 
time. The evidence of social accountability manifests in the increasing sales and net 
revenue of the respective medical device manufacturers. Research shows more social 
change in the area of quality management, whereby the industry has been able to police 
and report entry of counterfeit medical devices that have potential health risks, which 
indicates that the European market has a self-audit and social reporting framework and 
methods to protect the health and safety of the medical device users.  
Recommendations for Practice 
Recommendations for Practice on MDD 93/42/EEC Source Code 
The first recommendation is to make source code for all medical devices open and 
auditable. According to Sandler et al. (2010), this would enhance the safety and reliability 
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of these devices. Through this study, I established that the security of medical devices 
could vastly improve by making device software reliable (McCaffery, 2010). 
Recommendations for Practice on the EN/IEC/62304 Standard 
The second recommendation is that leaders of U.S. companies manufacturing 
medical software devices adopt this amended standard for all their product life cycles 
because it entails risk quality and risk management. This standard is important as it 
includes operationalization of the ISO 14971, which takes care of any additional hazards 
not captured by the EN/IEC/62304.  
Recommendation for Practice on Adoption and Use of Comprehensive Model-Based 
Approaches  
To eliminate less obvious errors and covert bugs during the project management 
advice (PMA) stage, medical device software manufacturers should have to adopt a 
model-based approach during the design of medical device software (McCaffery et al., 
2010). This will enable the use of detailed white-box testing and other recognized model-
checking methods to root out the errors and bugs before they enter the market, which will 
reduce the incidences of injuries, deaths, and recalls arising from defective software. The 
final recommendation is that the development of comprehensive use models such as 
illustrated in EN/IEC/62304 be a requirement for all manufacturers (McCaughey & 
Dorling, 2009). This will help to enhance the effectiveness of the regulation process and 
hence ensure safer and more effective medical device software that can also protect user 
privacy more effectively.  
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Conclusion 
The study involved evaluating the amendments of the MDD 93/42/EEC and the 
implications on medical device software. Via the interviews, I established that various 
procedures of medical device software coding have changed due to the introduction of 
the MDD 93/42/EEC, to which all manufacturers targeting the EU markets must 
conform. I examined past studies on the problem area through a systematic review of the 
literature from journals, articles, and other research databases such as the SEC and Yahoo 
Finance that cover the MDD and the performances of the involved companies. The 
literature review covered the impact of Directive 2007/47/EC, followed by the 
amendment to resolve issues surrounding software quality and efficacy. The literature 
review also included the competitiveness of medical devices in term of sales and revenue 
and the backdrop that certain software malfunctions have led to costly recalls for the 
manufacturing companies (European Council, 2007).  
The case study of the five companies and the literature review established firms’ 
income increased after complying with the MDD. The findings indicated that the training 
cost have significantly increased as leaders of firms seek compliance with the 
EN/IEC/62304. The graphical plots of the year-on-year expenditures in R&D showed a 
steady increase in the project costs. Finally, the study findings indicated that compliance 
to the MDD has created widespread commitment among the medical device 
manufacturers to improve device quality, thus resulting in lower device recalls and failure 
incidences that cause harm to the users, the medical device operators or service 
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personnel. Overall, the findings were useful in closing literature gap, as the various 
medical device manufacturers enhance the safety and performance of the embedded 
software. I will share or publish the findings of the study with the EU Commission 
Services to update their best practices for enforcing conformance with the 
EN/IEC/62304:2007. Furthermore, the outcomes of the study are applicable to various 
medical device manufacturers targeted by the MDD 93/42/EEC (Panesar-Walawege et 
al., 2010). 
The overall goal of the qualitative case study was to establish the impact of the 
MDD 93/42/EEC to the safety and reliability of the software system. The conclusion of 
this study was that the MDD 93/42/EEC has reorganized the medical industry and 
especially the software customization and design standards to ensure high success rates 
and low malfunctions that can pose material and health risks to patients or during hospital 
administration. The literature review and interviews revealed that a significant proportion 
of medical device recalls occurs after actual damage or hazards (Rakitin, 2006). The goal 
of the MDD 93/42/EEC and specifically Amendment M5 (2007/47/EC) is to create a 
proactive framework of a concept of proof that device software will function according to 
specifications and limit the risk to human health (European Council, 2007). Medical 
device manufacturers outside the EU initially viewed the introduction and amendment of 
the MDD 93/42/EEC as a social bureaucracy and as providing preferential treatment to 
the European medical industry, but the findings in this study indicated that the measures 
are defensible for the benefit of all stakeholders (Sobelman, 2008). 
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Appendix A: Questionnaire 
Purpose: 
The purpose of this study is to determine the effect of the EU Medical Device Directive 
on medical device software, on the project costs of medical device software firms in the 
U.S. 
The information obtained from this questionnaire will primarily be used for my 
dissertation research. 
Completing this Questionnaire: 
Please read each question carefully and do not skip an item unless you deem it not 
applicable to you. This questionnaire should take about 30-45 minutes to complete. 
Data Confidentiality 
I want to assure you that your individual responses will be kept completely confidential, 
by me, and your participation in this study is absolutely voluntary. 
My dissertation committee will be given an overview of my research findings and 
suggestions. No one at the University will see your responses. 
SECTION I: Background Information 
Objective: 
The information collected in this section will not be used in any manner to identify you. 
The objective of collecting this information is to be able to find any patterns in 
demography that may have an influence on management practices. 
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1. Could you please tell me briefly about yourself and your area of 
responsibility? 
2. Size of the company: 
3. Type of company: 
4. Current Job Title:_____________________________ 
5. Department:___________________________________ 
6. Gender 
a) Male   
b) Female 
7. In what age group are you? 
a) 25 and under    b). 26 to 35   c). 36 to 45 
d). 46 to 55    e). 55 and older 
8. Number of years with current employer: 
a). Less than 5 years   b) Less than 10 years  
c). Less than 15 years   d) over 20 years  
e). More than 30 years 
 
SECTION II: Effectiveness of Directive MDD 93/42/EEC on the Safety of Medical 
Devices 
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1. Based on your experience, how effective has the MDD 93/42/EEC been in 
enhancing the efficacy of medical devices? Please tick the appropriate boxes 
for each device type. 
Device type Very effective Effective  Not certain Not effective Not effective at all 
Class I devices      
Class IIa devices      
Class IIb devices      
Class III devices      
2. How effective has the MDD 93/42/EEC been in enhancing the safety of 
medical devices? Please tick the appropriate boxes for each class of device. 
Device type Very effective Effective  Not certain Not effective Not effective at all 
Class I devices      
Class IIa devices      
Class IIb devices      
Class III devices      
 
SECTION III:Impact of the MDD 93/42/EEC on the Costs of Medical Devices 
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1. How costly is the approval process for medical devices? Please tick the 
appropriate boxes for each class of device 
Device type Very costly costly Not costly Very cheap I do not know 
Class I devices      
Class IIa devices      
Class IIb devices      
Class III devices      
 
2. What effect have the Amendments had on the cost of approval? 
a. Increased the cost  
b. Reduced the cost 
c. No effect 
d. I don’t know 
3. How long does the approval process for medical devices take? 
a. Very long time (more than 180 days) 
b. Long time (more than 90 days) 
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c. Short time (90 days) 
d. Very short time (less than 90 days) 
 
SECTION IV: Better Conformity assessment 
1. What can be done to improve the process of conformity assessment? 
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------ 
2. What can be done to improve the designation and monitoring of notified 
bodies? 
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------ 
3. What can be done to make the clinical evaluation requirements clearer? 
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------ 
4. What can be done to improve the process of post market surveillance? 
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------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------ 
5. Is the process used to approve medical devices transparent? Please circle one 
a. Yes  
b. No (Please explain) 
_________________________________________________________ 
c. I don’t know 
6. What can be done to improve the transparency of the approval process? 
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------ 
7. Have the amendments had a significant impact on competition? 
a. Yes 
b. No  
c. I don’t know 
SECTION V: Market Surveillance - Medical Devices Recalls 
1. Have you had any recalls of your devices after 30th June, 2004? 
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a. Yes 
b. No  
2. If the answer to the previous question is yes, what was the number of recalls 
what factors led to these recalls? Please fill the table below appropriately 
Type of malfunction/ failure Number of recalls 
Software malfunction  
Behavior failure  
Failure of output  
Service failure  
Display failure  
Input failure  
Response failure  
Failure due to data  
User instruction failure  
Timing failure  
System failure  
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Quality failure  
Other  
3. Have you had any recalls of your devices after 21st March, 2010? 
a. Yes 
b. No  
4. If the answer to 3 above is yes, what was the number of recalls and what 
factors led to the recalls? Please fill the table below appropriately. 
Type of malfunction/ failure Number of recalls 
Software malfunction  
Behavior failure  
Failure of output  
Service failure  
Display failure  
Input failure  
Response failure  
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Failure due to data  
User instruction failure  
Timing failure  
System failure  
Quality failure  
Other  
 
SECTION VI: Impact of the MDD 93/42/EEC on the Firm’s Revenues 
1. What was the value of your company’s exports to Europe between 24th March 
2011 and 24th March 2012? 
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------ 
2. How has your share of the European market changed since 24th March, 2011? 
a. Has increased by____________________% 
b. Has not changed 
c. Has reduced by ____________________% 
d. I don’t know 
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3. How has the number of your employees changed since 24th March, 2011? 
a. Has increased by ____________________% 
b. Has not changed 
c. Has reduced by ____________________% 
d. I don’t know 
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Appendix B: Interview Questions 
Objective: To assess the impact of EN/IEC/62304 on your organization. 
Comment: EN/IEC 62304 standard has been embraced as a global benchmark for 
management of the software development lifecycle. 
Lead Question 1: Is EN/IEC/62304 implemented in your firm? 
Comment: According to a FDA’s analysis conducted between 2002 and 2010, about 1.5 
million software-based medical devices were recalled. During these eight years, the 
number of recalls of software-based medical devices has more than doubled. 
Lead Question 2: What in your opinion is attributable to this high percentage? 
Probing Question: What factors explain the emergence of these defects after the 
initial software release? You can give specific examples. 
Comment: EN/IEC/62304 provides a framework of software development lifecycle 
processes, by defining the majority of the software development and verification 
activities. 
Lead Question 3: Are best-practice (sound software development practices for 
medical devices from planning, requirement analysis, implementation and verification, 
integration, and software release) currently underway at your organization? 
Lead Question 4: How do you demonstrate compliance to the standard? 
Probing Question: Does your organization have a specific work instruction or 
SOP for EN/IEC/62304? 
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Comment: The FDA and the European Union have observed an increase use of off-the-
shelf software (SOUP) in automated medical devices prior to the introduction of 
EN/IEC/62304. 
Lead Question 5: What concerns do you have with the usage of SOUP in 
medical devices? 
Probing Question: Do you believe that EN/IEC/62304 fully addresses these 
concerns? 
Comment: According to the FDA, software validation is a requirement to software used 
as components in medical devices, to software that is itself a medical device, and to 
software used in production of the device or in implementation of the device 
manufacturer's quality system. 
Lead Question 6: Do you believe that the introduction of EN/IEC/62304 has 
made medical device software validation safer? 
Comment: Medical devices must be validated to ensure accuracy, reliability, consistent 
intended performance. 
Lead Question 7: Do you believe that EN/IEC/62304 has been effective in 
enhancing the safety of medical devices? 
Probing Question: In which way are medical devices produced under IEC 62034 
safer? 
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Comment: The U.S. medical device industry is expected to remain highly competitive 
globally, due in part to the introduction of innovative products to market. 
Lead Question 8: Do you believe that medical device software produced under 
the guidance of EN/IEC/62304 provides firms with a competitive advantage? 
Probing Question: How precisely does EN/IEC/62304 offers consumers greater 
value?  
Comment: Although EN/IEC 62304 standard has been embraced as a global benchmark 
for management of the software development lifecycle, implementation of the standard 
has been slow (Ken, 2010). 
Lead Question 9: What justifies the slow adoption of the standard by medical 
device manufacturers? 
Probing Question: In your opinion what must be done to improve the 
implementation of EN/IEC/62304? 
Comment: The ultimate objective of EN/IEC/62304 is to ensure that medical device 
software is not only effective but safe. 
Lead Question 10: Are you aware of any unintended consequences associated 
with the implementation of EN/IEC/62304? 
Probing Question: Are you aware of any effects of the implementation of 
EN/IEC/62304 on software costs and employees training?  
Probing Question: Any further comments? 
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Thank you for your participation. 
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Appendix C: Acronym Table 
Acronym Term 
510(k) Premarket Notification 
AARA American Recovery and Reinvestment Act 
AERs Adverse event reports 
AHWP Asian Harmonization Working Party 
ANSI American National Standards Institute 
BPA Bisphenol A 
CAD Computer-aided design 
CAM Computer-aided manufacturing 
CDRH Center for Devices and Radiological Health 
CE marking Conformité Européenne; meaning "European Conformity" 
CEN Comité Européen de Normalisation 
CENELEC 
Comité Européen de Normalisation Électrotechnique; English: 
European Committee for Electrotechnical Standardization 
CFC Chlorofluorocarbon 
CMS Center for Medical and Medicaid Services 
COC Cyclic olefin copolymers 
COP Cyclic olefin polymers 
DBS Deep brain stimulators  
DHEP di(2-ethylhexyl) phthalate 
DOS Denial of service 
EEA European Economic Area 
EEC European Economic Community 
EN European Norm 
ETSI European Telecommunication Standards Institute 
EU European Union 
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Acronym Term 
FDA Food and Drug Administration 
GAO Government Accountability Office 
GHTF Global Harmonization Task Force 
GMP Good manufacturing practices 
GPOs Group purchasing organizations 
HCMDSS High Confidence Medical Device Software and Systems 
HHS Health and Human Services 
HMOs Health management organizations 
ICD Implantable cardiac defibrillators 
ID Identification 
IEC International Electrotechnical Commission 
IMD Implantable medical devices 
IP Intellectual property 
IRB Institutional Review Board 
ISO International Organization for Standardization 
LAHWP Latin American Harmonization Working Party 
MAC Media access control 
MAUDE Manufacturer and User Facility Device Experience 
MCRs Minimum medical cost ratios 
MDD Medical Devices Directive 
MEMS Micro-electro-mechanical systems 
MHRA Medicines and Healthcare products Regulatory Agency 
MoH Ministry of Health 
NAFTA North American Free Trade Association 
NAIC North American Industry Classification 
NAICS North American Industry Classification System 
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Acronym Term 
NCMS New Cooperative Medical Scheme 
NCVA National Venture Capital Association 
onc Office of the National Coordinator for Health IT 
PMA Pre-market approval 
PVC Polyvinyl chloride 
QA Quality Assurance 
QS Quality System 
R&D Research and development 
RFID Radio-frequency identification 
SEC U.S. Securities and Exchange Commission 
SCC Standards Council of Canada 
SOP Standard Operating Procedure 
SOUP Software of Unknown Pedigree or Provenance 
U.K United Kingdom 
U.S United States of America 
UDI Unique Device Identifier 
UEBMI Urban Employee Basic Medical Insurance 
URBMI Urban Resident Basic Medical Insurance 
VOS Value of shipment 
WHO World Health Organization 
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Appendix D: List of International Standards 
Name Subject 
21 CFR part 820 
Code of Federal Regulations Title 21- PART 820: QUALITY 
SYSTEM REGULATION. 
Directive 76/64/EEC 
Directive 76/464/EEC of 4 May 1976 on pollution caused by 
certain dangerous substances discharged into the aquatic 
environment of the Community. 
Directive 84/539/EEC 
COUNCIL DIRECTIVE of 17 September 1984 on the 
approximation of the laws of the Member States relating to 
electro-medical equipment used in human or veterinary 
medicine (84/539/EEC). 
Directive 90/385/EEC 
Council Directive 90/385/EEC of 20 June 1990 on the 
approximation of the laws of the Member States relating to 
active implantable medical devices. 
Directive 93/42/EEC 
Council Directive 93/42/EEC of 14 June 1993 concerning 
medical devices. 
Directive 98/79/EC 
Directive 98/79/EC of the European Parliament and of the 
Council of 27 October 1998 on in vitro diagnostic medical 
device. 
EN ISO 13485  
Medical devices - Quality management systems - 
Requirements for regulatory purposes (ISO 13485:2003). 
EN/IEC 62304 Medical device software -- Software life cycle processes. 
IEC 60601-1-11:2010  
Medical electrical equipment -- Part 1-11: General 
requirements for basic safety and essential performance -- 
Collateral standard: Requirements for medical electrical 
equipment and medical electrical systems used in the home 
healthcare environment 
IEC 61010-1 
Safety requirements for electrical equipment for 
measurement, control, and laboratory use - Part 1: General 
requirements 
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Name Subject 
ISO 13488 
Quality systems -- Medical devices -- Particular requirements 
for the application of ISO 9002. 
ISO 14971 
Medical devices -- Application of risk management to medical 
devices. 
ISO/IEC 90003 
Software engineering -- Guidelines for the application of ISO 
9001:2000 to computer software. 
MDD 2007/47/EC 
Directive 2007/47/EC of the European parliament and of the 
council of 5 September 2007 amending MDD 93/42/EEC. 
MDD 76/764/EEC Medical Directive (repealed as from 1 January 1995). 
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Appendix E: Walden University IRB approval 
Original E-mail 
Subject: Notification of Approval to Conduct Research-Guy Didier Foe Owono 
Date: Tue, Nov 26, 2013 03:22 PM CST 
From: IRB IRB@waldenu.edu 
To Guy Didier Foe Owono <guydidier.foeowono@waldenu.edu> 
CC: "irmak.renda-tanali@waldenu.edu" <irmak.renda-tanali@waldenu.edu>, Walden 
University Research <research@waldenu.edu> 
 
Dear Mr. Foe Owono, 
This e-mail serves to inform you that your request for a change in procedures, submitted 
on 11/22/13 has been approved. Your interpretation of the steps associated with data 
collection is correct. You may implement the requested changes effective immediately. 
The approval number for this study will remain the same. 
This email also confirms receipt of the letters of cooperation for Spiracur Inc, and Robert 
Bosch Healthcare, Inc. and also serves as your notification that Walden University has 
approved BOTH your dissertation proposal and your application to the Institutional 
Review Board. As such, you are approved by Walden University to conduct research. 
Please contact the Office of Student Research Administration at research@waldenu.edu if 
you have any questions.  
Both students and faculty are invited to provide feedback on this IRB experience at the 
link below: 
http://www.surveymonkey.com/s.aspx?sm=qHBJzkJMUx43pZegKlmdiQ_3d_3d 
Sincerely, 
Jenny Sherer, M.Ed., CIP 
Associate Director 
Office of Research Ethics and Compliance 
Email: irb@waldenu.edu 
Fax: 626-605-0472 
 
Office address for Walden University: 
100 Washington Avenue South 
Suite 900 
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Minneapolis, MN 55401 
Information about the Walden University Institutional Review Board, including 
instructions for application, may be found at this link: 
http://researchcenter.waldenu.edu/Office-of-Research-Ethics-and-Compliance-IRB.htm 
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Appendix F: Walden University conditional IRB approval 
Original E-mail 
Subject: Conditional IRB Approval-Guy Didier Foe Owono 
Date: Fri, Sep 20, 2013 03:29 PM CDT 
From: IRB IRB@waldenu.edu 
To Guy Didier Foe Owono <guydidier.foeowono@waldenu.edu> 
CC: "irmak.renda-tanali@waldenu.edu" <irmak.renda-tanali@waldenu.edu>, Walden 
University Research <research@waldenu.edu> 
Dear Mr. Foe Owono, 
This email is to notify you that the Institutional Review Board (IRB) has approved your 
application for the study entitled, "Impact of EU Medical Device Directive on Medical 
Device Software." conditional upon the approval of the community research partners, as 
documented in signed letters of cooperation. Walden's IRB approval only goes into effect 
once the Walden IRB confirms receipt of those letters of cooperation. 
Your approval # is 09-20-13-0109393. You will need to reference this number in your 
doctoral study and in any future funding or publication submissions. Also attached to this 
e-mail are the IRB approved consent forms. Please note, if these are already in an on-line 
format, you will need to update those consent documents to include the IRB approval 
number and expiration date. 
Your IRB approval expires on September 19, 2014. One month before this expiration 
date, you will be sent a Continuing Review Form, which must be submitted if you wish to 
collect data beyond the approval expiration date. 
Please note that this letter indicates that the IRB has approved your research. You may 
NOT begin the research phase of your doctoral study, however, until you have received 
the Notification of Approval to Conduct Research e-mail. Once you have received this 
notification by email, you may begin your data collection. Your IRB approval is 
contingent upon your adherence to the exact procedures described in the final version of 
the IRB application materials that have been submitted as of this date. This includes 
maintaining your current status with the university. Your IRB approval is only valid 
while you are an actively enrolled student at Walden University. If you need to take a 
leave of absence or are otherwise unable to remain actively enrolled, your IRB approval 
is suspended. Absolutely NO participant recruitment or data collection may occur while a 
student is not actively enrolled. 
Your IRB approval is contingent upon your adherence to the exact procedures described 
in the final version of the IRB application materials that have been submitted as of this 
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date. If you need to make any changes to your research staff or procedures, you must 
obtain IRB approval by submitting the IRB Request for Change in Procedures Form. You 
will receive confirmation with a status update of the request within 1 week of submitting 
the change request form and are not permitted to implement changes prior to receiving 
approval. Please note that Walden University does not accept responsibility or liability 
for research activities conducted without the IRB's approval, and the University will not 
accept or grant credit for student work that fails to comply with the policies and 
procedures related to ethical standards in research. 
When you submitted your IRB application, you a made commitment to communicate 
both discrete adverse events and general problems to the IRB within 1 week of their 
occurrence/realization. Failure to do so may result in invalidation of data, loss of 
academic credit, and/or loss of legal protections otherwise available to the researcher. 
Both the Adverse Event Reporting form and Request for Change in Procedures form can 
be obtained at the IRB section of the Walden web site or by emailing irb@waldenu.edu: 
http://inside.waldenu.edu/c/Student_Faculty/StudentFaculty_4274.htm 
Researchers are expected to keep detailed records of their research activities (i.e., 
participant log sheets, completed consent forms, etc.) for the same period of time they 
retain the original data. If, in the future, you require copies of the originally submitted 
IRB materials, you may request them from Institutional Review Board. 
Both students and faculty are invited to provide feedback on this IRB experience at the 
link below: 
http://www.surveymonkey.com/s.aspx?sm=qHBJzkJMUx43pZegKlmdiQ_3d_3d 
Sincerely, 
Jenny Sherer, M.Ed., CIP 
Associate Director 
Office of Research Ethics and Compliance 
irb@waldenu.edu 
Phone: 612-312-1341 
Fax: 626-605-0472 
Office address for Walden University: 
100 Washington Avenue South 
Suite 900 
Minneapolis, MN 55401 
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Appendix G: Invitation to Participate in Research 
This form represents the original that was sent out to the participants in the organization 
under study requesting their participation in the research study. 
Guy D. Foe Owono 
3283 Mirage Way  
San Jose, CA 95135 
Tel: 1 408 667 9487 
 
 
October 28, 2013 
 
 
Attn: Kaleem Mohammed 
Manager QA & RA 
Robert Bosch Healthcare, Inc 
2400 Geng Rd Palo Alto, CA 94303 
 
Dear Kaleem, 
 
I am currently pursuing a PhD in Applied Management and Decision Sciences at Walden 
University’s College of Management and Technology, in the U.S. My dissertation will 
examine changes in the EU MDD, the impact on medical device software, and the impact 
to firm competitiveness. 
The medical device industry is a key component of healthcare systems. As more medical 
products have become dependent on embedded software, safety regulations for those 
devices have shifted to the reliability of software systems. The European Union believes 
that a consistent and coherent implementation of the Medical Devices Directive 
93/42/EEC (MDD) with amendment M5 (2007/47/EC) is necessary to ensure human 
health protection.  
 
The aim of the research, as stated in the previous section, is to examine changes in the 
EU MDD and the impact on medical device software.  
I plan on conducting an interview and administering a survey to about 2 employees. The 
SurveyMonkey.com website will be used to administer and store the survey. However, I 
will conduct the interviews personally in order to obtain the specific information that 
could support the intended study. Participants will complete a survey and subsequently be 
interviewed.  
 
I have estimated the burden for this collection of information at 90 to 120 minutes, 
including the time for reading the question, completing the questionnaire, and 
participating in the interview. 
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In addition, I welcome the opportunity to review any available data on company’s 
financial performance, in order to assess the impact of the EU MDD to firm 
competitiveness. 
In the event of a positive answer to my request, I plan on administrating the survey by 
early November 2013, and anticipate completing the process within few hours. I will 
appreciate if you could provide the names of two employees who are willing to 
participate in the study, so I can coordinate the exact times of data collection with them in 
order to minimize disruption to their activities. 
 
Once the data is collected, consolidated, and analyzed, I shall provide a copy to your 
office to ensure the integrity of the information. This information will then be 
incorporated into a doctoral research paper. 
Since this study will involve employees under your supervision, I hereby formerly 
request your approval to engage them in the study. I have attached herewith a 
“Recruitment letter”, and a consent form that will be emailed to the participants for your 
reading and review.  
I welcome the opportunity to discuss the planned data collection with you, and I am 
available to answer any questions you might have relating to this matter.  
 
I can be reached either by email at guydidier.foeowono@waldenu.eduor via phone at 
+1 408 667-9487. 
 
Thanks in advance for your cooperation. 
 
Sincerely 
 
Guy Foe Owono 
PhD Candidate 
Walden University, College of Management and Technology 
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Appendix H: Consent Form 
This form represents the original that was sent out to the participants in the organization 
under study informing them of their right to voluntary participation and confidentiality. 
 
You are invited to take part in a research study of Impact of EU Medical Device 
Directive on Medical Device Software.  
 
You were chosen for the study because:  
1. you have been working in the medical devices software field for a period not less 
than 5 years 
2. the company you are working for has released a EN/IEC/62304 compliant 
software since the publication of the standard in 2007 
3. you are at least 18 years old to participate in this reseach 
4. and you are able to speak and write in English 
 
This form is part of a process called “informed consent” to allow you to understand this 
study before deciding whether to take part. Please read this form and ask any questions 
you have before agreeing to be part of the study. 
This study is being conducted by a researcher named Guy Didier Foe Owono, who is a 
doctoral student at Walden University.  
Background Information: 
The purpose of this study is to study the impact of changes to the EU MDD on medical 
device software. 
 
Procedures: 
If you agree to be in this study, you will be asked to:  
 
 Read and sign this consent form agreeing or declining to participate in the study, 
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 Participate in a survey questionnaire administered in SurveyMonkey. The 
researcher has estimated the burden for this collection of information at 45 to 60 
minutes, including the time for reading the question and completing the 
questionnaire. 
 Participate in an interview to be conducted by the researcher. The researcher has 
estimated the burden for this collection of information at 60 minutes. The 
interview will be audio-recorded and transcribed to text. 
 
Here are some sample questions: 
 
1. What is the impact of changes to the EU MDD on medical device software? 
2. What is the impact of the EU MDD on Europeans medical device manufacturer’s 
competitiveness? 
3. How effective has the MDD 93/42/EEC been in enhancing the safety of medical 
devices? 
4. Have you had any recalls of your devices after 21st March, 2010? 
 
Voluntary Nature of the Study: 
Your participation in this research project is completely voluntary. You have the right to 
say no, and may withdraw at any time should you change your mind. You may choose 
not to answer specific questions or stop participating at any time. You may skip any 
questions that you feel are too personal. 
Whether you choose to participate or not will have no affect on your employment. 
 
Risks and Benefits of Being in the Study: 
The researcher has deemed the psychological stress associated with the participation in 
the study no greater than what one would experience in daily life. The only anticipated 
risk to the participants could result from the nature of the questions posed in the 
interviews or surveys. 
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The study could result in direct contribution to social change. 
The researcher hopes to provide the EU Commission Services input to improve the 
implementation of IEC 62304. 
 
Payment: 
The researcher does not plan on providing any compensation to the participants for their 
research participation. 
 
Privacy: 
Any information you provide as well as the records of this study will be kept confidential 
.The researcher will not use your personal information for any purposes outside of this 
research project. Also, the researcher will not include your name or anything else that 
could identify you in the study reports. The documents and recordings will be stored in a 
nonpublic location and will be kept for a period of at least 5 years, as required by the 
university. 
 
Contacts and Questions: 
The researcher’s name is Guy D. Foe Owono. The researcher’s faculty advisor is Dr. 
Irmak Renda-Tanali. You may ask any questions you have now. Or if you have 
questions later, you may contact the researcher via phone at +1 408 667-9487 or email at 
guydidier.foeowono@waldenu.edu or the advisor by phone at +1 240 684-2435 or 
email at irmak.renda-tanali@waldenu.edu.  
If you want to talk privately about your rights as a participant, you can call Dr. Leilani 
Endicott. She is the Director of the Research Center at Walden University. Her phone 
number is 1-800-925-3368, extension 3121210. 
Please retain a copy of this form for your records. 
Statement of Consent: 
 
I have read the above information and I feel I understand the study well enough to make a 
decision about my involvement.  
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By replying to this email with the words, “I consent” , I understand that I am agreeing to 
the terms described above. 
Please include in the email the telephone number at which you can be reached for the 
phone interview. 
 
Walden University policy on electronic signatures: An electronic signature is just as valid as a written 
signature as long as both parties have agreed to conduct the transaction electronically.  
Electronic signatures are regulated by the Uniform Electronic Transactions Act. Electronic signatures are 
only valid when the signer is either (a) the sender of the email, or (b) copied on the email containing the 
signed document.  
Legally an "electronic signature" can be the person’s typed name, their email address, or any other 
identifying marker. Walden University staff verify any electronic signatures that do not originate from a 
password-protected source (i.e., an email address officially on file with Walden). 
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Appendix I: Transcribed Interviews Responses 
Objective: To assess the impact of EN/IEC/62304 on your organization. 
Time: 8:00 A.M. PST 
Date: December 13, 2013 
Place: Milpitas, CA 
Interviewee: Mr. MOX 
Position of Interviewee: Manager 
Brief introduction by Interviewer. 
Interviewer: Thank you very much MOX. for accepting to be part of this research study. 
As you know the purpose of this study is to determine the impact of the MDD to medical 
firm. 
Interviewee: I am very excited that you are completing your PhD, this is significant 
achievement. 
Interviewer comment: EN/IEC 62304 standard has been embraced as a global 
benchmark for management of the software development lifecycle. 
Question 1: Is EN/IEC/62304 implemented in your firm? 
Responder 1: yes, 62304 was implemented in our organization at the beginning of this 
year. You have brought an outside consulting group. Our entire software group got 
trained on 62304. 
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Interviewer comment: According to a FDA’s analysis conducted between 2002 and 
2010, about 1.5 million software-based medical devices were recalled. During these eight 
years, the number of recalls of software-based medical devices has more than doubled. 
Question 2: What in your opinion is attributable to this high percentage? 
Interviewee: it all attributed to risk analysis. The initial risk analysis during the initial 
development phase and risk analysis during verification and Validation (V&V). Risk 
analysis should be a complete life cycle activity. It should start during the initial design 
phase. It should cover, supply chain, manufacturing, design transfer, how embedded 
software is transfer to manufacturing. Learning from post market surveillance activities. 
Probing Question: What factors explain the emergence of these defects after the initial 
software release? You can give specific examples. 
 
Interviewer comment: EN/IEC/62304 provides a framework of software development 
lifecycle processes, by defining the majority of the software development and verification 
activities. 
Question 3: Are best-practice (sound software development practices for medical devices 
from planning, requirement analysis, implementation and verification, integration, and 
software release) currently underway at your organization?  
Interviewee: We have implemented 62304 fully, we are practicing fully. All our 
procedures have been revised, and people have been trained. We have spent $100,000 
(100k) on training. We have about 265 associates globally. 
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Question 4: How do you demonstrate compliance to the standard? 
Interviewee: Again right now, everybody is going through a learning curve. It is an 
excellent process well structured.  
Probing Question: Does your organization have a specific work instruction or SOP for 
IEC 62304? 
Interviewee: We have a procedure for software development life cycle, and we revised it 
last year to comply with 62304. 
 
Interviewer comment: The FDA and the European Union have observed an increase use 
of off-the-shelf software (SOUP) in automated medical devices prior to the introduction 
of IEC 62304. 
Question 5: What concerns do you have with the usage of SOUP in medical devices? 
Interviewee: Yes it is a big concern, basically managing SOUP. We do not have a 
procedure on how to manage SOUP. That is one area where regulatory angencies will 
look into. 
Probing Question: Do you believe that EN/IEC/62304 fully addresses these concerns? 
Interviewee: To me it a concern. We need to have a documented procedure on how to 
manage SOUP. There should be a documented process; it should be part of our design 
process, and during all design activities. The Software design document, SDDs, must 
clearly document what off the shelf, commercial software we are using. A completely 
defining a maintenance plan. 
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Interviewer comment: According to the FDA, software validation is a requirement to 
software used as components in medical devices, to software that is itself a medical 
device, and to software used in production of the device or in implementation of the 
device manufacturer's quality system. 
Question 6: Do you believe that the introduction of EN/IEC/62304 has made medical 
device software validation safer? 
Interviewee: definitely, because it requires certain documentation, which aligns with the 
level of concern, and based on the classification of the software whether A, B &C the 
required documentation is clearly identified, which documentation you should have in 
place. But one thing I see that people may flag, is low level classification of product, they 
may not document. But I will recommend that the process should be applied the same to 
all classes, so that you have a standard practice, otherwise people may slip.  
 
Interviewer comment: Medical devices must be validated to ensure accuracy, reliability, 
consistent intended performance. 
Question 7: Do you believe that EN/IEC/62304 has been effective in enhancing the 
safety of medical devices? 
Interviewee: When you are classifying your software, it is based on what you call the 
defect, the adverse effects that you may see in the software. You have to define the 
classification based on the failure you may be seeing. If you do not do it meticulously, 
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then any auditor may found out that you skip it: that you overlook it. They will ask you to 
do it again. 
Probing Question: In which way are medical devices produced under IEC 62034 safer? 
Interviewee: Basically, the complete software design development documentation, the 
software architecture, the risk analysis, the V&V (verification and validation). 
 
Interviewer comment: The U.S. medical device industry is expected to remain highly 
competitive globally, due in part to the introduction of innovative products to market. 
Question 8: Do you believe that medical device software produced under the guidance of 
EN/IEC/62304 provides firms with a competitive advantage? 
Interviewee: Definitely, it will provide competitive advantage, because it is a harmonized 
standard. That mean the scientific community is behind it. 
Probing Question: How precisely does EN/IEC/62304 offers consumers greater value? 
Interviewee: again from the point of safety and efficacy of the product.  
 
Interviewer comment: Although EN/EN/IEC/62304 standard has been embraced as a 
global benchmark for management of the software development lifecycle, 
implementation of the standard has been slow (Ken, 2010). 
Question 9: What justifies the slow adoption of the standard by medical device 
manufacturers? 
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Interviewee: It is the understanding of the requirements, and also people do not have 
templates. For example, what should go in the design and development software 
document, what should go in software architecture documents? People are not clear on 
this. I am answering based on our own experience. We are struggling. What we are doing 
to do, we are going to buy some temples that are being used in the industry, which are 
develop by some experts. So we are going to buy them and use them. This is where 
people have struggled implementing that.  
Probing Question: In your opinion what must be done to improve the implementation of 
IEC 62304? 
Interviewee: Training: our firm invested $100,000 on training. 
 
Interviewer comment: The ultimate objective of EN/IEC/62304 is to ensure that 
medical device software is not only effective but safe. 
Question 10: Are you aware of any unintended consequences associated with the 
implementation of IEC 62304? 
Interviewee: So far, we have not seen any adverse even report business. 
Probing Question: Are you aware of any effects of the implementation of 
EN/IEC/62304 on software costs and employees training?  
Interviewee: the cost is the cost of compliance. If you are selling a product to the EU, you 
are required to comply with 62304; otherwise, you might not be able to sell the product. 
Probing Question: Any further comments? 
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Interviewee: I will say that, 62304 is a good standard. The only thing is that we need 
guidance and more for example, sample templates. If the standard is requiring software 
architecture document: they should be guidance at the minimum what the content of the 
software architecture should be. That should help the industry. 
Thank you for you participation. 
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